[go: up one dir, main page]

WO2025072313A1 - Anti-gpc4 antibodies - Google Patents

Anti-gpc4 antibodies Download PDF

Info

Publication number
WO2025072313A1
WO2025072313A1 PCT/US2024/048385 US2024048385W WO2025072313A1 WO 2025072313 A1 WO2025072313 A1 WO 2025072313A1 US 2024048385 W US2024048385 W US 2024048385W WO 2025072313 A1 WO2025072313 A1 WO 2025072313A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
sequence
antigen binding
seq
gpc4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/048385
Other languages
French (fr)
Inventor
Susannah Helene KASSMER-RODRIGUEZ
Anagha Ashok Divekar
Mong-Shang LIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolegend Inc
Original Assignee
Biolegend Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolegend Inc filed Critical Biolegend Inc
Publication of WO2025072313A1 publication Critical patent/WO2025072313A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present disclosure relates, in some aspects, to antibodies or antigen-binding fragments thereof that bind Glypican 4 (GPC4), as well as methods, systems and kits for detection of GPC4.
  • the present disclosure relates to antibodies or antigen binding fragments thereof for use in determining levels of GPC4 in a sample containing or suspected of containing GPC4.
  • the present disclosure relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with GPC4.
  • Glypican 4 is a glypican, a family of cell-surface heparan sulfate proteoglycans (HSPG) potentially involved in cell division and growth regulation.
  • HSPG family members may act as a reservoir or modulator for several growth factors and signaling molecules.
  • HSPG molecules contain a core protein anchored to the cytoplasmic membrane via a GPI anchor.
  • HSPGs function as coreceptors or modulators of Wnt activation.
  • GPCs are R-spondin co-receptors that regulate Wnt signaling.
  • GPC3 enhances Wnt signaling
  • GPC6 inhibits Wnt signaling.
  • GPC4 Wnt3a binding to frizzled and LRP6 stabilizes cytosolic beta-catenin, which translocates to the nucleus to activate TCF/LEF transcription factors.
  • GPC4 expressing cells show a higher activation of the beta-catenin pathway in response to Wnt3a. Knockdown of GPC4 suppresses activation of the beta-catenin pathway.
  • GPC4 is upregulated in pancreatic cancer and colorectal cancer, and is associated with resistance to fluorouracil (5FU) chemotherapy.
  • antibodies including antigen-binding fragments thereof, that bind all or a portion thereof of GPC4, compositions containing such antibodies or antigen-binding fragments thereof, combinations of such antibodies or antigen-binding fragments thereof and methods of use.
  • the antibodies or antigen-binding fragments thereof are used in methods of detecting the presence of GPC4 through imaging, including molecular, medical and diagnostic imaging.
  • antibodies or antigen-binding fragments thereof including those that specifically bind to a GPC4, such as a human GPC4, wherein the antibodies or antigen- binding fragments contain particular complementarity determining regions (CDRS), including heavy chain CDRS (i.e., CDRH1, CDRH2, and/or CDRH3) and light chain CDRS (i.e., CDRL1, CDRL2, and/or CDRL3), such as any described herein.
  • CDRS complementarity determining regions
  • the antibody or antigen-binding fragment thereof includes a heavy chain variable domain and a light chain variable domain, such as any described herein.
  • an antibody or antigen binding fragment thereof that binds GPC4 or a portion thereof, comprising a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementarity determining region 1 (CDRH1) comprising SEQ ID NO:2; (ii) a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO:3; (iii) a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO:4; and b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO:5; (ii) a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO:6; and (iii) a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO:7.
  • CDRH1 heavy chain complementarity determining region 1
  • CDRL2 light chain complementarity determining region
  • the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; PATENT BIOLEG-1007PCT and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 2, or
  • the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4.
  • the immunoglobulin light chain variable domain comprises: a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 5, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 6, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 7, or a sequence of amino acids
  • the immunoglobulin light chain variable domain comprises: a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 5; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 6; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 7.
  • the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 2; the CDRH2 comprises the sequence of amino acids set forth in SEQ ID NO: 3; the CDRH3 comprises the sequence of amino acids set forth in SEQ ID NO: 4; the CDRL1 comprises the sequence of amino acids set forth in SEQ ID NO: 5; the CDRL2 comprises the sequence of amino acids set forth in SEQ ID NO: 6; and the CDRL3 comprises the sequence of amino acids set forth in SEQ ID NO: 7.
  • the CDRH1 comprises the sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2
  • the CDRH2 comprises the sequence set forth in SEQ ID NO: 3 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3
  • the CDRH3 comprises the sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 8
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15.
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in any of SEQ ID NO: 15.
  • the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17.
  • the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17.
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17.
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17.
  • the antibody or antigen binding fragment comprises one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain.
  • the antibody or antigen binding fragment comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
  • the antibody or antigen binding fragment thereof is isolated.
  • the antibody or antigen binding fragment thereof is humanized.
  • the antibody or antigen binding fragment thereof is conjugated.
  • the antibody or antigen binding fragment further comprises an oligonucleotide.
  • the oligonucleotide comprises a sample barcode sequence.
  • the oligonucleotide comprises a binding site for a primer and an anchor.
  • the antibody or antigen binding fragment thereof is conjugated to a detectable marker or label.
  • the detectable marker or label is conjugated directly to the antigen or antigen binding fragment thereof.
  • the detectable marker or label is conjugated to the oligonucleotide.
  • the PATENT BIOLEG-1007PCT detectable marker or label comprises a detectable moiety.
  • the detectable moiety is a radioisotope, fluorescent label or enzyme-substrate label.
  • the antibody or antigen binding fragment thereof is non- diffusively immobilized on a solid support.
  • the disclosure provides an isolated antibody that specifically binds to GPC4, wherein the isolated antibody competes for binding to GPC4with an antibody described herein.
  • the antibody is a monoclonal antibody.
  • the antibody is a humanized antibody.
  • the antibody comprises one or more human framework regions.
  • the antibody or antigen binding fragment is a single chain fragment.
  • the single chain fragment is a single chain variable fragment (scFv).
  • scFv single chain variable fragment
  • the two or more antibodies or antigen-binding fragments comprise one or more first antibody or antigen-binding fragment thereof that binds to a first epitope or region within GPC4; and one or more second antibody or antigen-binding fragment thereof that binds to a second epitope or region within GPC4.
  • the one or more first antibody or antigen-binding fragments thereof, and the one or more second antibody or antigen-binding fragments thereof bind to a non-overlapping epitope or region of GPC4 (e.g., human GPC4) and/or do not compete for binding to GPC4.
  • the antibody is conjugated to a detectable marker or label.
  • the at least one of the antibodies or antigen-binding fragments of the combination of two or more anti- GPC4 antibodies or antigen-binding fragments described herein, optionally the one or more first antibody or antigen-binding fragment thereof or the one or more second antibody or antigen-binding fragment thereof, is conjugated to a label.
  • the at least one of the antibodies or antigen-binding fragments is attached or immobilized to a solid support.
  • the one or more first or second antibody or antigen-binding fragment is attached PATENT BIOLEG-1007PCT or immobilized to a solid support and the other of the one or more first or second antibody or antigen-binding fragment is conjugated to a label.
  • the label is a fluorescent dye, a fluorescent protein, a radioisotope, a chromophore, a metal ion, gold particles, silver particles, magnetic particles, a polypeptide, an enzyme, streptavidin, biotin, a luminescent compound, or an oligonucleotide.
  • the solid support is a bead, a column, an array, an assay plate, a microwell, a stick, a filter, or a strip.
  • the antibody is non-diffusively immobilized on a solid support.
  • the device is a rapid detection device or a rapid diagnostic device.
  • the disclosure features an isolated nucleic acid encoding an isolated antibody described herein.
  • the disclosure also provides an expression vector comprising the nucleic acid described herein. Further, the disclosure also provides an isolated host cell comprising the expression vector described herein.
  • the antibody or antigen binding fragment thereof provided herein can be used in the detection of GPC4 in a sample. In some embodiments, the antibody or antigen binding fragment thereof binds to a cell expressing GPC4 in a sample.
  • the sample comprises immune cells. In some embodiments, the sample comprises a heterogenous population of immune cells.
  • the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs).
  • the sample comprises a cell with a disease or disorder.
  • the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, a neurologic disorder, or an infection.
  • the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, breast, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
  • the detection includes the use of a single antibody or antigen binding fragment thereof to bind a portion of GPC4.
  • the detection includes the use of two antibody or antigen binding fragments thereof, each capable of binding to a different portion of GPC4.
  • the detection of GPC4 is on the surface of a cell.
  • the detection of GPC4 is PATENT BIOLEG-1007PCT intracellular. In some embodiments, the detection of GPC4 indicates the presence or absence of a disease or disorder. In some embodiments, the detection is performed in vitro. In some embodiments, the detection is performed in vivo. [0031] In some embodiments, the antibody or antigen binding fragment thereof binds to a GPC4 expressing cell. [0032] Provided herein is a diagnostic antibody or antigen binding fragment thereof which includes any of the antibody or antigen binding fragment thereof described herein. Provided herein is a kit comprising the antibody or antigen binding fragment thereof of any one of embodiments described herein.
  • the kit is a diagnostics kit configured to detect GPC4 in a biological sample.
  • a composition comprising the antibody or antigen binding fragment thereof of any of the embodiments described herein and a pharmaceutically acceptable excipient.
  • the antibody or antigen binding fragment thereof of is used as an adjuvant or in conjunction with an adjuvant.
  • an isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the agent of any of embodiments described herein.
  • an isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin light chain variable domain of the agent of any of the embodiments described herein.
  • sequence encoding the immunoglobulin heavy chain variable domain of the agent of any of embodiments described herein and the sequence encoding the immunoglobulin light chain variable domain of the agent of any of the embodiments described herein can be on the same isolated nucleic acid or different isolated nucleic acids.
  • an isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any of the embodiments described herein.
  • a recombinant expression vector comprising the isolated nucleic acid of any of the embodiments described herein.
  • a recombinant expression vector comprising a first expression cassette and a second expression cassette
  • the first PATENT BIOLEG-1007PCT expression cassette includes a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of the embodiments described herein
  • the second expression cassette includes a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any one of any of the embodiments described herein.
  • a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette includes a nucleic acid molecule comprising the nucleotide sequence of any of the embodiments described herein, and the second expression cassette includes a nucleic acid molecule comprising the nucleotide sequence of any of the embodiments described herein.
  • the first and second expression cassettes include a promoter.
  • a host cell transfected with the recombinant expression vector of any of the embodiments described herein.
  • an agent-drug conjugate comprising antibody or antigen binding fragment thereof of any of the embodiments described herein.
  • a composition comprising the antibody-drug conjugate and a pharmaceutically acceptable carrier.
  • a method of detecting GPC4 comprising a) contacting a sample with the antibody or antigen binding fragment thereof of any of the embodiments described herein, under conditions to bind said antibody or antigen binding fragment thereof to a GPC4 receptor on said sample, wherein the binding generates the production of a receptor/antibody or antigen binding fragment thereof complex; b) detecting the presence of the receptor/antibody or antigen binding fragment thereof complexes; and c) wherein the detecting comprises the presence or absence of the GPC4 receptor on said sample.
  • a method of treating or preventing a disease or disorder associated with GPC4 in a subject comprising a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof of any of the embodiments described herein; b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a PATENT BIOLEG-1007PCT disease or disorder; and c) administering to the subject the antibody or antigen binding fragment thereof of any of the embodiments described herein.
  • a method of diagnosing a disease or disorder comprising a) isolating a sample from a subject; b) incubating the sample with the antibody or antigen binding fragment thereof of any of the embodiments described herein, for a period of time sufficient to generate GPC4:anti-GPC4 complexes; c) detecting the presence or absence of the GPC4:anti-GPC4 complexes from the isolated tissue, and d) associating presence or abundance of GPC4 with a location of interest of a tissue sample.
  • the increase of GPC4 over a control level in the location of interest of the tissue sample is indicative of a disease or disorder in a subject.
  • the method is performed in vitro. In some embodiments, the method is performed in vivo. In some embodiments, the detection comprises intracellular detection. In some embodiments, the detection comprises detection on the surface of a cell. In some embodiments, the detection comprises hybridization of a detectable moiety to the antibody or antigen binding fragment thereof. In some embodiments, the sample is contacted with a second antibody. In some embodiments, the second antibody is an antibody comprising a detectable moiety. In some embodiments, the detectable moiety comprises an oligonucleotide. In some embodiments, the detectable moiety comprises a fluorescent label. In some embodiments, the detecting comprises sequencing. In some embodiments, the detectable moiety comprises immunofluorescence.
  • the sample is a formalin-fixed paraffin- embedded sample.
  • the sample comprises a cell.
  • the sample comprises a tissue sample.
  • the sample comprises immune cells.
  • the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs).
  • the sample comprises a tissue or cells associated with a disease or disorder.
  • the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, or an infection.
  • the disease or disorder is chosen from non-viral cancers, virus-associated cancers, cancers associated PATENT BIOLEG-1007PCT with HBV infection, cancers associated with Epstein-Barr virus (EBV) infection, cancers associated with polyomavirus infection, erythema nodosum leprosum (ENL), autoimmune diseases, autoimmune inflammation, autoimmune thyroid diseases, B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, B-cell leukemias, myel
  • the antibody or antigen binding fragment thereof can be used in a method of associating presence or abundance of GPC4 with a location of interest of a tissue sample. [0045] In some embodiments, the antibody or antigen binding fragment thereof can be used in a method of detecting GPC4 in a tissue sample. In some embodiments, the method comprises generating a nucleic acid molecule comprising all or a portion of the sequence of the oligonucleotide or a complement thereof. [0046] In some embodiments, the antibody or antigen binding fragment thereof can be used in the construction of a protein library. In some embodiments, the construction of a protein library comprises sequencing. In some embodiments, the construction of a protein library comprises the use of flow cytometry.
  • FIG. 1 are graphs showing GPC4 antibody AB2 positively stained NTERA-2 cells.
  • Figure 2 are graphs showing GPC4 antibody AB2 demonstrated negative staining on U- 937 cells.
  • PATENT BIOLEG-1007PCT [0050]
  • Figures 3A-3C are graphs showing GPC4 antibody AB2 did not cross react with GPC1 (FIG. 3A), GPC2 (FIG. 3B) or GPC6 (FIG.
  • Figure 4 is a bar graph showing GPC4 antibody AB2 is capable of reducing Wnt3a- induced translocation of beta-catenin to the nucleus.
  • Figure 5 are images showing GPC4 antibody AB2 is capable of reducing Wnt3a induced beta-catenin translocation to the nucleus, whereas the commercially available GPC4 antibody did not demonstrate this effect.
  • Figure 6 is a bar graph showing GPC4 antibody AB2 is capable of reducing Wnt3a induced beta-catenin translocation to the nucleus at all concentrations tested, whereas the commercially available antibody did not demonstrate this effect.
  • antibodies that bind GPC4 including antigen-binding fragments thereof, nucleic acids encoding such antibodies and antigen-binding fragments, and cells, such as recombinant cells for expressing and production of these antibodies and antigen-binding fragments that can bind to GPC4 under physiological and/or in vitro conditions.
  • Also provided are methods of producing and using the antibodies and antigen-binding fragments such as in methods for detecting GPC4 in a sample from an individual, including methods for laboratory/ research purposes (e.g., flow cytometry, ELISA, and/or Western blot), and/or for the use and treatment and/or prevention of various diseases or disorders through the delivery of pharmaceutical or other compositions that contain such antibodies or antigen-binding fragments thereof.
  • methods for laboratory/ research purposes e.g., flow cytometry, ELISA, and/or Western blot
  • methods for producing and using the antibodies and antigen-binding fragments such as in methods for detecting GPC4 in a sample from an individual, including methods for laboratory/ research purposes (e.g., flow cytometry, ELISA, and/or Western blot), and/or for the use and treatment and/or prevention of various diseases or disorders through the delivery of pharmaceutical or other compositions that contain such antibodies or antigen-binding fragments thereof.
  • antibody as used herein includes antigen binding fragments thereof that retain binding specificity. For example, there are a number of well characterized antigen binding fragments. Thus, for example, pepsin digests an antibody C-terminal to the disulfide linkages in the hinge region to produce F(ab)’2, a dimer of Fab which itself is a light chain joined to VH- CH1 by a disulfide bond.
  • the F(ab)’2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab’)2 dimer into an Fab’ monomer.
  • the Fab’ monomer is essentially an Fab with part of the hinge region (see, Fundamental Immunology, W.E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antigen binding fragments). While various antigen binding fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that fragments can be synthesized de novo either chemically or by utilizing recombinant DNA methodology.
  • an antibody as used herein also includes antigen binding fragments either produced by the modification of whole antibodies or synthesized using recombinant DNA methodologies.
  • An antibody as described herein can consist of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes.
  • the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda.
  • Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, PATENT BIOLEG-1007PCT respectively.
  • the antibody is IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgM, IgA, IgD, or IgE.
  • a typical immunoglobulin (antibody) structural unit is known to comprise a tetramer.
  • Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD).
  • the N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.
  • substitution variants have at least one amino acid residue removed and a different residue inserted in its place.
  • the sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but framework alterations are also contemplated. Examples of conservative substitutions are described herein.
  • Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a ⁇ -sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • Naturally occurring residues are divided into groups based on common side- chain properties: (1) Non-polar: Norleucine, Met, Ala, Val, Leu, Ile; (2) Polar without charge: Cys, Ser, Thr, Asn, Gln; (3) Acidic (negatively charged): Asp, Glu; (4) Basic (positively charged): Lys, Arg; (5) Residues that influence chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe, His. Non-conservative substitutions are made by exchanging a member of one of these classes for another class.
  • substitution is to change one or more cysteines in the antibody, which may be chemically reactive, to another residue, such as, without limitation, PATENT BIOLEG-1007PCT alanine or serine.
  • cysteines in the antibody which may be chemically reactive
  • another residue such as, without limitation, PATENT BIOLEG-1007PCT alanine or serine.
  • the substitution can be made in a CDR or framework region of a variable domain or in the constant region of an antibody.
  • the cysteine is canonical (e.g., involved in di- sulfide bond formation).
  • Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant cross-linking.
  • Antibodies include VH-VL dimers, including single chain antibodies (antibodies that exist as a single polypeptide chain), such as single chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light domain are joined together (directly or through a peptide linker) to form a continuous polypeptide.
  • VH-VL dimers including single chain antibodies (antibodies that exist as a single polypeptide chain), such as single chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light domain are joined together (directly or through a peptide linker) to form a continuous polypeptide.
  • the single chain Fv antibody is a covalently linked VH-VL which may be expressed from a nucleic acid including VH- and VL- encoding sequences either joined directly or joined by a peptide-encoding linker (e.g., Huston, et al. Proc. Nat. Acad. Sci. USA, 85:5879-5883, 1988). While the VH and VL are connected to each as a single polypeptide chain, the VH and VL domains associate non-covalently. Alternatively, the antibody can be another fragment. Other fragments can also be generated, e.g., using recombinant techniques, as soluble proteins or as fragments obtained from display methods. Antibodies can also include diantibodies and miniantibodies.
  • Antibodies of the disclosure also include heavy chain dimers, such as antibodies from camelids.
  • an antibody is dimeric.
  • the antibody may be in a monomeric form that has an active isotype.
  • the antibody is in a multivalent form, e.g., a trivalent or tetravalent form.
  • An “antibody fragment” or “antigen binging fragment thereof” comprises a portion of an intact antibody, the antigen binding and/or the variable region of the intact antibody.
  • Antibody fragments or antigen binding fragments thereof include but are not limited to Fab fragments, Fab’ fragments, F(ab’)2 fragments, Fv fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fd’ fragments; diabodies; linear antibodies (see U.S. Pat. No.5,641,870, Example 2; Zapata et al, Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules, including single-chain Fvs (scFv) or single-chain Fabs (scFab); antigen-binding fragments of any of the above and multispecific antibodies from antibody fragments.
  • Fv is composed of one heavy- and one light-chain variable region domain linked by non-covalent association. From the folding of these two domains emanate six complementarity determining regions (CDR) (3 in each from the heavy and light chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although, in some cases, at a lower affinity than the entire binding site.
  • CDR complementarity determining regions
  • dsFv refers to an Fv with an engineered intermolecular disulfide bond, which stabilizes the VH-VL pair.
  • An “Fd fragment” is a fragment of an antibody containing a variable domain (VH) and one constant region domain (CHI) of an antibody heavy chain.
  • a “Fab fragment” is an antibody fragment that results from digestion of a full-length immunoglobulin with papain, or a fragment having the same structure that is produced synthetically, e.g., by recombinant methods.
  • a Fab fragment contains a light chain (containing a VL and CL) and another chain containing a variable domain of a heavy chain (VH) and one constant region domain of the heavy chain (CHI).
  • a “F(ab’)2 fragment” is an antibody fragment that results from digestion of an immunoglobulin with pepsin at pH 4.0-4.5, or a fragment having the same structure that is produced synthetically, e.g., by recombinant methods.
  • the F(ab’)2 fragment essentially contains two Fab fragments where each heavy chain portion contains an additional few amino acids, including cysteine residues that form disulfide linkages joining the two fragments.
  • a “Fab’ fragment” is a fragment containing one half (one heavy chain and one light chain) of the F(ab’)2 fragment.
  • An “Fd’ fragment” is a fragment of an antibody containing one heavy chain portion of a F(ab’)2 fragment.
  • An “Fv’ fragment” is a fragment containing only the VH and VL domains of an antibody molecule.
  • PATENT BIOLEG-1007PCT [0074]
  • An “scFv fragment” refers to an antibody fragment that contains a variable light chain (VL) and variable heavy chain (VH), covalently connected by a polypeptide linker in any order.
  • the linker is of a length such that the two variable domains are bridged without substantial interference.
  • Exemplary linkers are (Gly-Ser)n residues with some Glu or Lys residues dispersed throughout to increase solubility.
  • “Diabodies” are dimeric scFv; diabodies typically have shorter peptide linkers than scFvs, and preferentially dimerize.
  • the terms “variable region” and “variable domain” refer to the portions of the light and heavy chains of an antibody that include amino acid sequences of complementarity determining regions (CDRs, e.g., HCDR1, HCDR2, HCR3, LCDR1, LCDR2, and LCDR3) and framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • the variable domain for the heavy and light chains is commonly designated VH and VL, respectively.
  • variable domain is included on Fab, F(ab’)2, Fv and scFv antigen binding fragments described herein, and is involved in specific antigen recognition.
  • CDR complementarity-determining region
  • the CDRs are primarily responsible for binding to an epitope of an antigen.
  • the CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located.
  • a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found
  • a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found.
  • the sequences of the framework regions of different light or heavy chains are relatively conserved within a species.
  • the framework region of an antibody that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space.
  • the amino acid sequences of the CDRs and framework regions can be determined using various well-known definitions in the art, e.g., Kabat, North method (see, e.g., North et al., J Mol Biol.
  • chimeric antibody refers to an immunoglobulin molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region, or portion thereof, having a different or altered antigen specificity; or with corresponding sequences from another species or from another antibody class or subclass.
  • humanized antibody refers to an immunoglobulin molecule in CDRs from a donor antibody are grafted onto human framework sequences. Humanized antibodies may also comprise residues of donor origin in the framework sequences. The humanized antibody can also comprise at least a portion of a human immunoglobulin constant region. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • Humanization can be performed using methods known in the art (e.g., Jones et al., Nature 321:522-525; 1986; Riechmann et al., Nature 332:323-327, 1988; Verhoeyen et al., Science 239:1534-1536, 1988); Presta, Curr. Op. Struct. Biol. 2:593-596, 1992; U.S. Patent No. 4,816,567), including techniques such as PATENT BIOLEG-1007PCT “superhumanizing” antibodies (Tan et al., J. Immunol. 169: 1119, 2002) and “resurfacing” (e.g., Staelens et al., Mol. Immunol.
  • recombinant when used with a reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified.
  • recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
  • antigen a molecule, compound, or complex that is recognized by an antibody, i.e., can be specifically bound by the antibody.
  • the term can refer to any molecule that can be specifically recognized by an antibody, e.g., a polypeptide, polynucleotide, carbohydrate, lipid, chemical moiety, or combinations thereof (e.g., phosphorylated or glycosylated polypeptides, etc.).
  • a polypeptide polynucleotide
  • carbohydrate e.g., lipid, chemical moiety, or combinations thereof (e.g., phosphorylated or glycosylated polypeptides, etc.).
  • Antibodies bind to an “epitope” on an antigen.
  • the epitope is the localized site on the antigen that is recognized and bound by the antibody.
  • Epitopes can include a few amino acids or portions of a few amino acids, e.g., 5 or 6, or more, e.g., 20 or more amino acids, or portions of those amino acids.
  • the epitope includes non-protein components, e.g., from a carbohydrate, nucleic acid, or lipid.
  • the epitope is a three-dimensional moiety.
  • the epitope can be comprised of consecutive amino acids, or amino acids from different parts of the protein that are brought into proximity by protein folding (e.g., a discontinuous epitope).
  • a discontinuous epitope e.g., a discontinuous epitope.
  • An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation.
  • Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2- dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996).
  • a “label” or a “detectable moiety” is a diagnostic agent or component detectable by spectroscopic, radiological, photochemical, biochemical, immunochemical, chemical, or other physical means.
  • exemplary labels include radiolabels (e.g., 111 In, 99m Tc, 131 I, 67 Ga) and other FDA-approved imaging agents.
  • Additional labels include 32 P, fluorescent dyes, electron-dense reagents, enzymes, biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the targeting agent.
  • a “labeled” or “tagged” antibody or agent is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the antibody or agent may be detected by detecting the presence of the label bound to the antibody or agent.
  • the terms “specific for,” “specifically binds,” and like terms refer to a molecule (e.g., antibody or antigen binding fragment) that binds to a target with at least 2-fold greater affinity than non-target compounds, e.g., at least any of 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10- fold, 20-fold, 25-fold, 50-fold, or 100-fold greater affinity.
  • a target e.g., GPC4
  • GPC4 binds the target with at least a 2-fold greater affinity than a non-target.
  • Specificity can be determined using standard methods, e.g., solid- phase ELISA immunoassays (see, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual PATENT BIOLEG-1007PCT (1998) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
  • an antibody target e.g., antigen, analyte, immune complex
  • an antibody that binds a given antibody target typically binds to at least 2/3 of the antibody targets in a solution (e.g., at least any of 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%).
  • a solution e.g., at least any of 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%.
  • a “control” sample or value refers to a sample that serves as a reference, usually a known reference, for comparison to a test sample.
  • a test sample can be taken from a test condition, e.g., in the presence of a test compound, and compared to samples from known conditions, e.g., in the absence of the test compound (negative control), or in the presence of a known compound (positive control).
  • a control can also represent an average value or a range gathered from a number of tests or results.
  • controls can be designed for assessment of any number of parameters. For example, a control can be devised to compare therapeutic benefit based on pharmacological data (e.g., half-life) or therapeutic measures (e.g., comparison of benefit and/or side effects). Controls can be designed for in vitro applications.
  • Controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant.
  • nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site ncbi.nlm.nih.gov/BLAST/ or PATENT BIOLEG-1007PCT the like).
  • sequences are then said to be “substantially identical.”
  • the preferred algorithms can account for gaps and the like.
  • identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 or more amino acids or nucleotides in length.
  • sequence comparison algorithm typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
  • default program parameters can be used, or alternative parameters can be designated.
  • a “comparison window”, as used herein, is a reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well- known in the art.
  • An algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res.
  • HSPs high scoring sequence pairs
  • T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. PATENT BIOLEG-1007PCT Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always ⁇ 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score.
  • Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • the BLASTP program uses as defaults a wordlength of 3, and expectation I of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad.
  • nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof.
  • the term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides.
  • nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated.
  • degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
  • the terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
  • amino acid polymers in PATENT BIOLEG-1007PCT which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non- naturally occurring amino acid polymer.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an ⁇ carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • a first antibody can inhibit the binding of a second antibody to its epitope without that second antibody inhibiting the binding of the first antibody to its respective epitope.
  • each antibody detectably inhibits the binding of the other antibody with its cognate epitope or ligand whether to the same, greater, or lesser extent, the antibodies are said to “cross-compete” with each other for binding of their respective epitope(s).
  • PATENT BIOLEG-1007PCT competing and cross-competing antibodies are encompassed by the present disclosure.
  • RIA solid phase direct or indirect radioimmunoassay
  • EIA solid phase direct or indirect enzyme immunoassay
  • sandwich competition assay see Stahli et al., Methods in Enzymology 9:242-253 (1983)
  • solid phase direct biotin-avidin EIA see Kirkland et al., J. Immunol. 137:3614-3619 (1986)
  • solid phase direct labeled assay solid phase direct labeled sandwich assay
  • solid phase direct labeled sandwich assay see Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press (1988)
  • solid phase direct label RIA using I-125 label see Morel et al., Molec. Immunol.
  • human GPC4 can refer to a variant, such as an allelic variant or splice variant, that exhibits at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence PATENT BIOLEG-1007PCT identity to any of SEQ ID NO: 1.
  • the provided antibodies or antigen-binding fragments may exhibit cross-reactive binding to another mammalian GPC4 protein, such as murine GPC4, or a primate GPC4.
  • GPC4 The amino acid sequence of GPC4 is: MARFGLPALLCTLAVLSAALLAAELKSKSCSEVRRLYVSKGFNKNDAPLHEINGDHLKI CPQGSTCCSQEMEEKYSLQSKDDFKSVVSEQCNHLQAVFASRYKKFDEFFKELLENAEK SLNDMFVKTYGHLYMQNSELFKDLFVELKRYYVVGNVNLEEMLNDFWARLLERMFRL VNSQYHFTDEYLECVSKYTEQLKPFGDVPRKLKLQVTRAFVAARTFAQGLAVAGDVVS KVSVVNPTAQCTHALLKMIYCSHCRGLVTVKPCYNYCSNIMRGCLANQGDLDFEWNN FIDAMLMVAERLEGPFNIESVMDPIDVKISDAIMNMQDNSVQVSQKVFQGCGPPKPLPA GRISRSISESAFSARFRPHHPEERPTTAAGTSLDRLVTDVKEKLKQAKKFWSSLPSNVCN DERMAAGNGNEDDCWNGKGKS
  • solid support is meant a non-aqueous matrix to which an antibody according to the provided disclosure can adhere or attach.
  • solid supports include, but are not limited to, a microtiter plate, a membrane (e.g., nitrocellulose), a bead, a dipstick, a thin-layer chromatographic plate, or other solid medium.
  • an “individual” or a “subject” is a mammal.
  • a “mammal” for purposes of treatment includes humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc.
  • the individual or subject is human.
  • Antibodies that bind GPC4 [0105] Provided herein are antibodies, including antigen binding fragments thereof, that specifically bind to GPC4. The provided antibodies include monoclonal antibodies and antigen- binding fragments thereof that bind GPC4 and provide superior target specificity, signal-to-noise ratios, and the like as compared to other reported antibodies. Also provided herein are methods for producing anti-GPC4 antibodies, and methods for detecting and using such antibodies. PATENT BIOLEG-1007PCT [0106] Any of the antibodies of antigen binding fragments thereof provided herein can bind all or a portion of GPC4.
  • any of the antibodies of antigen binding fragments thereof provided herein can bind all or a portion of the extracellular domain of GPC4.
  • Any of the antibodies or antigen binding fragments thereof is a GPC4 antibody or antigen binding fragment thereof.
  • the antibody or antigen binding fragment thereof is isolated (e.g., separated from a component of its natural environment (e.g., an animal, a biological sample)).
  • the anti- antibody is a humanized antibody, or an antigen binding fragment thereof.
  • the antibody is a derivative of a humanized antibody that binds.
  • the antibody binds under laboratory conditions (e.g., binds in vitro, binds in a flow cytometry assay, binds in an ELISA). In some embodiments, the antibody binds under physiological conditions (e.g., binds in a cell in a subject).
  • the antibodies provided herein comprise at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain.
  • an antibody described herein comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
  • each immunoglobulin heavy chain variable domain of the antibody comprises first, second, and third heavy chain complementarity determining regions (CDRs; CDRH1, CDRH2, and CDRH3), and each immunoglobulin light chain variable domain of the antibody comprises first, second, and third light chain CDRs (CDRL1, CDRL2, and CDRL3).
  • the antibodies can be antigen binding fragments such as Fab, F(ab’)2, Fv or scFv.
  • the antigen binding fragments can be generated using any means known in the art including, chemical digestion (e.g., papain or pepsin) and recombinant methods.
  • the antibodies can be expressed in a variety of host cells, including E. coli, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO, and HeLa cells lines and myeloma cell lines.
  • antibodies or antigen-binding fragments thereof including those that specifically bind to a GPC4, such as a human GPC4, wherein the antibodies or antigen- PATENT BIOLEG-1007PCT binding fragments contain particular complementarity determining regions (CDRS), including heavy chain CDRS (i.e., CDRH1, CDRH2, and/or CDRH3) and light chain CDRS (i.e., CDRL1, CDRL2, and/or CDRL3), such as any described herein.
  • CDRS complementarity determining regions
  • the antibody or antigen-binding fragment thereof includes a heavy chain variable domain and a light chain variable domain, such as any described herein.
  • an antibody or antigen binding fragment thereof that binds GPC4 or a portion thereof, comprising a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementarity determining region 1 (CDRH1) comprising SEQ ID NO:2; (ii) a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO:3; (iii) a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO:4; and b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO:5; (ii) a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO:6; and (iii) a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO:7.
  • CDRH1 heavy chain complementarity determining region 1
  • CDRL2 light chain complementarity determining region
  • the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4, or a sequence of amino acids that exhibits at least
  • the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4.
  • the immunoglobulin light chain variable domain comprises: a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 5, or a sequence of amino acids PATENT BIOLEG-1007PCT that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 6, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO:
  • the immunoglobulin light chain variable domain comprises: a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 5; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 6; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 7.
  • the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 2; the CDRH2 comprises the sequence of amino acids set forth in SEQ ID NO: 3; the CDRH3 comprises the sequence of amino acids set forth in SEQ ID NO: 4; the CDRL1 comprises the sequence of amino acids set forth in SEQ ID NO: 5; the CDRL2 comprises the sequence of amino acids set forth in SEQ ID NO: 6; and the CDRL3 comprises the sequence of amino acids set forth in SEQ ID NO: 7.
  • the CDRH1 comprises the sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2
  • the CDRH2 comprises the sequence set forth in SEQ ID NO: 3 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3
  • the CDRH3 comprises the sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 8
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15.
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in any of SEQ ID NO: 15.
  • the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17.
  • the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17.
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17.
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17.
  • Antibodies that competitively bind with an anti-GPC4 antibody [0124] Also provided herein are antibodies that competitively bind, or are capable of competitively binding (e.g., competitor antibodies), with one or more GPC4 antibodies described herein. In certain instances, an antibody (e.g., competitor antibody) may be considered to compete for binding to GPC4 when the competitor binds to the same general region of GPC4 as an antibody described herein.
  • an antibody e.g., competitor antibody
  • an antibody may be considered to compete for binding to GPC4 when the competitor binds to the exact same region of GPC4 as an antibody described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)).
  • an antibody e.g., competitor antibody
  • an antibody may be considered capable of competing for binding to GPC4 when the competitor binds to the same general region of GPC4 as an antibody described herein (e.g., extracellular region or leucine-rich binding domain) under suitable assay conditions.
  • an antibody e.g., competitor agent
  • an antibody described herein e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)
  • an antibody e.g., competitor antibody
  • an antibody may be considered to compete for binding to GPC4 when the competitor blocks the binding of one or more antibodies described herein to GPC4, for example, under suitable assay conditions.
  • Whether a competitor blocks the binding of one or more antibodies described herein to GPC4 may be determined using a suitable competition assay or blocking assay, such as, for example, a blocking assay as described in herein.
  • a competitor antibody may block binding of one or more antibodies described herein to GPC4 in a competition or blocking assay by 50% or more (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more, or 100%), and conversely, one or more antibodies described herein may block binding of the competitor antibody to GPC4 in a competition or blocking assay by about 50% or more (e.g., e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more, or 100%).
  • an antibody e.g., competitor antibody
  • an antibody may be considered to compete for binding to GPC4 when the competitor binds to GPC4 with a similar affinity as one or more antibodies described herein, for example, under suitable assay conditions.
  • an antibody i.e., competitor antibody
  • an affinity is at least about 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) of the affinity of one or more antibodies described herein.
  • antibodies that bind to, or are capable of binding to, the same epitope as one or more antibodies described herein are provided herein.
  • antibodies that compete with one or more antibodies described herein for binding to the same epitope e.g., same peptide (linear epitope) or same surface amino acids (conformational epitope)
  • epitope competitors Such antibodies that bind the same epitope may be referred to as epitope competitors.
  • Polyclonal and monoclonal antibodies may be raised in animals (vertebrate or invertebrates, including mammals, birds and fish, including cartilaginous fish) by multiple subcutaneous (sc) or intraperitoneal (ip) injections of a relevant antigen and an adjuvant.
  • animals vertebrate or invertebrates, including mammals, birds and fish, including cartilaginous fish
  • sc subcutaneous
  • ip intraperitoneal
  • a protein or other carrier that is immunogenic in the species to be immunized e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor
  • Non-protein carriers e.g., colloidal gold
  • Animals can be immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 ⁇ g or 5 ⁇ g of the protein or conjugate (for rabbits or mice, respectively) with three volumes of Freund’s complete adjuvant and injecting the solution intradermally at multiple sites.
  • the animals are boosted with one-fifth to one-tenth of the original amount of peptide or conjugate in Freund’s complete adjuvant by subcutaneous injection at multiple sites.
  • Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
  • conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.
  • Monoclonal antibodies may be made using a hybridoma, e.g., the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by other methods such as recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).
  • a mouse or other appropriate host animal such as a hamster or macaque monkey
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (see, e.g., Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
  • the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that may contain one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • a suitable culture medium that may contain one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • HAT medium hypoxanthine, aminopterin, and thymidine
  • Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Md. USA.
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells may be determined by immunoprecipitation, by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbant assay PATENT BIOLEG-1007PCT (ELISA), or by flow cytometric analysis of cells expressing the membrane antigen.
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbant assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980).
  • the clones may be subcloned by limiting dilution procedures and grown by standard methods (see, e.g., Goding, Monoclonal Antibodies: Principles and Practice, pp.59- 103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D- MEM or RPMI-1640 medium.
  • the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • DNA encoding the monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
  • cDNA may be prepared from mRNA and the cDNA then subjected to DNA sequencing.
  • the antibody is a humanized antibody, i.e., an antibody that retains the reactivity of a non-human antibody while being less immunogenic in humans. This can be achieved, for instance, by retaining the non-human CDR regions and replacing the remaining parts of the antibody with their human counterparts. See, e.g., Morrison et al., PNAS USA, 81 :6851-6855 (1984) ; Morrison and Oi, Adv. Immunol., 44 :65-92 (1988) ; Verhoeyen et al., Science, 239 :1534-1536 (1988) ; Padlan, Molec.
  • Humanized antibodies are further described in, e.g., Winter and Milstein (1991) Nature 349:293.
  • polynucleotides comprising a first sequence coding for humanized immunoglobulin framework regions and a second sequence set coding for the desired immunoglobulin complementarity determining regions can be produced synthetically or by combining appropriate cDNA and genomic DNA segments.
  • Human constant region DNA sequences can be isolated in accordance with well-known procedures from a variety of human cells.
  • the CDRs for producing the immunoglobulins of the present disclosure can be similarly derived from monoclonal antibodies capable of specifically binding to GPC4.
  • Amino acid sequence variants of the antibody can be prepared by introducing appropriate nucleotide changes into the antibody DNA, or by peptide synthesis.
  • Such variants include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibodies for the examples herein. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics.
  • the amino acid changes also may alter post- translational processes of the humanized or variant antibody, such as changing the number or position of glycosylation sites.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • terminal insertions include an N-terminal methionyl residue or the antibody fused to an epitope tag.
  • Naturally occurring residues are divided into groups based on common side- chain properties: [0161] (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; [0162] (2) neutral hydrophilic: Cys, Ser, Thr; [0163] (3) acidic: Asp, Glu; PATENT BIOLEG-1007PCT [0164] (4) basic: Asn, Gln, His, Lys, Arg; [0165] (5) residues that influence chain orientation: Gly, Pro; and [0166] (6) aromatic: Trp, Tyr, Phe [0167] Non-conservative substitutions will entail exchanging a member of one of the above classes for another class.
  • Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antigen binding fragment such as an Fv fragment).
  • One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody. Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants is affinity maturation using phage display.
  • hypervariable region sites e.g., 6-7 sites
  • the antibody variants thus generated can be displayed in the monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle.
  • the phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as herein disclosed.
  • alanine- scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding.
  • Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one of more carbohydrate moieties found PATENT BIOLEG-1007PCT in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody. Glycosylation of antibodies is typically either N-linked and/or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue.
  • the tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the most common recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
  • O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5- hydroxylysine may also be used.
  • technology herein also pertains to immunoconjugates comprising an antibody described herein conjugated to a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (for example, a radioconjugate), or a cytotoxic drug.
  • a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (for example, a radioconjugate), or a cytotoxic drug.
  • Conjugates can be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis- (p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)- ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene).
  • SPDP N-succinimidyl-3-(2-pyridyld
  • liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Fab’ fragments of an antibody provided herein can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem. 257:286-288 (1982) via a disulfide interchange reaction. Another active ingredient is optionally contained within the liposome.
  • Enzymes or other polypeptides can be covalently bound to an antibody by techniques well known in the art such as the use of the heterobifunctional cross-linking reagents discussed above.
  • fusion proteins comprising at least the antigen binding region of an antibody provided herein linked to at least a functionally active portion of an enzyme can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature 312:604-608 (1984)).
  • any of the antibodies or antigen fragments thereof disclosed herein are conjugated or hybridized to an oligonucleotide.
  • the oligonucleotide includes a sample barcode sequence, a binding site for a primer and an anchor.
  • the oligonucleotide can be conjugated or hybridized to any of the detectable markers or labels disclosed herein.
  • the oligonucleotide is a polymeric sequence.
  • the terms “oligonucleotide” and “polynucleotide” are used interchangeably to refer to a single-stranded multimer of nucleotides from about 2 to PATENT BIOLEG-1007PCT about 500 nucleotides in length.
  • any of the oligonucleotides described herein can be synthetic, made enzymatically (e.g., via polymerization), or using a “split-pool” method.
  • any of the oligonucleotides described herein can include ribonucleotide monomers (i.e., can be oligoribonucleotides) and/or deoxyribonucleotide monomers (i.e., oligodeoxyribonucleotides).
  • any of the oligonucleotides described herein can include a combination of both deoxyribonucleotide monomers and ribonucleotide monomers in the oligonucleotide (e.g., random or ordered combination of deoxyribonucleotide monomers and ribonucleotide monomers).
  • the anchor is a defined polymer, e.g., a polynucleotide or oligonucleotide sequence, which is designed to hybridize to a complementary oligonucleotide sequence.
  • the anchor is designed for the purpose of generating a double stranded construct oligonucleotide sequence.
  • the anchor is positioned at the 3’ end of the construct oligonucleotide sequence. In other embodiments, the anchor is positioned at the 5’ end of the construct oligonucleotide sequence.
  • Each anchor is specific for its intended complementary sequence.
  • the sample barcode sequence is a polymer, e.g., a polynucleotide, which when it is a functional element, is specific for a single ligand.
  • the sample barcode sequence can be used for identifying a particular cell or substrate, e.g., Drop-seq microbead.
  • the sample barcode sequence can be formed of a defined sequence of DNA, RNA, modified bases or combinations of these bases, as well as any other polymer defined above.
  • the sample barcode sequence is about 2 to 4 monomeric components, e.g., nucleotide bases, in length.
  • the barcode is at least about 1 to 100 monomeric components, e.g., nucleotides, in length.
  • the barcode is formed of a sequence of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, PATENT BIOLEG-1007PCT 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 80, 91, 92, 93, 94, 95, 96, 97
  • sample barcode sequence is a particular barcode that can be unique relative to other barcodes.
  • sample barcode sequences can have a variety of different formats.
  • sample barcode sequences can include polynucleotide barcodes, random nucleic acid and/or amino acid sequences, and synthetic nucleic acid and/or amino acid sequences.
  • a sample barcode sequence can be attached to an analyte or to another moiety or structure in a reversible or irreversible manner.
  • a sample barcode sequences can be added to, for example, a fragment of a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sample before or during sequencing of the sample.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • Sample barcode sequences can allow for identification and/or quantification of individual sequencing-reads (e.g., a barcode can be or can include a unique molecular identifier or “UMI”).
  • Sample barcode sequences can spatially-resolve molecular components found in biological samples, for example, at single-cell resolution (e.g., a barcode can be or can include a “spatial barcode”).
  • a barcode includes both a UMI and a spatial barcode.
  • a barcode includes two or more sub-barcodes that together function as a single barcode.
  • a polynucleotide barcode can include two or more polynucleotide sequences (e.g., sub-barcodes) that are separated by one or more non-barcode sequences.
  • the binding site for a primer is a functional component of the oligonucleotide which itself is an oligonucleotide or polynucleotide sequence that provides an annealing site for amplification of the oligonucleotide.
  • the binding site for a primer can be formed of polymers of DNA, RNA, PNA, modified bases or combinations of these bases, or polyamides, etc.
  • the binding site for a primer is about 10 of such monomeric components, e.g., nucleotide bases, in length. In other embodiments, the binding site for a primer is at least about 5 to 100 monomeric components, e.g., nucleotides, in length.
  • the binding site for a primer is formed of a sequence of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, PATENT BIOLEG-1007PCT 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 80, 91, 92, 93, 94, 95, 96, 97, 98, 99 or up to 100 monomeric components, e.g., nucleic acids.
  • the binding site for a primer can be a generic sequence suitable as a annealing site for a variety of amplification technologies.
  • Amplification technologies include, but are not limited to, DNA-polymerase based amplification systems, such as polymerase chain reaction (PCR), real-time PCR, loop mediated isothermal amplification (LAMP, MALBAC), strand displacement amplification (SDA), multiple displacement amplification (MDA), recombinase polymerase amplification (RPA) and polymerization by any number of DNA polymerases (for example, T4 DNA polymerase, Sulfulobus DNA polymerase, Klenow DNA polymerase, Bst polymerase, Phi29 polymerase) and RNA-polymerase based amplification systems (such as T7-, T3-, and SP6-RNA-polymerase amplification), nucleic acid sequence based amplification (NASBA), self-sustained sequence replication (3SR), rolling circle amplification (RCA),
  • a modification can optionally be introduced into the antibodies (e.g., within the polypeptide chain or at either the N- or C-terminal), e.g., to extend in vivo half- life, such as PEGylation or incorporation of long-chain polyethylene glycol polymers (PEG).
  • a lysine residue in the sequence is conjugated to PEG directly or through a linker.
  • linker can be, for example, a Glu residue or an acyl residue containing a thiol functional group for linkage to the appropriately modified PEG chain.
  • An alternative method for introducing a PEG chain is to first introduce a Cys residue at the C-terminus or at solvent exposed residues such as replacements for Arg or Lys residues. This Cys residue is then site-specifically attached to a PEG chain containing, for example, a maleimide function.
  • covalent modifications of an antibody are introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues.
  • Example covalent modifications of polypeptides are described in U.S. Pat. No. 5,534,615, specifically incorporated herein by reference.
  • a preferred type of covalent modification of the antibody comprises linking the antibody to one of a variety of non- proteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in, e.g., U.S. Pat. Nos.
  • nucleic acids, vectors, host cells, and recombinant methods [0183] The disclosure also provides isolated nucleic acids encoding an antibody, vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody.
  • a nucleic acid herein may include one or more subsequences, each referred to as a polynucleotide.
  • nucleic acids comprising SEQ ID NO:8-14 and 16.
  • nucleic acids e.g., isolated nucleic acids
  • a nucleic acid encodes an immunoglobulin heavy chain variable domain of an antibody provided herein.
  • a nucleic acid encodes an immunoglobulin light chain variable domain of an antibody provided herein.
  • a nucleic acid encodes an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain of an antibody provided herein.
  • a nucleic acid comprises a nucleotide sequence that encodes an amino acid sequence of any one of SEQ ID Nos: 2-7, 15 or 17.
  • DNA encoding an antibody can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
  • Many vectors are available.
  • the vector components generally include, but are not limited to, one or more of the following: a signal sequence, and origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
  • Suitable host cells for cloning or expressing DNA in vectors herein can be prokaryote, yeast, or higher eukaryote cells.
  • Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis, Pseudomonas such as P. aeruginosa, and Streptomyces.
  • E. coli cloning host is E.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors. Saccharomyces cerevisiae, or common baker’s yeast, is the most commonly used among lower eukaryotic host microorganisms.
  • K. lactis K. fragilis
  • K. bulgaricus ATCC 16,045)
  • K. wickeramii ATCC 24,178
  • K. waltii ATCC 56,500
  • K. drosophilarum ATCC 36,906
  • K. thermotolerans K.
  • Suitable host cells for the expression of antibodies can also be derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells.
  • baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori (silk moth) have been identified.
  • a variety of viral strains for transfection are publicly available, e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present technology, particularly for transfection of Spodoptera frugiperda cells.
  • Suitable host cells for the expression of antibodies also may include vertebrate cells (e.g., mammalian cells). Vertebrate cells may be propagated in culture (tissue culture). Examples of useful mammalian host cell lines include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol.
  • monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).
  • Host cells may be transformed with the above-described expression or cloning vectors for antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • Host cells used to produce antibodies provided herein may be cultured in a variety of media.
  • Commercially available media such as Ham’s F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco’s Modified Eagle’s Medium ((DMEM), Sigma) are suitable for culturing the host cells.
  • any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCINTM), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
  • the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • antibodies can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163- 167 (1992) describe a procedure for isolating antibodies that are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min.
  • sodium acetate pH 3.5
  • EDTA EDTA
  • PMSF phenylmethylsulfonylfluoride
  • Cell debris can be removed by centrifugation.
  • supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • a protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • the antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique.
  • protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody.
  • Protein A can be used to purify antibodies that are based on human heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)).
  • Protein G is recommended for PATENT BIOLEG-1007PCT all mouse isotypes and for human ⁇ 3 (Guss et al., EMBO J. 5:15671575 (1986)).
  • the matrix to which the affinity ligand is attached is most often agarose, but other matrices are available.
  • Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose.
  • the antibody comprises a CH3 domain
  • Bakerbond ABX.TM. resin J. T. Baker, Phillipsburg, N.J. is useful for purification.
  • the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between, e.g., about 2.5-4.5, and may be performed at low salt concentrations (e.g., from about 0-0.25M salt).
  • elution buffer at a pH between, e.g., about 2.5-4.5
  • salt concentrations e.g., from about 0-0.25M salt.
  • any of the antibodies or antigen binding fragments thereof may be formulated in a pharmaceutical composition that is useful for a variety of purposes, including the treatment of diseases or disorders.
  • Pharmaceutical compositions comprising one or more antibodies may be administered using a pharmaceutical device to a patient in need thereof, and according to one embodiment of the technology, kits are provided that include such devices. Such devices and kits may be designed for routine administration, including self-administration, of the pharmaceutical compositions herein.
  • Therapeutic formulations of an antibody may be prepared for storage by mixing the agent or antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington’s Pharmaceutical Sciences 16 th edition, Osol, A. PATENT BIOLEG-1007PCT Ed.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues ) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino
  • the disease or disorder is associated with GPC4 expression. In some embodiments, the disease or disorder is associated with aberrant GPC4 expression. In some embodiments, the disease or disorder is associated with Natural Killer (NK), alpha beta T cells, gamma delta T cells, CD8+ T cells, monocytes, or dendritic cells. In some embodiments, the disease or disorder is associated with Natural Killer (NK) cells. In some embodiments, the disease or disorder is associated with alpha beta T cells. In some embodiments, the disease or disorder is associated with gamma delta T cells. In some embodiments, the disease or disorder is associated with CD8+ T cells. In some embodiments, the disease or disorder is associated with monocytes.
  • NK Natural Killer
  • alpha beta T cells In some embodiments, the disease or disorder is associated with gamma delta T cells. In some embodiments, the disease or disorder is associated with CD8+ T cells. In some embodiments, the disease or disorder is associated with monocytes.
  • the disease or disorder is associated with dendritic cells.
  • the disease or disorder is a cancer, an infectious disease, or an autoimmune disorder.
  • the disease or disorder is a cancer.
  • the cancer is, e.g., metastatic melanoma, a solid tumor, bladder cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, hepatic metastasis of colonic origin, papillary thyroid carcinoma, acute myeloid leukemia, or asymptomatic myeloma.
  • PATENT BIOLEG-1007PCT [0201]
  • the disease or disorder is an infectious disease.
  • the infectious disease is, e.g., human immunodeficiency virus (HIV), chronic hepatitis C, cytomegalovirus, or hantavirus.
  • the disease or disorder is an autoimmune disorder.
  • the autoimmune disorder is, e.g., Crohn’s disease, multiple sclerosis, systemic sclerosis, ocular myasthenia gravis, psoriasis or rheumatoid arthritis.
  • any of the antibodies or antigen binding fragments thereof described herein can be used to decrease the production of androgenic hormones in prostate cancer cells.
  • any of the antibodies or antigen binding fragments thereof described herein can be used to inhibit or reduce cleavage of coronavirus spike glycoproteins. In some embodiments, any of the antibodies or antigen binding fragments thereof described herein can be used to inhibit or reduce viral uptake into a host cell.
  • Formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • Formulations for in vivo administration generally are sterile. This may be accomplished for instance by filtration through sterile filtration membranes, for example.
  • Sustained-release preparations may be prepared.
  • sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the agent/antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule.
  • sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly (vinyl alcohol)), polylactides (U.S. Pat. No.
  • copolymers of L-glutamic acid and gamma ethyl-L-glutamate non-degradable ethylene-vinyl acetate
  • degradable lactic acid-glycolic acid copolymers such as the Lupron Depot® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)
  • poly-D-(-)-3-hydroxybutyric acid While polymers such as such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain PATENT BIOLEG-1007PCT hydrogels release proteins for shorter time periods.
  • encapsulated agents/antibodies When encapsulated agents/antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37 °C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thiol-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
  • antibodies provided herein are administered to a mammal, e.g., a human, in a pharmaceutically acceptable dosage form such as those discussed above, including those that may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, or by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.
  • a mammal e.g., a human
  • a pharmaceutically acceptable dosage form such as those discussed above, including those that may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, or by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.
  • the appropriate dosage of agent or antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventative or therapeutic purposes, previous therapy, the patient’s clinical history and response to the antibody, and the discretion of the attending physician.
  • the antibody is suitably administered to the patient at one time or over a series of treatments.
  • about 1 ⁇ g/kg to about 50 mg/kg (e.g., 0.1-20 mg/kg) of antibody may be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
  • a typical daily or weekly dosage might range from about 1 ⁇ g/kg to about 20 mg/kg or more, depending on the factors mentioned above.
  • the treatment is repeated until a desired suppression of disease symptoms occurs.
  • other dosage regimens may be useful.
  • the progress of this therapy is easily monitored by conventional techniques and assays, including, for example, radiographic imaging. Detection methods using the antibody to determine GPC4 levels in bodily fluids or tissues may be used to optimize patient exposure to the therapeutic antibody.
  • PATENT BIOLEG-1007PCT [0210]
  • a composition comprising an antibody herein can be administered as a monotherapy, and in some embodiments, the composition comprising the antibody can be administered as part of a combination therapy.
  • the effectiveness of the antibody in preventing or treating diseases may be improved by administering the antibody serially or in combination with another drug that is effective for those purposes, such as a chemotherapeutic drug for treatment of cancer or a microbial infection.
  • the antibody may serve to enhance or sensitize cells to chemotherapeutic treatment, thus permitting efficacy at lower doses and with lower toxicity.
  • Certain combination therapies include, in addition to administration of the composition comprising an antibody that reduces the number of -expressing cells, delivering a second therapeutic regimen selected from the group consisting of a chemotherapeutic agent, radiation therapy, surgery, and a combination of any of the foregoing.
  • Such other agents may be present in the composition being administered or may be administered separately.
  • the antibody may be suitably administered serially or in combination with the other agent or modality, e.g., chemotherapeutic drug or radiation for treatment of cancer, infection, and the like, or an immunosuppressive drug.
  • diagnostic reagents comprising an antibody described herein.
  • antibodies provided herein may be used to detect and/or purify GPC4 from bodily fluid(s) or tissues.
  • methods for detecting GPC4 For example, a method may comprise contacting a sample (e.g., a biological sample known or suspected to contain) with an antibody provided herein, and, if the sample contains GPC4, detecting GPC4:antibody complexes.
  • an antibody comprises a detectable marker or label.
  • an antibody is conjugated to a detectable marker or label. For example, for research and diagnostic PATENT BIOLEG-1007PCT applications, an antibody may be labeled with a detectable moiety.
  • Radioisotopes such as 35S, 14C, 125I, 3H, and 131I.
  • the antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al., Ed. Wiley-Interscience, New York, N.Y., Pubs. (1991), for example, and radioactivity can be measured using scintillation counting.
  • Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin, Texas Red and Brilliant VioletTM are available.
  • the fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a flow cytometer, imaging microscope or fluorimeter.
  • Various enzyme-substrate labels are available.
  • the enzyme generally catalyzes a chemical alteration of the chromogenic substrate that can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above.
  • the chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light that can be measured (using a chemilluminometer, for example) or donates energy to a fluorescent acceptor.
  • enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclicoxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxida
  • Examples of enzyme-substrate combinations include, for example: PATENT BIOLEG-1007PCT (i) Horseradish peroxidase (HRP) with hydrogen peroxidase as a substrate, where the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3’,5,5’-tetramethyl benzidine hydrochloride (TMB)); (ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and (iii) ⁇ -D-galactosidase ( ⁇ -D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl- ⁇ -D-galactosidase) or fluorogenic substrate 4-methylumbelliferyl- ⁇ -D-galactosidase.
  • HRP Horseradish peroxidase
  • OPD orthophenylene diamine
  • TMB 3,3
  • the label is indirectly conjugated with the agent or antibody.
  • an antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner.
  • the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody).
  • a small hapten e.g., digoxin
  • an anti-hapten antibody e.g., anti-digoxin antibody
  • an antibody herein is immobilized on a solid support or substrate. In some embodiments, an antibody herein is non-diffusively immobilized on a solid support (e.g., the antibody does not detach from the solid support).
  • a solid support or substrate can be any physically separable solid to which an antibody can be directly or indirectly attached including, but not limited to, surfaces provided by microarrays and wells, and particles such as beads (e.g., paramagnetic beads, magnetic beads, microbeads, nanobeads), microparticles, and nanoparticles.
  • Solid supports also can include, for example, chips, columns, optical fibers, wipes, filters (e.g., flat surface filters), one or more capillaries, glass and modified or functionalized glass (e.g., controlled-pore glass (CPG)), quartz, mica, diazotized membranes (paper or nylon), polyformaldehyde, cellulose, cellulose acetate, paper, ceramics, metals, metalloids, semiconductive materials, quantum dots, coated beads or particles, other chromatographic materials, magnetic particles; plastics (including acrylics, polystyrene, PATENT BIOLEG-1007PCT copolymers of styrene or other materials, polybutylene, polyurethanes, TEFLONTM, polyethylene, polypropylene, polyamide, polyester, polyvinylidenedifluoride (PVDF), and the like), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon, silica gel, and modified silicon, Sephadex®,
  • the solid support or substrate may be coated using passive or chemically-derivatized coatings with any number of materials, including polymers, such as dextrans, acrylamides, gelatins or agarose. Beads and/or particles may be free or in connection with one another (e.g., sintered).
  • a solid support or substrate can be a collection of particles.
  • the particles can comprise silica, and the silica may comprise silica dioxide.
  • the silica can be porous, and in certain embodiments the silica can be non-porous.
  • the particles further comprise an agent that confers a paramagnetic property to the particles.
  • Antibodies and antigen binding fragments thereof provided herein may be employed in any known assay method, such as flow cytometry, immunohistochemistry, immunofluorescence, mass cytometry (e.g., Cytof instrument), competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc. 1987). Flow cytometry and mass cytometry assays generally involve the use of a single primary antibody to specifically identify the presence of the target molecule expressed on the surface of a dispersed suspension of individual cells.
  • the dispersed cells are typically obtained from a biological fluid sample, e.g., blood, but may also be obtained from a dispersion of single cells prepared from a solid tissue sample such as spleen or tumor biopsy.
  • the primary antibody may be directly conjugated with a detectable moiety, e.g., a PATENT BIOLEG-1007PCT fluorophore such as phycoerythrin for flow cytometry or a heavy metal chelate for mass cytometry.
  • the primary antibody may be unlabeled or labeled with an undetectable tag such as biotin, and the primary antibody is then detected by a detectably labeled secondary antibody that specifically recognizes the primary antibody itself or the tag on the primary antibody.
  • the labeled cells are then analyzed in an instrument capable of single cell detection, e.g., flow cytometer, mass cytometer, fluorescence microscope or brightfield light microscope, to identify those individual cells in the dispersed population or tissue sample that express the target recognized by the primary antibody.
  • an instrument capable of single cell detection e.g., flow cytometer, mass cytometer, fluorescence microscope or brightfield light microscope.
  • flow cytometry principles may be found in, e.g., Shapiro, Practical Flow Cytometry, 4 th Edition, Wiley, 2003.
  • Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein that is detected.
  • the test sample analyte is bound by a first antibody that is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex.
  • the second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay).
  • sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.
  • the target cell population may be attached to the solid support using antibodies first attached to the support and that recognize different cell surface proteins. These first antibodies capture the cells to the support. GPC4 on the surface of the cells can then be detected by adding any of the anti-GPC4 antibodies or antigen-binding fragments thereof described herein to the captured cells and detecting the amount of the anti-GPC4 antibody or antigen binding fragment thereof attached to the cells. In certain instances, fixed and permeabilized cells may be used, and in such instances, both surface GPC4 and intracellular GPC4 may be detected. [0220] In some embodiments, any of the antibodies or antigen binding fragments thereof provided herein are formulated for immunohistochemical analysis. In some embodiments, immunohistochemical analysis includes the use of samples.
  • immunohistochemical analysis includes the use of blood and/or tissue samples.
  • the sample may be fresh or frozen or may be embedded in paraffin and fixed with PATENT BIOLEG-1007PCT a preservative such as formalin.
  • the sample is a formalin-fixed paraffin- embedded (FFPE) sample.
  • the FFPE sample is saturated with formalin (i.e. formaldehyde) and then embedded in a block of paraffin wax.
  • the FFPE sample is stable at room temperature.
  • all of the structures in the FFPE sample are preserved.
  • the intracellular and surface proteins in the FFPE sample are preserved.
  • the mRNA in the FFPE sample is preserved. In some embodiments, the mRNA, intracellular and surface proteins in the FFPE sample are preserved. In some embodiments, the surface proteins in the FFPE sample are denatured. [0221] In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 in a formalin-fixed paraffin-embedded sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 on the surface of a cell in a formalin-fixed paraffin-embedded sample.
  • any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting intracellular GPC4 in a formalin-fixed paraffin-embedded sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting intracellular GPC4, and GPC4 on the surface of a formalin-fixed paraffin-embedded sample.
  • the sample is a fresh sample that has been frozen. In some embodiments, the sample is a fresh sample that has been cryogenically frozen. In some embodiments, the sample is flash frozen. In some embodiments, the sample if flash frozen and stored at 80°C.
  • any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 in a frozen sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 on the surface of a frozen sample.
  • any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are PATENT BIOLEG-1007PCT capable of detecting intracellular GPC4 in a frozen sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting intracellular GPC4, and GPC4 on the surface of a frozen sample.
  • the antibodies herein also may be used for in vivo diagnostic assays. Generally, the antibody is labeled with a radionuclide (such as 111In, 99Tc, 14C, 131I, 125I, 3H, 32P, or 35S) so that the bound target molecule can be localized using immunoscintillography.
  • a radionuclide such as 111In, 99Tc, 14C, 131I, 125I, 3H, 32P, or 35S
  • reagents comprising anti-GPC4 agent/antibody described herein for non-diagnostic use. Also provided herein are reagents comprising anti-GPC4 agent/antibody described herein for non-therapeutic use. Also provided herein are reagents comprising anti-GPC4 agent/antibody described herein for non-diagnostic and non-therapeutic use. For example, provided herein are reagents comprising an anti-GPC4 agent/antibody described herein for use in research applications.
  • Research applications may include investigating GPC4 and its role in one or more of cell division, growth regulation, cell signaling (e.g., Wnt, BMP, FGF signaling), cancer (e.g., pancreatic cancer, colorectal cancer), and the like.
  • cell signaling e.g., Wnt, BMP, FGF signaling
  • cancer e.g., pancreatic cancer, colorectal cancer
  • methods for detecting GPC4 and/or measuring GPC4 levels in a non-biological sample may comprise contacting a non-biological sample (e.g., a laboratory research sample known or suspected to contain GPC4) with an antibody provided herein, and, if the sample contains GPC4, detecting GPC4:antibody complexes.
  • Laboratory research samples may include non-human animal models, samples from non-human animal models, cell lines, products produced by cell lines, and the like.
  • Detection of GPC4 [0225] Provided herein are antibodies and methods for detecting GPC4. In some embodiments, antibodies and methods are provided for detecting GPC4 in a biological sample. In some embodiments, the biological sample is a solid tissue, fluid, or cell. In some embodiments, the GPC4 is detected on the surface of the cell. In some embodiments, the GPC4 is detected intracellularly. In some embodiments, the detection of GPC4 is in vitro. In some embodiments, the detection of GPC4 is in vivo.
  • the solid tissue may comprise solid tissue from one or more of adipose tissue, bladder, bone, brain breast cervix, endothelium, gallbladder, kidney, liver, lung, lymph, ovary, prostate, PATENT BIOLEG-1007PCT salivary gland, stomach, testis, thyroid, urethra, uterus, vagina, and vulva.
  • the fluid comprises one or more of amniotic fluid, bile, blood, breast milk, breast fluid, cerebrospinal fluid, lavage fluid, lymphatic fluid, mucous, plasma, saliva, semen, serum, spinal fluid, sputum, tears, umbilical cord blood, urine, and vaginal fluid.
  • a single cell sequencing platform suitable for integration with the antibodies or antigen binding fragments thereof described herein is the Drop-seq method, including, but not limited to, microfluidic, plate-based, or microwell, Seq-WellTM method and adaptations of the basic protocol, and InDropTM method.
  • a single cell sequencing platform suitable for integration with the antibodies or antigen binding fragments thereof described herein is l0x genomics single cell 3’ solution or single cell V(D)J solution, either run on Chromium controller, or dedicated Chromium single cell controller.
  • Other suitable sequencing methods include Wafergen iCell8TM method, Microwell-seq method, Fluidigm CITM method and equivalent single cell products.
  • Still other known sequencing protocols useful with the antibodies or antigen binding fragments thereof described herein include BD ResolveTM single cell analysis platform and ddSeq (from Illumina® Bio-Rad® SureCellTM WTA 3’ Library Prep Kit for the ddSEQTM System, 2017, Pub. No. 1070-2016-014-B, Illumina Inc., Bio-Rad Laboratories, Inc.).
  • the antibodies or antigen binding fragments thereof described herein are useful with combinatorial indexing based approaches (sci-RNA-seqTM method or SPLiT-seqTM method) and Spatial Transcriptomics, or comparable spatially resolved sequencing approaches.
  • any of the antibodies or antigen binding fragments thereof described herein can be used to detect the presence, absence or amount of the various nucleic acids, proteins, targets, oligonucleotides, amplification products and barcodes described herein.
  • the biological sample is from a healthy subject.
  • the sample is from a subject with a disease or condition.
  • the detection of GPC4 indicates the presence or absence of a disease or disorder.
  • the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, a neurologic disorder, or an infection.
  • the cancer is the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
  • the disease or disorder is associated with GPC4 expression
  • the disease or disorder is associated with aberrant GPC4 expression.
  • the disease or disorder is associated with Natural Killer (NK), alpha beta T cells, gamma delta T cells, CD8+ T cells, monocytes, or dendritic cells.
  • NK Natural Killer
  • the disease or disorder is associated with alpha beta T cells.
  • the disease or disorder is associated with gamma delta T cells.
  • the disease or disorder is associated with CD8+ T cells.
  • the disease or disorder is associated with monocytes.
  • the disease or disorder is associated with dendritic cells.
  • the disease or disorder is a cancer, an infectious disease, or an autoimmune disorder.
  • the disease or disorder is a cancer.
  • the cancer is metastatic melanoma, a solid tumor, bladder cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, hepatic metastasis of colonic origin, papillary thyroid carcinoma, acute myeloid leukemia, or asymptomatic myeloma.
  • the disease or disorder is an infectious disease.
  • the infectious disease is human immunodeficiency virus (HIV), chronic hepatitis C, cytomegalovirus, or hantavirus.
  • the antibody or antigen binding fragment thereof can be used in a method of associating presence or abundance of GPC4 with a location of interest of a tissue sample.
  • any of the antibodies or antigen binding fragments thereof can be used in the construction of a protein library.
  • the construction of a protein library comprises sequencing.
  • the construction of a protein library comprises the use of flow cytometry.
  • a method of detecting GPC4, comprising PATENT BIOLEG-1007PCT [0239] a) contacting a sample with the antibody or antigen binding fragment thereof of any of the antibodies or antigen binding fragments thereof under conditions to bind said antibody or antigen binding fragment thereof to a GPC4 receptor on said sample, wherein the binding generates the production of a receptor/antibody or antigen binding fragment thereof of complex; b) detecting the presence of the receptor/antibody or antigen binding fragment thereof of complexes; c) wherein the detecting comprises the presence or absence of the GPC4 receptor on said sample.
  • a method of treating or preventing a disease or disorder associated with GPC4 in a subject comprising: a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof any of the antibodies or antigen binding fragments thereof, b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the antibody or antigen binding fragment thereof of any of the antibodies or antigen binding fragments thereof.
  • a method of diagnosing a disease or disorder comprising: a) isolating a sample from a subject, b) incubating the sample with the antibody or antigen binding fragment thereof of any of any of the antibodies or antigen binding fragments thereof, for a period of time sufficient to generate GPC4:anti-GPC4 complexes; c) detecting the presence or absence of the GPC4:anti-GPC4 complexes from the isolated tissue, and d) associating presence or abundance of GPC4 with a location of interest of a tissue sample.
  • the increase of GPC4 over a control level in the location of interest of the tissue sample is indicative of a disease or disorder in a subject.
  • the detection comprises hybridization of a detectable moiety to the antibody or antigen binding fragment thereof.
  • the sample is contacted with a second antibody.
  • the second antibody is an antibody comprising a detectable moiety.
  • the detectable moiety comprises an oligonucleotide.
  • the detectable moiety comprises a fluorescent label.
  • the measurement comprises sequencing.
  • the detectable moiety comprises immunofluorescence.
  • the sample is a formalin-fixed paraffin-embedded sample.
  • the sample comprises a cell.
  • the sample comprises a tissue sample.
  • XI. Kits incorporating anti- antibodies An antibody herein may be provided in a kit, for example, a packaged combination of reagents in predetermined amounts with instructions for use (e.g., instructions for performing a diagnostic assay; instructions for performing a laboratory assay).
  • the kit is a diagnostic kit configured to detect GPC4 in a sample (e.g., a biological sample).
  • the kit may include an identical isotype negative control irrelevant antibody to control for non-specific binding of the antibody.
  • the kit may include substrates and cofactors required by the enzyme (e.g., substrate precursor which provides the detectable chromophore or fluorophore). Additional additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer), and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay.
  • reagents may be provided as dry powders (e.g., lyophilized powder), including excipients that on dissolution will provide a reagent solution having the appropriate concentration.
  • dry powders e.g., lyophilized powder
  • excipients that on dissolution will provide a reagent solution having the appropriate concentration.
  • An antibody or antigen binding fragment thereof that binds GPC4 or a portion thereof comprising: a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementarity determining region 1 (CDRH1) comprising SEQ ID NO:2; (ii) a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO:3; (iii) a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO:4; and PATENT BIOLEG-1007PCT b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO:5; (ii) a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO:6; and (iii) a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO:7.
  • CDRL1 light chain complementarity determining region 1
  • the antibody or antigen binding fragment thereof of embodiment A1, wherein the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO
  • the antibody or antigen binding fragment thereof of embodiment A1 or A2, wherein the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4.
  • a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2
  • a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3
  • a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4.
  • the immunoglobulin light chain variable domain comprises: a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 5, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5; a CDRL2 comprising PATENT BIOLEG-1007PCT the sequence of amino acids set forth in SEQ ID NO: 6, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 5, or a sequence of
  • the antibody or antigen binding fragment thereof of any one of embodiments A1-A4, wherein the immunoglobulin light chain variable domain comprises: a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 5; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 6; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 7.
  • a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 5
  • a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 6
  • a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 7.
  • the CDRH1 comprises the sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2
  • the CDRH2 comprises the sequence set forth in SEQ ID NO: 3 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3
  • the CDRH3 comprises the sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that exhibits at least 80%, 81%, 82%
  • A8 The antibody or antigen binding fragment thereof of any one of embodiments A1-A7, wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15.
  • A9 The antibody or antigen binding fragment thereof of any one of embodiments A1-A8, wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in any of SEQ ID NO: 15. A10.
  • the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15; and wherein the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17.
  • A13 The antibody or antigen binding fragment thereof of any one of embodiments A1-A12, wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15; and wherein the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17.
  • A14 The antibody or antigen binding fragment thereof of any one of embodiments A1-A13, comprising one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain.
  • A15 The antibody or antigen binding fragment thereof of any one of embodiments A1-A13, comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
  • A17. The antibody or antigen binding fragment thereof of any one of embodiments A1-A16, wherein the antibody or antigen binding fragment thereof is humanized.
  • A18. The antibody or antigen binding fragment thereof of any one of embodiments A1-A17, wherein the antibody or antigen binding fragment thereof is conjugated.
  • PATENT BIOLEG-1007PCT A19.
  • A20. The antibody or antigen binding fragment thereof of embodiment A19, wherein the oligonucleotide comprises a sample barcode sequence.
  • the antibody or antigen binding fragment thereof of embodiment A22, wherein the detectable marker or label comprises a detectable moiety.
  • PATENT BIOLEG-1007PCT A28 The antibody or antigen binding fragment thereof of any one of embodiments A1-A27, that is a single chain fragment. A29.
  • A32. The antibody or antigen binding fragment of embodiment A30 or A31, wherein the sample comprises immune cells.
  • the antibody or antigen binding fragment of embodiment A32 or A33 wherein the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs).
  • pDCs plasmacytoid dendritic cells
  • mDCs myeloid dendritic cells
  • innate lymphoid cells mast cells
  • eosinophils basophils
  • natural killer cells and peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • the antibody or antigen binding fragment thereof of embodiment A35 wherein the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, a neurologic disorder, or an infection.
  • PATENT BIOLEG-1007PCT A37 The antibody or antigen binding fragment thereof of embodiment A36, wherein the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, breast, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
  • the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, breast, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancrea
  • the antibody or antigen binding fragment thereof of any one of embodiments A30-A37, wherein the detection of GPC4 is on the surface of a cell.
  • the antibody or antigen binding fragment thereof of any one of embodiments A30-A37, wherein the detection of GPC4 is intracellular.
  • A45. The antibody or antigen binding fragment thereof of any one of embodiments A1-A44, wherein the antibody or antigen binding fragment thereof binds to a GPC4 expressing cell. PATENT BIOLEG-1007PCT A46.
  • composition of embodiment C1, wherein the antibody or antigen binding fragment thereof of is used as an adjuvant or in conjunction with an adjuvant.
  • D1. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the antibody or antigen binding fragment thereof of any of embodiments A1-A45.
  • D2. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any of embodiments A1-A45.
  • D3. A recombinant expression vector comprising the isolated nucleic acid of embodiment D1 or D2. PATENT BIOLEG-1007PCT D4.
  • a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of embodiments A1-A45, and the second expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any one of embodiments A1-A45.
  • D5. The recombinant expression vector of embodiment D4, wherein the first and second expression cassettes comprise a promoter.
  • D6. A host cell transfected with the recombinant expression vector of embodiments D3-D5. E1.
  • An agent-drug conjugate comprising antibody or antigen binding fragment thereof of any of embodiments A1-A45.
  • E2. A composition comprising the antibody-drug conjugate of embodiment E1, and a pharmaceutically acceptable carrier.
  • F1. A method of detecting GPC4 comprising a) contacting a sample with the antibody or antigen binding fragment thereof of any of embodiments A1-A45, under conditions to bind said antibody or antigen binding fragment thereof to a GPC4 receptor on said sample, wherein the binding generates the production of a receptor/antibody or antigen binding fragment thereof complex; b) detecting the presence of the receptor/antibody or antigen binding fragment thereof complexes; c) wherein the detecting comprises the presence or absence of the GPC4 receptor on said sample.
  • a method of treating or preventing a disease or disorder associated with GPC4 in a subject comprising: PATENT BIOLEG-1007PCT a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof of any of embodiments A1-A45, b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the antibody or antigen binding fragment thereof of any of embodiments A1-A45.
  • PATENT BIOLEG-1007PCT a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof of any of embodiments A1-A45, b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the antibody or antigen binding fragment thereof of
  • a method of diagnosing a disease or disorder comprising: a) isolating a sample from a subject b) incubating the sample with the antibody or antigen binding fragment thereof of any of embodiments A1-A45, for a period of time sufficient to generate GPC4:anti-GPC4 complexes; c) detecting the presence or absence of the GPC4:anti-GPC4 complexes from the isolated tissue, and d) associating presence or abundance of GPC4 with a location of interest of a tissue sample.
  • F4 The method of embodiment F3, wherein the increase of GPC4 over a control level in the location of interest of the tissue sample is indicative of a disease or disorder in a subject.
  • the method of embodiment F10, wherein the second antibody is an antibody comprising a detectable moiety.
  • F12 The method of embodiment F11, wherein the detectable moiety comprises an oligonucleotide.
  • F13 The method of embodiment F11, wherein the detectable moiety comprises a fluorescent label.
  • F14 The method of any one of embodiments F1-F9, wherein the detecting comprises sequencing.
  • F15 The method of embodiment F11, wherein the detectable moiety comprises immunofluorescence.
  • F16 The method of any one of embodiments F1-F13 and F15, wherein the sample is a formalin-fixed paraffin-embedded sample.
  • F17 The method of any one of embodiments F1-F16, wherein the sample comprises a cell.
  • F18 The method of any one of embodiments F1-F16, wherein the sample comprises a cell.
  • pDCs plasmacytoid dendritic cells
  • mDCs myeloid dendritic cells
  • innate lymphoid cells mast cells
  • eosinophils basophils
  • natural killer cells and peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood
  • any one of embodiments F1-F16 wherein the sample comprises a tissue or cells associated with a disease or disorder.
  • F22. The method of embodiment F21, wherein the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, or an infection.
  • the disease or disorder is chosen from non-viral cancers, virus-associated cancers, cancers associated with HBV infection, cancers associated with Epstein-Barr virus (EBV) infection, cancers associated with polyomavirus infection, erythema nodosum leprosum (ENL), autoimmune diseases, autoimmune inflammation, autoimmune thyroid diseases, B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin’s Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, B- cell leukemias, myelodysplastic syndromes, solid phase cancer, herpes viral infections, and/or rejection of transplanted tissues or organs.
  • EBV Epstein-Barr virus
  • G1 The antibody or antigen binding fragment thereof of any of embodiments A1-A45, for use in a method of associating presence or abundance of GPC4 with a location of interest of a tissue sample.
  • G2. The antibody or antigen binding fragment thereof of any of embodiments A1-A45, for use in a method of detecting GPC4 in a tissue sample.
  • the antibody or antigen binding fragment thereof embodiment G1 or G2, wherein the method comprises generating a nucleic acid molecule comprising all or a portion of the sequence of the oligonucleotide or a complement thereof.
  • G4. The antibody or antigen binding fragment thereof of any of embodiments A1-A45, for use in the construction of a protein library.
  • the antibody or antigen binding fragment thereof of embodiment G4, wherein the construction of a protein library comprises sequencing.
  • the antibody or antigen binding fragment thereof of embodiment G4, wherein the construction of a protein library comprises the use of flow cytometry.
  • EXAMPLES [0245] The examples set forth below illustrate certain embodiments and do not limit the technology.
  • EXAMPLE 1 CREATION AND CHARACTERIZATION OF ANTI-GPC4 HYBRIDOMAS
  • the Hybridomas that secrete monoclonal antibodies that react with GPC4 as expressed in vivo were prepared as described in this Example.
  • a common strain of laboratory mice e.g., BALB/c or C57/Bl6, or rats, e.g., Sprague Dawley, were immunized with a GPC4 immunogen.
  • hybridomas were formed using standard protocols to fuse myeloma cells with spleen and to drain lymph node cells harvested from the animals.
  • the culture supernatants were tested against GPC4-expressing cell transfectants, e.g., HEK 293 or RBL, by flow cytometry.
  • the Exemplary clones were selected based on strong reactivity against immune cells that express GPC4 (e.g., lymphocytes) but no appreciable reactivity against other blood cell populations, detection of GPC4 on the cell surface of immune cells (e.g., lymphocytes), and/or intracellular detection of GPC4.
  • EXAMPLE 2 SEQUENCING OF THE ANTI-GPC4 ANTIBODY VARIABLE REGIONS [0249] Cells from well-performing anti-GPC4 hybridoma cell lines (described in Example 1, above) were grown in standard mammalian tissue culture media.
  • exemplary anti-GPC4 antibod AB2 was assessed on cells from a human cell line exhibiting a phenotype resembling committed CNS neuronal precursor cells (NTERA-2; ATCC® CRL-1973 TM ).
  • NTERA-2 a phenotype resembling committed CNS neuronal precursor cells
  • ANTERA-2 cells were grown in DMEM media supplemented with 10% FBS in T75 culture flask, to about 80% confluency.
  • Exemplary generated PE-conjugated anti-GPC4 antibody was added at a concentration of 1 ⁇ g/1 million cells, and allowed to incubate for 15 minutes.
  • a commercially available antibody (CAb) was used as control. Cells where washed with FACS buffer and analyzed on a BD LSRII flow cytometer.
  • AB2 positively stained NTERA-2 cells.
  • AB2 was further assessed on a cell line that does not express GPC4 (U-937; ATCC® CRL-1539.2 TM ).
  • GPC4 U-937; ATCC® CRL-1539.2 TM .
  • AB2 demonstrated negative staining on U-937 cells.
  • anti-GPC4 antibody AB2 or a commercially available antibody were tested for cross-reactivity with GPC homologues GPC1 (45% homology), GPC2 (42% homology) and GPC6 (65% homology), using cell lines known to express each respective GPC, including A431 cells (GPC1), Molt4 cells (GPC2) and HepG2 cells (GPC6).
  • GPC1 45% homology
  • GPC2 42% homology
  • GPC6 65% homology
  • cell lines known to express each respective GPC including A431 cells (GPC1), Molt4 cells (GPC2) and HepG2 cells (GPC6).
  • anti-GPC4 antibody AB2 did not show cross reactivity with GPC1 (FIG. 3A), GPC2 (FIG. 3B) or GPC6 (FIG. 3C).
  • EXAMPLE 4 ASSESSMENT OF GPC4 MEDIATED WNT3A SIGNALING [0256] This example describes a functional assay based on the ability of exemplary generated anti-GPC4 antibody AB2 to block GPC4-mediated enhancement of Wnt3a signaling. In another experiment, AB2 was assessed for its ability to block Wnt3a signaling in NTERA-2 cells.
  • NTERA-2 cells were cultured in black 96 well plates with glass bottom to about 80% confluency after which 5 ⁇ g/mL of exemplary antibody AB2, a commercially available antibody (CAb) or isotype control were added in culture media for 15 minutes. After antibody incubation, cells were stimulated with 200ng/ml recombinant human Wnt3a (R&D Systems) for 3h or left unstimulated. Cells were fixed using True Nuclear Transcription Factor Fix (BioLegend True Nuclear Buffer Set, cat# 424401) 1x working solution for 30 minutes and washed twice with True Nuclear Perm Buffer (BioLegend True Nuclear Buffer Set, cat# 424401).
  • AB2 is capable of reducing Wnt3a-induced translocation of beta-catenin to the nucleus.
  • exemplary antibody AB2 was capable of reducing Wnt3a induced beta- catenin translocation to the nucleus, whereas the commercially available antibody did not demonstrate this effect.
  • exemplary antibody AB2 was capable of reducing Wnt3a induced beta-catenin translocation to the nucleus at all concentrations tested, whereas the commercially available antibody did not demonstrate this effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are antibodies, including antigen-binding fragments thereof, that bind all or a portion thereof of GPC4, compositions containing such antibodies or antigen-binding fragments thereof, combinations of such antibodies or antigen-binding fragments thereof and methods of use. In particular embodiments, the antibodies or antigen-binding fragments thereof are used in methods of detecting the presence of GPC4 through imaging, including molecular, medical and diagnostic imaging.

Description

PATENT BIOLEG-1007PCT ANTI-GPC4 ANTIBODIES RELATED PATENT APPLICATION(S) This patent application claims the benefit of U.S. provisional patent application no. 63/540,896 filed on September 27, 2023, entitled ANTI-GPC4 ANTIBODIES, naming Susannah Kassmer et al. as inventors, and designated by attorney docket no. 102738-1379830-003000US. The entire content of the foregoing patent application is incorporated herein by reference for all purposes, including all text, tables and drawings. FIELD [0001] The present disclosure relates, in some aspects, to antibodies or antigen-binding fragments thereof that bind Glypican 4 (GPC4), as well as methods, systems and kits for detection of GPC4. In certain aspects, the present disclosure relates to antibodies or antigen binding fragments thereof for use in determining levels of GPC4 in a sample containing or suspected of containing GPC4. In some aspects, the present disclosure relates to antibodies or antigen-binding fragments thereof for use in diagnosing or treating an individual with or suspected of having a disease or disorder associated with GPC4. BACKGROUND [0002] Glypican 4 (GPC4) is a glypican, a family of cell-surface heparan sulfate proteoglycans (HSPG) potentially involved in cell division and growth regulation. HSPG family members may act as a reservoir or modulator for several growth factors and signaling molecules. HSPG molecules contain a core protein anchored to the cytoplasmic membrane via a GPI anchor. HSPGs function as coreceptors or modulators of Wnt activation. GPCs are R-spondin co-receptors that regulate Wnt signaling. GPC3 enhances Wnt signaling, GPC6 inhibits Wnt signaling. Wnt3a binding to frizzled and LRP6 stabilizes cytosolic beta-catenin, which translocates to the nucleus to activate TCF/LEF transcription factors. GPC4 expressing cells show a higher activation of the beta-catenin pathway in response to Wnt3a. Knockdown of GPC4 suppresses activation of the beta-catenin pathway. GPC4 is upregulated in pancreatic cancer and colorectal cancer, and is associated with resistance to fluorouracil (5FU) chemotherapy. PATENT BIOLEG-1007PCT BRIEF SUMMARY [0003] Provided herein are antibodies, including antigen-binding fragments thereof, that bind all or a portion thereof of GPC4, compositions containing such antibodies or antigen-binding fragments thereof, combinations of such antibodies or antigen-binding fragments thereof and methods of use. In particular embodiments, the antibodies or antigen-binding fragments thereof are used in methods of detecting the presence of GPC4 through imaging, including molecular, medical and diagnostic imaging. [0004] Provided herein are antibodies or antigen-binding fragments thereof, including those that specifically bind to a GPC4, such as a human GPC4, wherein the antibodies or antigen- binding fragments contain particular complementarity determining regions (CDRS), including heavy chain CDRS (i.e., CDRH1, CDRH2, and/or CDRH3) and light chain CDRS (i.e., CDRL1, CDRL2, and/or CDRL3), such as any described herein. in some embodiments, the antibody or antigen-binding fragment thereof includes a heavy chain variable domain and a light chain variable domain, such as any described herein. [0005] Provided herein is an antibody or antigen binding fragment thereof that binds GPC4 or a portion thereof, comprising a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementarity determining region 1 (CDRH1) comprising SEQ ID NO:2; (ii) a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO:3; (iii) a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO:4; and b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO:5; (ii) a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO:6; and (iii) a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO:7. [0006] In some embodiments, the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; PATENT BIOLEG-1007PCT and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:4. [0007] In some embodiments, the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4. [0008] In some embodiments, the immunoglobulin light chain variable domain comprises: a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 5, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 6, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 7, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 7. [0009] In some embodiments, the immunoglobulin light chain variable domain comprises: a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 5; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 6; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 7. [0010] In some embodiments, the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 2; the CDRH2 comprises the sequence of amino acids set forth in SEQ ID NO: 3; the CDRH3 comprises the sequence of amino acids set forth in SEQ ID NO: 4; the CDRL1 comprises the sequence of amino acids set forth in SEQ ID NO: 5; the CDRL2 comprises the sequence of amino acids set forth in SEQ ID NO: 6; and the CDRL3 comprises the sequence of amino acids set forth in SEQ ID NO: 7. PATENT BIOLEG-1007PCT [0011] In some embodiments, the CDRH1 comprises the sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2, the CDRH2 comprises the sequence set forth in SEQ ID NO: 3 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; the CDRH3 comprises the sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 4; the CDRL1 comprises the sequence set forth in SEQ ID NO: 5 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5, the CDRL2 comprises the sequence set forth in SEQ ID NO: 6 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 7 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 7. [0012] In some embodiments, the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15. [0013] In some embodiments, the immunoglobulin heavy chain comprises the amino acid sequence set forth in any of SEQ ID NO: 15. [0014] In some embodiments, the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17. [0015] In some embodiments, the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17. PATENT BIOLEG-1007PCT [0016] In some embodiments, the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17. [0017] In some embodiments, the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17. [0018] In some embodiments, the antibody or antigen binding fragment comprises one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain. [0019] In some embodiments, the antibody or antigen binding fragment comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. [0020] In some embodiments, the antibody or antigen binding fragment thereof is isolated. [0021] In some embodiments, the antibody or antigen binding fragment thereof is humanized. [0022] In some embodiments, the antibody or antigen binding fragment thereof is conjugated. [0023] In some embodiments, the antibody or antigen binding fragment further comprises an oligonucleotide. In some embodiments, the oligonucleotide comprises a sample barcode sequence. In some embodiments, the oligonucleotide comprises a binding site for a primer and an anchor. [0024] In some embodiments, the antibody or antigen binding fragment thereof is conjugated to a detectable marker or label. In some embodiments, the detectable marker or label is conjugated directly to the antigen or antigen binding fragment thereof. In some embodiments, the detectable marker or label is conjugated to the oligonucleotide. In some embodiments, the PATENT BIOLEG-1007PCT detectable marker or label comprises a detectable moiety. In some embodiments, the detectable moiety is a radioisotope, fluorescent label or enzyme-substrate label. [0025] In some embodiments, the antibody or antigen binding fragment thereof is non- diffusively immobilized on a solid support. [0026] In some embodiments, the disclosure provides an isolated antibody that specifically binds to GPC4, wherein the isolated antibody competes for binding to GPC4with an antibody described herein. [0027] In some embodiments of the antibodies described herein, the antibody is a monoclonal antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody comprises one or more human framework regions. In some embodiments, the antibody or antigen binding fragment is a single chain fragment. In some embodiments, the single chain fragment is a single chain variable fragment (scFv). [0028] In some aspects, provided herein is a combination of antibodies or antigen-binding fragments thereof, wherein the combination comprises two or more anti-GPC4 antibodies or antigen-binding fragments described herein. In some embodiments, the two or more antibodies or antigen-binding fragments comprise one or more first antibody or antigen-binding fragment thereof that binds to a first epitope or region within GPC4; and one or more second antibody or antigen-binding fragment thereof that binds to a second epitope or region within GPC4. In some further embodiments, the one or more first antibody or antigen-binding fragments thereof, and the one or more second antibody or antigen-binding fragments thereof bind to a non-overlapping epitope or region of GPC4 (e.g., human GPC4) and/or do not compete for binding to GPC4. Further, in some embodiments, the antibody is conjugated to a detectable marker or label. In some embodiments, the at least one of the antibodies or antigen-binding fragments of the combination of two or more anti- GPC4 antibodies or antigen-binding fragments described herein, optionally the one or more first antibody or antigen-binding fragment thereof or the one or more second antibody or antigen-binding fragment thereof, is conjugated to a label. In some embodiments, the at least one of the antibodies or antigen-binding fragments, optionally the one or more first antibody or antigen-binding fragment thereof or the one or more second antibody or antigen-binding fragment thereof, is attached or immobilized to a solid support. In some embodiments, the one or more first or second antibody or antigen-binding fragment is attached PATENT BIOLEG-1007PCT or immobilized to a solid support and the other of the one or more first or second antibody or antigen-binding fragment is conjugated to a label. In some embodiments, the label is a fluorescent dye, a fluorescent protein, a radioisotope, a chromophore, a metal ion, gold particles, silver particles, magnetic particles, a polypeptide, an enzyme, streptavidin, biotin, a luminescent compound, or an oligonucleotide. In some embodiments, the solid support is a bead, a column, an array, an assay plate, a microwell, a stick, a filter, or a strip. In certain embodiments, the antibody is non-diffusively immobilized on a solid support. In a further embodiment, the device is a rapid detection device or a rapid diagnostic device. [0029] In another aspect, the disclosure features an isolated nucleic acid encoding an isolated antibody described herein. The disclosure also provides an expression vector comprising the nucleic acid described herein. Further, the disclosure also provides an isolated host cell comprising the expression vector described herein. [0030] In some embodiments, the antibody or antigen binding fragment thereof provided herein can be used in the detection of GPC4 in a sample. In some embodiments, the antibody or antigen binding fragment thereof binds to a cell expressing GPC4 in a sample. In some embodiments, the sample comprises immune cells. In some embodiments, the sample comprises a heterogenous population of immune cells. In some embodiments, the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs). In some embodiments, the sample comprises a cell with a disease or disorder. In some embodiments, the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, a neurologic disorder, or an infection. In some embodiments, the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, breast, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma. In some embodiments, the detection includes the use of a single antibody or antigen binding fragment thereof to bind a portion of GPC4. In some embodiments, the detection includes the use of two antibody or antigen binding fragments thereof, each capable of binding to a different portion of GPC4. In some embodiments, the detection of GPC4 is on the surface of a cell. In some embodiments, the detection of GPC4 is PATENT BIOLEG-1007PCT intracellular. In some embodiments, the detection of GPC4 indicates the presence or absence of a disease or disorder. In some embodiments, the detection is performed in vitro. In some embodiments, the detection is performed in vivo. [0031] In some embodiments, the antibody or antigen binding fragment thereof binds to a GPC4 expressing cell. [0032] Provided herein is a diagnostic antibody or antigen binding fragment thereof which includes any of the antibody or antigen binding fragment thereof described herein. Provided herein is a kit comprising the antibody or antigen binding fragment thereof of any one of embodiments described herein. In some embodiments, the kit is a diagnostics kit configured to detect GPC4 in a biological sample. [0033] Provided herein is a composition comprising the antibody or antigen binding fragment thereof of any of the embodiments described herein and a pharmaceutically acceptable excipient. In some embodiments, the antibody or antigen binding fragment thereof of is used as an adjuvant or in conjunction with an adjuvant. [0034] Provided herein is an isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the agent of any of embodiments described herein. Also provided herein is an isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin light chain variable domain of the agent of any of the embodiments described herein. The sequence encoding the immunoglobulin heavy chain variable domain of the agent of any of embodiments described herein and the sequence encoding the immunoglobulin light chain variable domain of the agent of any of the embodiments described herein can be on the same isolated nucleic acid or different isolated nucleic acids. Thus, also provided herein is an isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any of the embodiments described herein. [0035] Provided herein is a recombinant expression vector comprising the isolated nucleic acid of any of the embodiments described herein. Provided herein is a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first PATENT BIOLEG-1007PCT expression cassette includes a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of the embodiments described herein and the second expression cassette includes a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any one of any of the embodiments described herein. [0036] Provided herein is a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette includes a nucleic acid molecule comprising the nucleotide sequence of any of the embodiments described herein, and the second expression cassette includes a nucleic acid molecule comprising the nucleotide sequence of any of the embodiments described herein. In some embodiments, the first and second expression cassettes include a promoter. [0037] Provided herein is a host cell transfected with the recombinant expression vector of any of the embodiments described herein. [0038] Provided herein is an agent-drug conjugate comprising antibody or antigen binding fragment thereof of any of the embodiments described herein. Provided herein is a composition comprising the antibody-drug conjugate and a pharmaceutically acceptable carrier. [0039] Provided herein is a method of detecting GPC4 comprising a) contacting a sample with the antibody or antigen binding fragment thereof of any of the embodiments described herein, under conditions to bind said antibody or antigen binding fragment thereof to a GPC4 receptor on said sample, wherein the binding generates the production of a receptor/antibody or antigen binding fragment thereof complex; b) detecting the presence of the receptor/antibody or antigen binding fragment thereof complexes; and c) wherein the detecting comprises the presence or absence of the GPC4 receptor on said sample. [0040] Provided herein is a method of treating or preventing a disease or disorder associated with GPC4 in a subject, comprising a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof of any of the embodiments described herein; b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a PATENT BIOLEG-1007PCT disease or disorder; and c) administering to the subject the antibody or antigen binding fragment thereof of any of the embodiments described herein. [0041] Provided herein is a method of diagnosing a disease or disorder, comprising a) isolating a sample from a subject; b) incubating the sample with the antibody or antigen binding fragment thereof of any of the embodiments described herein, for a period of time sufficient to generate GPC4:anti-GPC4 complexes; c) detecting the presence or absence of the GPC4:anti-GPC4 complexes from the isolated tissue, and d) associating presence or abundance of GPC4 with a location of interest of a tissue sample. In some embodiments, the increase of GPC4 over a control level in the location of interest of the tissue sample is indicative of a disease or disorder in a subject. [0042] In some embodiments, the method is performed in vitro. In some embodiments, the method is performed in vivo. In some embodiments, the detection comprises intracellular detection. In some embodiments, the detection comprises detection on the surface of a cell. In some embodiments, the detection comprises hybridization of a detectable moiety to the antibody or antigen binding fragment thereof. In some embodiments, the sample is contacted with a second antibody. In some embodiments, the second antibody is an antibody comprising a detectable moiety. In some embodiments, the detectable moiety comprises an oligonucleotide. In some embodiments, the detectable moiety comprises a fluorescent label. In some embodiments, the detecting comprises sequencing. In some embodiments, the detectable moiety comprises immunofluorescence. In some embodiments, the sample is a formalin-fixed paraffin- embedded sample. In some embodiments, the sample comprises a cell. In some embodiments, the sample comprises a tissue sample. [0043] In some embodiments, the sample comprises immune cells. In some embodiments, the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs). In some embodiments, the sample comprises a tissue or cells associated with a disease or disorder. In some embodiments, the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, or an infection. In some embodiments, the disease or disorder is chosen from non-viral cancers, virus-associated cancers, cancers associated PATENT BIOLEG-1007PCT with HBV infection, cancers associated with Epstein-Barr virus (EBV) infection, cancers associated with polyomavirus infection, erythema nodosum leprosum (ENL), autoimmune diseases, autoimmune inflammation, autoimmune thyroid diseases, B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin's Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, B-cell leukemias, myelodysplastic syndromes, solid phase cancer, herpes viral infections, and/or rejection of transplanted tissues or organs. [0044] In some embodiments, the antibody or antigen binding fragment thereof can be used in a method of associating presence or abundance of GPC4 with a location of interest of a tissue sample. [0045] In some embodiments, the antibody or antigen binding fragment thereof can be used in a method of detecting GPC4 in a tissue sample. In some embodiments, the method comprises generating a nucleic acid molecule comprising all or a portion of the sequence of the oligonucleotide or a complement thereof. [0046] In some embodiments, the antibody or antigen binding fragment thereof can be used in the construction of a protein library. In some embodiments, the construction of a protein library comprises sequencing. In some embodiments, the construction of a protein library comprises the use of flow cytometry. BRIEF DESCRIPTION OF THE DRAWINGS [0047] The drawings illustrate certain embodiments of the technology and are not limiting. For clarity and ease of illustration, the drawings are not made to scale and, in some instances, various aspects may be shown exaggerated or enlarged to facilitate an understanding of particular embodiments. [0048] Figure 1 are graphs showing GPC4 antibody AB2 positively stained NTERA-2 cells. [0049] Figure 2 are graphs showing GPC4 antibody AB2 demonstrated negative staining on U- 937 cells. PATENT BIOLEG-1007PCT [0050] Figures 3A-3C are graphs showing GPC4 antibody AB2 did not cross react with GPC1 (FIG. 3A), GPC2 (FIG. 3B) or GPC6 (FIG. 3C). [0051] Figure 4 is a bar graph showing GPC4 antibody AB2 is capable of reducing Wnt3a- induced translocation of beta-catenin to the nucleus. [0052] Figure 5 are images showing GPC4 antibody AB2 is capable of reducing Wnt3a induced beta-catenin translocation to the nucleus, whereas the commercially available GPC4 antibody did not demonstrate this effect. [0053] Figure 6 is a bar graph showing GPC4 antibody AB2 is capable of reducing Wnt3a induced beta-catenin translocation to the nucleus at all concentrations tested, whereas the commercially available antibody did not demonstrate this effect. DETAILED DESCRIPTION [0054] Provided herein are antibodies that bind GPC4, including antigen-binding fragments thereof, nucleic acids encoding such antibodies and antigen-binding fragments, and cells, such as recombinant cells for expressing and production of these antibodies and antigen-binding fragments that can bind to GPC4 under physiological and/or in vitro conditions. Also provided are methods of producing and using the antibodies and antigen-binding fragments such as in methods for detecting GPC4 in a sample from an individual, including methods for laboratory/ research purposes (e.g., flow cytometry, ELISA, and/or Western blot), and/or for the use and treatment and/or prevention of various diseases or disorders through the delivery of pharmaceutical or other compositions that contain such antibodies or antigen-binding fragments thereof. [0055] All references cited herein, including patent applications, patent publications, and scientific literature and databases, are herein incorporated by reference in their entirety for all purposes to the same extent as if each individual reference were specifically and individually indicated to be incorporated by reference. [0056] For clarity of disclosure, and not by way of limitation, the detailed description is divided into the subsections that follow. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. PATENT BIOLEG-1007PCT I. Definitions [0057] Unless defined otherwise, all terms of art, notations and other technical and scientific terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. It is to be understood that the disclosure provided herein is not limited to particular compositions or biological systems. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not to be construed as limiting. [0058] The term “antibody” as used herein includes antigen binding fragments thereof that retain binding specificity. For example, there are a number of well characterized antigen binding fragments. Thus, for example, pepsin digests an antibody C-terminal to the disulfide linkages in the hinge region to produce F(ab)’2, a dimer of Fab which itself is a light chain joined to VH- CH1 by a disulfide bond. The F(ab)’2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab’)2 dimer into an Fab’ monomer. The Fab’ monomer is essentially an Fab with part of the hinge region (see, Fundamental Immunology, W.E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antigen binding fragments). While various antigen binding fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that fragments can be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein also includes antigen binding fragments either produced by the modification of whole antibodies or synthesized using recombinant DNA methodologies. [0059] An antibody as described herein can consist of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, PATENT BIOLEG-1007PCT respectively. In some embodiments, the antibody is IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgM, IgA, IgD, or IgE. [0060] A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively. [0061] In an antibody, substitution variants have at least one amino acid residue removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but framework alterations are also contemplated. Examples of conservative substitutions are described herein. [0062] Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a β-sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side- chain properties: (1) Non-polar: Norleucine, Met, Ala, Val, Leu, Ile; (2) Polar without charge: Cys, Ser, Thr, Asn, Gln; (3) Acidic (negatively charged): Asp, Glu; (4) Basic (positively charged): Lys, Arg; (5) Residues that influence chain orientation: Gly, Pro; and (6) Aromatic: Trp, Tyr, Phe, His. Non-conservative substitutions are made by exchanging a member of one of these classes for another class. [0063] One type of substitution that can be made is to change one or more cysteines in the antibody, which may be chemically reactive, to another residue, such as, without limitation, PATENT BIOLEG-1007PCT alanine or serine. For example, there can be a substitution of a non-canonical cysteine. The substitution can be made in a CDR or framework region of a variable domain or in the constant region of an antibody. In some embodiments, the cysteine is canonical (e.g., involved in di- sulfide bond formation). Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant cross-linking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability, particularly where the antibody is an antigen binding fragment such as an Fv fragment. [0064] Antibodies include VH-VL dimers, including single chain antibodies (antibodies that exist as a single polypeptide chain), such as single chain Fv antibodies (sFv or scFv) in which a variable heavy and a variable light domain are joined together (directly or through a peptide linker) to form a continuous polypeptide. The single chain Fv antibody is a covalently linked VH-VL which may be expressed from a nucleic acid including VH- and VL- encoding sequences either joined directly or joined by a peptide-encoding linker (e.g., Huston, et al. Proc. Nat. Acad. Sci. USA, 85:5879-5883, 1988). While the VH and VL are connected to each as a single polypeptide chain, the VH and VL domains associate non-covalently. Alternatively, the antibody can be another fragment. Other fragments can also be generated, e.g., using recombinant techniques, as soluble proteins or as fragments obtained from display methods. Antibodies can also include diantibodies and miniantibodies. Antibodies of the disclosure also include heavy chain dimers, such as antibodies from camelids. In some embodiments an antibody is dimeric. In other embodiments, the antibody may be in a monomeric form that has an active isotype. In some embodiments the antibody is in a multivalent form, e.g., a trivalent or tetravalent form. [0065] An “antibody fragment” or “antigen binging fragment thereof” comprises a portion of an intact antibody, the antigen binding and/or the variable region of the intact antibody. Antibody fragments or antigen binding fragments thereof, include but are not limited to Fab fragments, Fab’ fragments, F(ab’)2 fragments, Fv fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fd’ fragments; diabodies; linear antibodies (see U.S. Pat. No.5,641,870, Example 2; Zapata et al, Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules, including single-chain Fvs (scFv) or single-chain Fabs (scFab); antigen-binding fragments of any of the above and multispecific antibodies from antibody fragments. PATENT BIOLEG-1007PCT [0066] “Fv” is composed of one heavy- and one light-chain variable region domain linked by non-covalent association. From the folding of these two domains emanate six complementarity determining regions (CDR) (3 in each from the heavy and light chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although, in some cases, at a lower affinity than the entire binding site. [0067] “dsFv” refers to an Fv with an engineered intermolecular disulfide bond, which stabilizes the VH-VL pair. [0068] An “Fd fragment” is a fragment of an antibody containing a variable domain (VH) and one constant region domain (CHI) of an antibody heavy chain. [0069] A “Fab fragment” is an antibody fragment that results from digestion of a full-length immunoglobulin with papain, or a fragment having the same structure that is produced synthetically, e.g., by recombinant methods. A Fab fragment contains a light chain (containing a VL and CL) and another chain containing a variable domain of a heavy chain (VH) and one constant region domain of the heavy chain (CHI). [0070] A “F(ab’)2 fragment” is an antibody fragment that results from digestion of an immunoglobulin with pepsin at pH 4.0-4.5, or a fragment having the same structure that is produced synthetically, e.g., by recombinant methods. The F(ab’)2 fragment essentially contains two Fab fragments where each heavy chain portion contains an additional few amino acids, including cysteine residues that form disulfide linkages joining the two fragments. [0071] A “Fab’ fragment” is a fragment containing one half (one heavy chain and one light chain) of the F(ab’)2 fragment. [0072] An “Fd’ fragment” is a fragment of an antibody containing one heavy chain portion of a F(ab’)2 fragment. [0073] An “Fv’ fragment” is a fragment containing only the VH and VL domains of an antibody molecule. PATENT BIOLEG-1007PCT [0074] An “scFv fragment” refers to an antibody fragment that contains a variable light chain (VL) and variable heavy chain (VH), covalently connected by a polypeptide linker in any order. The linker is of a length such that the two variable domains are bridged without substantial interference. Exemplary linkers are (Gly-Ser)n residues with some Glu or Lys residues dispersed throughout to increase solubility. [0075] “Diabodies” are dimeric scFv; diabodies typically have shorter peptide linkers than scFvs, and preferentially dimerize. [0076] As used herein, the terms “variable region” and “variable domain” refer to the portions of the light and heavy chains of an antibody that include amino acid sequences of complementarity determining regions (CDRs, e.g., HCDR1, HCDR2, HCR3, LCDR1, LCDR2, and LCDR3) and framework regions (FRs). The variable domain for the heavy and light chains is commonly designated VH and VL, respectively. The variable domain is included on Fab, F(ab’)2, Fv and scFv antigen binding fragments described herein, and is involved in specific antigen recognition. [0077] As used herein, “complementarity-determining region (CDR)” refers to the three hypervariable regions in each chain that interrupt the four framework regions established by the light and heavy chain variable regions. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found. [0078] The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space. [0079] The amino acid sequences of the CDRs and framework regions can be determined using various well-known definitions in the art, e.g., Kabat, North method (see, e.g., North et al., J Mol Biol. 406(2):228-256, 2011), Chothia, international ImMunoGeneTics database (IMGT), PATENT BIOLEG-1007PCT and AbM (see, e.g., Johnson et al., supra; Chothia & Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917; Chothia C. et al., 1989, Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883; Chothia C. et al., 1992, structural repertoire of the human VH segments J. Mol. Biol. 227, 799-817; Al- Lazikani et al., J.Mol.Biol 1997, 273(4)). Definitions of antigen combining sites are also described in the following: Ruiz et al., IMGT, the international ImMunoGeneTics database. Nucleic Acids Res., 28, 219–221 (2000); and Lefranc,M.-P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. Jan 1;29(1):207-9 (2001); MacCallum et al, Antibody-antigen interactions: Contact analysis and binding site topography, J. Mol. Biol., 262 (5), 732-745 (1996); and Martin et al, Proc. Natl Acad. Sci. USA, 86, 9268–9272 (1989); Martin, et al, Methods Enzymol., 203, 121–153, (1991); Pedersen et al, Immunomethods, 1, 126, (1992); and Rees et al, In Sternberg M.J.E. (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141–1721996). [0080] As used herein, “chimeric antibody” refers to an immunoglobulin molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region, or portion thereof, having a different or altered antigen specificity; or with corresponding sequences from another species or from another antibody class or subclass. [0081] As used herein, “humanized antibody” refers to an immunoglobulin molecule in CDRs from a donor antibody are grafted onto human framework sequences. Humanized antibodies may also comprise residues of donor origin in the framework sequences. The humanized antibody can also comprise at least a portion of a human immunoglobulin constant region. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Humanization can be performed using methods known in the art (e.g., Jones et al., Nature 321:522-525; 1986; Riechmann et al., Nature 332:323-327, 1988; Verhoeyen et al., Science 239:1534-1536, 1988); Presta, Curr. Op. Struct. Biol. 2:593-596, 1992; U.S. Patent No. 4,816,567), including techniques such as PATENT BIOLEG-1007PCT “superhumanizing” antibodies (Tan et al., J. Immunol. 169: 1119, 2002) and “resurfacing” (e.g., Staelens et al., Mol. Immunol. 43: 1243, 2006; and Roguska et al., Proc. Natl. Acad. Sci USA 91: 969, 1994). [0082] The term “recombinant” when used with a reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. [0083] The terms “antigen,” “immunogen,” “antibody target,” “target analyte,” and like terms are used herein to refer to a molecule, compound, or complex that is recognized by an antibody, i.e., can be specifically bound by the antibody. The term can refer to any molecule that can be specifically recognized by an antibody, e.g., a polypeptide, polynucleotide, carbohydrate, lipid, chemical moiety, or combinations thereof (e.g., phosphorylated or glycosylated polypeptides, etc.). One of skill will understand that the term does not indicate that the molecule is immunogenic in every context, but simply indicates that it can be targeted by an antibody. [0084] Antibodies bind to an “epitope” on an antigen. The epitope is the localized site on the antigen that is recognized and bound by the antibody. Epitopes can include a few amino acids or portions of a few amino acids, e.g., 5 or 6, or more, e.g., 20 or more amino acids, or portions of those amino acids. In some cases, the epitope includes non-protein components, e.g., from a carbohydrate, nucleic acid, or lipid. In some cases, the epitope is a three-dimensional moiety. Thus, for example, where the target is a protein, the epitope can be comprised of consecutive amino acids, or amino acids from different parts of the protein that are brought into proximity by protein folding (e.g., a discontinuous epitope). The same is true for other types of target molecules that form three-dimensional structures. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2- dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996). PATENT BIOLEG-1007PCT [0085] A “label” or a “detectable moiety” is a diagnostic agent or component detectable by spectroscopic, radiological, photochemical, biochemical, immunochemical, chemical, or other physical means. Exemplary labels include radiolabels (e.g., 111In, 99mTc, 131I, 67Ga) and other FDA-approved imaging agents. Additional labels include 32P, fluorescent dyes, electron-dense reagents, enzymes, biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the targeting agent. Any method known in the art for conjugating a nucleic acid or nanocarrier to the label may be employed, e.g., using methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc., San Diego. [0086] A “labeled” or “tagged” antibody or agent is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the antibody or agent may be detected by detecting the presence of the label bound to the antibody or agent. [0087] Techniques for conjugating detectable and therapeutic agents to antibodies are well known (see, e.g., Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243- 56 (Alan R. Liss, Inc. 1985); Hellstrom et al., “Antibodies For Drug Delivery”in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review” in Monoclonal Antibodies ‘84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev., 62:119-58 (1982)). [0088] The terms “specific for,” “specifically binds,” and like terms refer to a molecule (e.g., antibody or antigen binding fragment) that binds to a target with at least 2-fold greater affinity than non-target compounds, e.g., at least any of 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10- fold, 20-fold, 25-fold, 50-fold, or 100-fold greater affinity. For example, an antibody that specifically binds a target (e.g., GPC4) will typically bind the target with at least a 2-fold greater affinity than a non-target. Specificity can be determined using standard methods, e.g., solid- phase ELISA immunoassays (see, e.g., Harlow & Lane, Using Antibodies, A Laboratory Manual PATENT BIOLEG-1007PCT (1998) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). [0089] The term “binds” with respect to an antibody target (e.g., antigen, analyte, immune complex), typically indicates that an antibody binds a majority of the antibody targets in a pure population (assuming appropriate molar ratios). For example, an antibody that binds a given antibody target typically binds to at least 2/3 of the antibody targets in a solution (e.g., at least any of 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%). One of skill will recognize that some variability will arise depending on the method and/or threshold of determining binding. [0090] A “control” sample or value refers to a sample that serves as a reference, usually a known reference, for comparison to a test sample. For example, a test sample can be taken from a test condition, e.g., in the presence of a test compound, and compared to samples from known conditions, e.g., in the absence of the test compound (negative control), or in the presence of a known compound (positive control). A control can also represent an average value or a range gathered from a number of tests or results. One of skill in the art will recognize that controls can be designed for assessment of any number of parameters. For example, a control can be devised to compare therapeutic benefit based on pharmacological data (e.g., half-life) or therapeutic measures (e.g., comparison of benefit and/or side effects). Controls can be designed for in vitro applications. One of skill in the art will understand which controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant. [0091] The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site ncbi.nlm.nih.gov/BLAST/ or PATENT BIOLEG-1007PCT the like). Such sequences are then said to be “substantially identical.” As described herein, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 or more amino acids or nucleotides in length. [0092] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. [0093] A “comparison window”, as used herein, is a reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well- known in the art. [0094] An algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the disclosure. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (//www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. PATENT BIOLEG-1007PCT Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation I of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation I of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation I of 10, M=5, N=-4, and a comparison of both strands. [0095] The term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O- methyl ribonucleotides, peptide-nucleic acids (PNAs). [0096] Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). [0097] The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms encompass to amino acid polymers in PATENT BIOLEG-1007PCT which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non- naturally occurring amino acid polymer. [0098] The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. [0099] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes. [0100] The term “compete”, as used herein with regard to an antibody, means that a first antibody, or an antigen-binding portion thereof, competes for binding with a second antibody, or an antigen-binding portion thereof, where binding of the first antibody with its cognate epitope is detectably decreased in the presence of the second antibody compared to the binding of the first antibody in the absence of the second antibody. The alternative, where the binding of the second antibody to its epitope is also detectably decreased in the presence of the first antibody, can, but need not be the case. That is, a first antibody can inhibit the binding of a second antibody to its epitope without that second antibody inhibiting the binding of the first antibody to its respective epitope. However, where each antibody detectably inhibits the binding of the other antibody with its cognate epitope or ligand, whether to the same, greater, or lesser extent, the antibodies are said to “cross-compete” with each other for binding of their respective epitope(s). Both PATENT BIOLEG-1007PCT competing and cross-competing antibodies are encompassed by the present disclosure. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope, or portion thereof, and the like), the skilled artisan would appreciate, based upon the teachings provided herein, that such competing and/or cross-competing antibodies are encompassed and can be useful for the methods disclosed herein. [0101] Numerous types of competitive binding assays are known, for example: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see Stahli et al., Methods in Enzymology 9:242-253 (1983)); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614-3619 (1986)); solid phase direct labeled assay, solid phase direct labeled sandwich assay (see Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press (1988)); solid phase direct label RIA using I-125 label (see Morel et al., Molec. Immunol. 25(1):7-15 (1988)); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546-552 (1990)); and direct labeled RIA (Moldenhauer et al., Scand. J. Immunol. 32:77-82 (1990)). Typically, such an assay involves the use of purified antigen bound to a solid surface or cells bearing either of these, an un-labelled test immunoglobulin and a labeled reference immunoglobulin. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin. Usually the test immunoglobulin is present in excess. Antibodies identified by competition assay (competing antibodies) include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur. Usually, when a competing antibody is present in excess, it will inhibit specific binding of a reference antibody to a common antigen by at least 50 or 75%. [0102] The term “GPC4” as used herein refers to human glypican 4 (GPC4) proteins, isoforms or variants thereof, including naturally occurring variants of human GPC4, such as splice variants or allelic variants. The amino acid sequence of an exemplary human GPC4 is shown in SEQ ID NO: 1 (Uniprot ID: O75487). In some embodiments, human GPC4 can refer to a variant, such as an allelic variant or splice variant, that exhibits at least or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence PATENT BIOLEG-1007PCT identity to any of SEQ ID NO: 1. In some embodiments, it is understood that the provided antibodies or antigen-binding fragments may exhibit cross-reactive binding to another mammalian GPC4 protein, such as murine GPC4, or a primate GPC4. The amino acid sequence of GPC4 is: MARFGLPALLCTLAVLSAALLAAELKSKSCSEVRRLYVSKGFNKNDAPLHEINGDHLKI CPQGSTCCSQEMEEKYSLQSKDDFKSVVSEQCNHLQAVFASRYKKFDEFFKELLENAEK SLNDMFVKTYGHLYMQNSELFKDLFVELKRYYVVGNVNLEEMLNDFWARLLERMFRL VNSQYHFTDEYLECVSKYTEQLKPFGDVPRKLKLQVTRAFVAARTFAQGLAVAGDVVS KVSVVNPTAQCTHALLKMIYCSHCRGLVTVKPCYNYCSNIMRGCLANQGDLDFEWNN FIDAMLMVAERLEGPFNIESVMDPIDVKISDAIMNMQDNSVQVSQKVFQGCGPPKPLPA GRISRSISESAFSARFRPHHPEERPTTAAGTSLDRLVTDVKEKLKQAKKFWSSLPSNVCN DERMAAGNGNEDDCWNGKGKSRYLFAVTGNGLANQGNNPEVQVDTSKPDILILRQIM ALRVMTSKMKNAYNGNDVDFFDISDESSGEGSGSGCEYQQCPSEFDYNATDHAGKSAN EKADSAGVRPGAQAYLLTVFCILFLVMQREWR (SEQ ID NO: 1). [0103] By “solid support” is meant a non-aqueous matrix to which an antibody according to the provided disclosure can adhere or attach. For example, solid supports include, but are not limited to, a microtiter plate, a membrane (e.g., nitrocellulose), a bead, a dipstick, a thin-layer chromatographic plate, or other solid medium. [0104] As used herein, an “individual” or a “subject” is a mammal. A “mammal” for purposes of treatment includes humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, rabbits, cattle, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the individual or subject is human. II. Antibodies that bind GPC4 [0105] Provided herein are antibodies, including antigen binding fragments thereof, that specifically bind to GPC4. The provided antibodies include monoclonal antibodies and antigen- binding fragments thereof that bind GPC4 and provide superior target specificity, signal-to-noise ratios, and the like as compared to other reported antibodies. Also provided herein are methods for producing anti-GPC4 antibodies, and methods for detecting and using such antibodies. PATENT BIOLEG-1007PCT [0106] Any of the antibodies of antigen binding fragments thereof provided herein can bind all or a portion of GPC4. Optionally, any of the antibodies of antigen binding fragments thereof provided herein can bind all or a portion of the extracellular domain of GPC4. [0107] Any of the antibodies or antigen binding fragments thereof is a GPC4 antibody or antigen binding fragment thereof. In some embodiments, the antibody or antigen binding fragment thereof is isolated (e.g., separated from a component of its natural environment (e.g., an animal, a biological sample)). In some embodiments, the anti- antibody is a humanized antibody, or an antigen binding fragment thereof. In some embodiments, the antibody is a derivative of a humanized antibody that binds. In some embodiments, the antibody binds under laboratory conditions (e.g., binds in vitro, binds in a flow cytometry assay, binds in an ELISA). In some embodiments, the antibody binds under physiological conditions (e.g., binds in a cell in a subject). [0108] Generally, the antibodies provided herein comprise at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain. In some embodiments, an antibody described herein comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. Typically, each immunoglobulin heavy chain variable domain of the antibody comprises first, second, and third heavy chain complementarity determining regions (CDRs; CDRH1, CDRH2, and CDRH3), and each immunoglobulin light chain variable domain of the antibody comprises first, second, and third light chain CDRs (CDRL1, CDRL2, and CDRL3). [0109] The antibodies can be antigen binding fragments such as Fab, F(ab’)2, Fv or scFv. The antigen binding fragments can be generated using any means known in the art including, chemical digestion (e.g., papain or pepsin) and recombinant methods. Methods for isolating and preparing recombinant nucleic acids are known to those skilled in the art (see, Sambrook et al., Molecular Cloning. A Laboratory Manual (2d ed. 1989); Ausubel et al., Current Protocols in Molecular Biology (1995)). The antibodies can be expressed in a variety of host cells, including E. coli, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO, and HeLa cells lines and myeloma cell lines. [0110] Provided herein are antibodies or antigen-binding fragments thereof, including those that specifically bind to a GPC4, such as a human GPC4, wherein the antibodies or antigen- PATENT BIOLEG-1007PCT binding fragments contain particular complementarity determining regions (CDRS), including heavy chain CDRS (i.e., CDRH1, CDRH2, and/or CDRH3) and light chain CDRS (i.e., CDRL1, CDRL2, and/or CDRL3), such as any described herein. in some embodiments, the antibody or antigen-binding fragment thereof includes a heavy chain variable domain and a light chain variable domain, such as any described herein. [0111] Provided herein is an antibody or antigen binding fragment thereof that binds GPC4 or a portion thereof, comprising a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementarity determining region 1 (CDRH1) comprising SEQ ID NO:2; (ii) a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO:3; (iii) a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO:4; and b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO:5; (ii) a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO:6; and (iii) a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO:7. [0112] Optionally, the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:4. [0113] Optionally, the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4. [0114] Optionally, the immunoglobulin light chain variable domain comprises: a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 5, or a sequence of amino acids PATENT BIOLEG-1007PCT that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 6, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 7, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 7. [0115] Optionally, the immunoglobulin light chain variable domain comprises: a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 5; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 6; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 7. [0116] Optionally, the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 2; the CDRH2 comprises the sequence of amino acids set forth in SEQ ID NO: 3; the CDRH3 comprises the sequence of amino acids set forth in SEQ ID NO: 4; the CDRL1 comprises the sequence of amino acids set forth in SEQ ID NO: 5; the CDRL2 comprises the sequence of amino acids set forth in SEQ ID NO: 6; and the CDRL3 comprises the sequence of amino acids set forth in SEQ ID NO: 7. [0117] Optionally, the CDRH1 comprises the sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2, the CDRH2 comprises the sequence set forth in SEQ ID NO: 3 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; the CDRH3 comprises the sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 4; the CDRL1 comprises the sequence set forth in SEQ ID NO: 5 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5, the CDRL2 comprises PATENT BIOLEG-1007PCT the sequence set forth in SEQ ID NO: 6 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 7 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 7. [0118] Optionally, the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15. [0119] Optionally, the immunoglobulin heavy chain comprises the amino acid sequence set forth in any of SEQ ID NO: 15. [0120] Optionally, the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17. [0121] Optionally, the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17. [0122] Optionally, the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17. [0123] Optionally, the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15; and the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17. PATENT BIOLEG-1007PCT III. Antibodies that competitively bind with an anti-GPC4 antibody [0124] Also provided herein are antibodies that competitively bind, or are capable of competitively binding (e.g., competitor antibodies), with one or more GPC4 antibodies described herein. In certain instances, an antibody (e.g., competitor antibody) may be considered to compete for binding to GPC4 when the competitor binds to the same general region of GPC4 as an antibody described herein. In certain instances, an antibody (e.g., competitor antibody) may be considered to compete for binding to GPC4 when the competitor binds to the exact same region of GPC4 as an antibody described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)). In certain instances, an antibody (e.g., competitor antibody) may be considered capable of competing for binding to GPC4 when the competitor binds to the same general region of GPC4 as an antibody described herein (e.g., extracellular region or leucine-rich binding domain) under suitable assay conditions. In certain instances, an antibody (e.g., competitor agent) may be considered capable of competing for binding to GPC4 when the competitor binds to the exact same region of GPC4 as an antibody described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)) under suitable assay conditions. [0125] In certain instances, an antibody (e.g., competitor antibody) may be considered to compete for binding to GPC4 when the competitor blocks the binding of one or more antibodies described herein to GPC4, for example, under suitable assay conditions. Whether a competitor blocks the binding of one or more antibodies described herein to GPC4 may be determined using a suitable competition assay or blocking assay, such as, for example, a blocking assay as described in herein. A competitor antibody may block binding of one or more antibodies described herein to GPC4 in a competition or blocking assay by 50% or more (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more, or 100%), and conversely, one or more antibodies described herein may block binding of the competitor antibody to GPC4 in a competition or blocking assay by about 50% or more (e.g., e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more, or 100%). PATENT BIOLEG-1007PCT [0126] In certain instances, an antibody (e.g., competitor antibody) may be considered to compete for binding to GPC4 when the competitor binds to GPC4 with a similar affinity as one or more antibodies described herein, for example, under suitable assay conditions. In some embodiments, an antibody (i.e., competitor antibody) is considered to compete for binding to GPC4 when the competitor binds to GPC4 with an affinity that is at least about 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) of the affinity of one or more antibodies described herein. [0127] Also provided herein are antibodies that bind to, or are capable of binding to, the same epitope as one or more antibodies described herein. In particular, provided herein are antibodies that compete with one or more antibodies described herein for binding to the same epitope (e.g., same peptide (linear epitope) or same surface amino acids (conformational epitope)) on GPC4. Such antibodies that bind the same epitope may be referred to as epitope competitors. IV. Polyclonal and monoclonal antibodies [0128] Polyclonal antibodies may be raised in animals (vertebrate or invertebrates, including mammals, birds and fish, including cartilaginous fish) by multiple subcutaneous (sc) or intraperitoneal (ip) injections of a relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein or other carrier that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N- hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl2, or R1N=C=NR, where R and R1 are different alkyl groups. Non-protein carriers (e.g., colloidal gold) also may be used for antibody production. [0129] Animals can be immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 µg or 5 µg of the protein or conjugate (for rabbits or mice, respectively) with three volumes of Freund’s complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with one-fifth to one-tenth of the original amount of peptide or conjugate in Freund’s complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Often, the animal is boosted with the conjugate PATENT BIOLEG-1007PCT of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response. [0130] Monoclonal antibodies may be made using a hybridoma, e.g., the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by other methods such as recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). In the hybridoma method, a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (see, e.g., Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). [0131] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that may contain one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells. Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Md. USA. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)). [0132] Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. The binding specificity of monoclonal antibodies produced by hybridoma cells may be determined by immunoprecipitation, by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbant assay PATENT BIOLEG-1007PCT (ELISA), or by flow cytometric analysis of cells expressing the membrane antigen. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980). [0133] After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (see, e.g., Goding, Monoclonal Antibodies: Principles and Practice, pp.59- 103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D- MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal. The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. [0134] DNA encoding the monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). Alternatively, cDNA may be prepared from mRNA and the cDNA then subjected to DNA sequencing. The hybridoma cells serve as a preferred source of such genomic DNA or RNA for cDNA preparation. Once isolated, the DNA may be placed into expression vectors, which are well known in the art, and which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. V. Humanization and amino acid variants [0135] General methods for humanization of antibodies are described, for example, in U.S. Patent Nos. 5861155, 6479284, 6407213, 6639055, 6500931, 5530101, 5585089, 5693761, 5693762, 6180370, 5714350, 6350861, 5777085, 5834597, 5882644, 5932448, 6013256, 6129914, 6210671, 6329511, 5225539, 6548640, and 5624821. In certain embodiments, it may be desirable to generate amino acid sequence variants of these humanized antibodies, particularly where these improve the binding affinity or other biological properties (e.g., half-life) of the antibody. PATENT BIOLEG-1007PCT [0136] In some embodiments, the antibody is a humanized antibody, i.e., an antibody that retains the reactivity of a non-human antibody while being less immunogenic in humans. This can be achieved, for instance, by retaining the non-human CDR regions and replacing the remaining parts of the antibody with their human counterparts. See, e.g., Morrison et al., PNAS USA, 81 :6851-6855 (1984) ; Morrison and Oi, Adv. Immunol., 44 :65-92 (1988) ; Verhoeyen et al., Science, 239 :1534-1536 (1988) ; Padlan, Molec. Immun., 28:489-498 (1991); Padlan, Molec. Immun., 31(3):169-217 (1994). Techniques for humanizing antibodies are well known in the art and are described in e.g., U.S. Patent Nos. 4,816,567; 5,530,101; 5,859,205; 5,585,089; 5,693,761; 5,693,762; 5,777,085; 6,180,370; 6,210,671; and 6,329,511; WO 87/02671; EP Patent Application 0173494; Jones et al. (1986) Nature 321:522; and Verhoyen et al. (1988) Science 239:1534. Humanized antibodies are further described in, e.g., Winter and Milstein (1991) Nature 349:293. For example, polynucleotides comprising a first sequence coding for humanized immunoglobulin framework regions and a second sequence set coding for the desired immunoglobulin complementarity determining regions can be produced synthetically or by combining appropriate cDNA and genomic DNA segments. Human constant region DNA sequences can be isolated in accordance with well-known procedures from a variety of human cells. The CDRs for producing the immunoglobulins of the present disclosure can be similarly derived from monoclonal antibodies capable of specifically binding to GPC4. [0137] Amino acid sequence variants of the antibody can be prepared by introducing appropriate nucleotide changes into the antibody DNA, or by peptide synthesis. Such variants include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the antibodies for the examples herein. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post- translational processes of the humanized or variant antibody, such as changing the number or position of glycosylation sites. [0138] One method for identification of certain residues or regions of the antibody that are preferred locations for mutagenesis is called “alanine scanning mutagenesis,” as described by, e.g., Cunningham and Wells, Science, 244:1081-1085 (1989). Here, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced PATENT BIOLEG-1007PCT by a neutral or negatively charged amino acid (most preferably Ala or poly-Ala) to affect the interaction of the amino acids with antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, alanine scanning or random mutagenesis is conducted at the target codon or region and the expressed antibody variants are screened for the desired activity. Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an N-terminal methionyl residue or the antibody fused to an epitope tag. Other insertional variants include the fusion of an enzyme or a polypeptide that increases the serum half-life of the antibody to the N- or C-terminus of the antibody. [0139] Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue removed from the antibody molecule and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are preferred, but more substantial changes may be introduced and the products may be screened. Examples of substitutions are listed below: [0140] Ala (A): Val; Leu; Ile; Val [0141] Arg €: Lys; Gln; Asn; Lys [0142] Asn (N): Gln; His; Asp, Lys; Gln; Arg [0143] Asp (D): Glu; Asn [0144] Cys €: Ser; Ala [0145] Gln (Q): Asn; Glu [0146] Glu €: Asp; Gln PATENT BIOLEG-1007PCT [0147] Gly (G): Ala [0148] His (H): Asn; Gln; Lys; Arg [0149] Ile (I): Leu; Val; Met; Ala; Leu; Phe; Norleucine [0150] Leu (L): Norleucine; Ile; Val; Ile; Met; Ala; Phe [0151] Lys (K): Arg; Gln; Asn [0152] Met (M): Leu; Phe; Ile [0153] Phe (F): Leu; Val; Ile; Ala; Tyr [0154] Pro (P): Ala [0155] Ser (S): Thr [0156] Thr (T): Ser [0157] Trp (W): Tyr; Phe [0158] Tyr (Y): Trp; Phe; Thr; Ser [0159] Val (V): Ile; Leu; Met; Phe; Ala; Norleucine [0160] Substantial modifications in the biological properties of an antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side- chain properties: [0161] (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; [0162] (2) neutral hydrophilic: Cys, Ser, Thr; [0163] (3) acidic: Asp, Glu; PATENT BIOLEG-1007PCT [0164] (4) basic: Asn, Gln, His, Lys, Arg; [0165] (5) residues that influence chain orientation: Gly, Pro; and [0166] (6) aromatic: Trp, Tyr, Phe [0167] Non-conservative substitutions will entail exchanging a member of one of the above classes for another class. [0168] Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antigen binding fragment such as an Fv fragment). [0169] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody. Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants is affinity maturation using phage display. Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino acid substitutions at each site. The antibody variants thus generated can be displayed in the monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as herein disclosed. [0170] In order to identify candidate hypervariable region sites for modification, alanine- scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or in addition, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development. [0171] Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one of more carbohydrate moieties found PATENT BIOLEG-1007PCT in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody. Glycosylation of antibodies is typically either N-linked and/or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the most common recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5- hydroxylysine may also be used. Addition of glycosylation sites to the antibody can be accomplished by altering the amino acid sequence such that it contains one or more of the above- described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites). VI. Other modifications [0172] Other modifications of an antibody are contemplated. For example, technology herein also pertains to immunoconjugates comprising an antibody described herein conjugated to a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (for example, a radioconjugate), or a cytotoxic drug. Such conjugates are sometimes referred to as “antibody-drug conjugates” or “ADC.” Conjugates can be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis- (p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)- ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). [0173] In some of any embodiments, any of the antibodies or antigen binding fragments thereof disclosed herein may be formulated as immunoliposomes. Liposomes containing an antibody are prepared by methods know in the art, such as described in Epstein et al., Proc. Natl. PATENT BIOLEG-1007PCT Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556. For example, liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab’ fragments of an antibody provided herein can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem. 257:286-288 (1982) via a disulfide interchange reaction. Another active ingredient is optionally contained within the liposome. [0174] Enzymes or other polypeptides can be covalently bound to an antibody by techniques well known in the art such as the use of the heterobifunctional cross-linking reagents discussed above. In some embodiments, fusion proteins comprising at least the antigen binding region of an antibody provided herein linked to at least a functionally active portion of an enzyme can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature 312:604-608 (1984)). [0175] In certain embodiments, it may be desirable to use an antigen binding fragment, rather than an intact antibody, to increase penetration of target tissues and cells, for example. In such instances, it may be desirable to modify the antigen binding fragment to increase its serum half- life. This may be achieved, for example, by incorporation of a salvage receptor binding epitope into the antigen binding fragment (e.g., by mutation of the appropriate region in the antigen binding fragment or by incorporating the epitope into a peptide tag that is then fused to the antigen binding fragment at either end or in the middle, e.g., by DNA or peptide synthesis; see, e.g., WO96/32478 published Oct. 17, 1996). [0176] In some embodiments, any of the antibodies or antigen fragments thereof disclosed herein are conjugated or hybridized to an oligonucleotide. In some embodiments, the oligonucleotide includes a sample barcode sequence, a binding site for a primer and an anchor. In some embodiments, the oligonucleotide can be conjugated or hybridized to any of the detectable markers or labels disclosed herein. In some embodiments, the oligonucleotide is a polymeric sequence. In some embodiments, the terms “oligonucleotide” and “polynucleotide” are used interchangeably to refer to a single-stranded multimer of nucleotides from about 2 to PATENT BIOLEG-1007PCT about 500 nucleotides in length. In some embodiments, any of the oligonucleotides described herein can be synthetic, made enzymatically (e.g., via polymerization), or using a “split-pool” method. In some embodiments, any of the oligonucleotides described herein can include ribonucleotide monomers (i.e., can be oligoribonucleotides) and/or deoxyribonucleotide monomers (i.e., oligodeoxyribonucleotides). In some embodiments, any of the oligonucleotides described herein can include a combination of both deoxyribonucleotide monomers and ribonucleotide monomers in the oligonucleotide (e.g., random or ordered combination of deoxyribonucleotide monomers and ribonucleotide monomers). In some embodiments, the oligonucleotide can be 4 to 10, 10 to 20, 21 to 30, 31 to 40, 41 to 50, 51 to 60, 61 to 70, 71 to 80, 80 to 100, 100 to 150, 150 to 200, 200 to 250, 250 to 300, 300 to 350, 350 to 400, or 400-500 nucleotides in length. In some embodiments, any of the oligonucleotides described herein can include one or more functional moieties that are attached (e.g., covalently or non-covalently) to another structure. In some embodiments, any of the oligonucleotides described herein can include one or more detectable labels (e.g., a radioisotope or fluorophore). In some embodiments, the anchor is a defined polymer, e.g., a polynucleotide or oligonucleotide sequence, which is designed to hybridize to a complementary oligonucleotide sequence. In some embodiments, the anchor is designed for the purpose of generating a double stranded construct oligonucleotide sequence. In some embodiments, the anchor is positioned at the 3’ end of the construct oligonucleotide sequence. In other embodiments, the anchor is positioned at the 5’ end of the construct oligonucleotide sequence. Each anchor is specific for its intended complementary sequence. [0177] In some embodiments, the sample barcode sequence is a polymer, e.g., a polynucleotide, which when it is a functional element, is specific for a single ligand. In some embodiments, the sample barcode sequence can be used for identifying a particular cell or substrate, e.g., Drop-seq microbead. In some embodiments, the sample barcode sequence can be formed of a defined sequence of DNA, RNA, modified bases or combinations of these bases, as well as any other polymer defined above. In some embodiments, the sample barcode sequence is about 2 to 4 monomeric components, e.g., nucleotide bases, in length. In other embodiments, the barcode is at least about 1 to 100 monomeric components, e.g., nucleotides, in length. Thus in various embodiments, the barcode is formed of a sequence of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, PATENT BIOLEG-1007PCT 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 80, 91, 92, 93, 94, 95, 96, 97, 98, 99 or up to 100 monomeric components, e.g., nucleic acids. In some embodiments, the sample barcode sequence is a particular barcode that can be unique relative to other barcodes. [0178] In some of any embodiments, the sample barcode sequences can have a variety of different formats. For example, sample barcode sequences can include polynucleotide barcodes, random nucleic acid and/or amino acid sequences, and synthetic nucleic acid and/or amino acid sequences. A sample barcode sequence can be attached to an analyte or to another moiety or structure in a reversible or irreversible manner. A sample barcode sequences can be added to, for example, a fragment of a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sample before or during sequencing of the sample. Sample barcode sequences can allow for identification and/or quantification of individual sequencing-reads (e.g., a barcode can be or can include a unique molecular identifier or “UMI”). [0179] Sample barcode sequences can spatially-resolve molecular components found in biological samples, for example, at single-cell resolution (e.g., a barcode can be or can include a “spatial barcode”). In some embodiments, a barcode includes both a UMI and a spatial barcode. In some embodiments, a barcode includes two or more sub-barcodes that together function as a single barcode. For example, a polynucleotide barcode can include two or more polynucleotide sequences (e.g., sub-barcodes) that are separated by one or more non-barcode sequences. [0180] In some embodiments, the binding site for a primer is a functional component of the oligonucleotide which itself is an oligonucleotide or polynucleotide sequence that provides an annealing site for amplification of the oligonucleotide. The binding site for a primer can be formed of polymers of DNA, RNA, PNA, modified bases or combinations of these bases, or polyamides, etc. In some embodiments, the binding site for a primer is about 10 of such monomeric components, e.g., nucleotide bases, in length. In other embodiments, the binding site for a primer is at least about 5 to 100 monomeric components, e.g., nucleotides, in length. Thus in various embodiments, the binding site for a primer is formed of a sequence of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, PATENT BIOLEG-1007PCT 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 80, 91, 92, 93, 94, 95, 96, 97, 98, 99 or up to 100 monomeric components, e.g., nucleic acids. In certain embodiments, the binding site for a primer can be a generic sequence suitable as a annealing site for a variety of amplification technologies. Amplification technologies include, but are not limited to, DNA-polymerase based amplification systems, such as polymerase chain reaction (PCR), real-time PCR, loop mediated isothermal amplification (LAMP, MALBAC), strand displacement amplification (SDA), multiple displacement amplification (MDA), recombinase polymerase amplification (RPA) and polymerization by any number of DNA polymerases (for example, T4 DNA polymerase, Sulfulobus DNA polymerase, Klenow DNA polymerase, Bst polymerase, Phi29 polymerase) and RNA-polymerase based amplification systems (such as T7-, T3-, and SP6-RNA-polymerase amplification), nucleic acid sequence based amplification (NASBA), self-sustained sequence replication (3SR), rolling circle amplification (RCA), ligase chain reaction (LCR), helicase dependent amplification (I), ramification amplification method and RNA-seq. Methods for conjugating or hybridizing an oligonucleotide can be performed in a manner set forth in WO/2018/144813, WO/2016/018960, WO/2018/089438, WO/2014/182528, WO/2018/026873, WO/2021/188838. [0181] In some embodiments, a modification can optionally be introduced into the antibodies (e.g., within the polypeptide chain or at either the N- or C-terminal), e.g., to extend in vivo half- life, such as PEGylation or incorporation of long-chain polyethylene glycol polymers (PEG). Introduction of PEG or long chain polymers of PEG increases the effective molecular weight of the polypeptides, for example, to prevent rapid filtration into the urine. In some embodiments, a lysine residue in the sequence is conjugated to PEG directly or through a linker. Such linker can be, for example, a Glu residue or an acyl residue containing a thiol functional group for linkage to the appropriately modified PEG chain. An alternative method for introducing a PEG chain is to first introduce a Cys residue at the C-terminus or at solvent exposed residues such as replacements for Arg or Lys residues. This Cys residue is then site-specifically attached to a PEG chain containing, for example, a maleimide function. Methods for incorporating PEG or long chain polymers of PEG are known in the art (described, for example, in Veronese, F. M., et al., Drug Disc. Today 10: 1451-8 (2005); Greenwald, R. B., et al., Adv. Drug Deliv. Rev. 55: 217-50 (2003); Roberts, M. J., et al., Adv. Drug Deliv. Rev., 54: 459-76 (2002)), the contents of which are incorporated herein by reference. PATENT BIOLEG-1007PCT [0182] Covalent modifications of an antibody are also included within the scope of this technology. For example, modifications may be made by chemical synthesis or by enzymatic or chemical cleavage of an antibody. Other types of covalent modifications of an antibody are introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues. Example covalent modifications of polypeptides are described in U.S. Pat. No. 5,534,615, specifically incorporated herein by reference. A preferred type of covalent modification of the antibody comprises linking the antibody to one of a variety of non- proteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in, e.g., U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. VII. Nucleic acids, vectors, host cells, and recombinant methods [0183] The disclosure also provides isolated nucleic acids encoding an antibody, vectors and host cells comprising the nucleic acid, and recombinant techniques for the production of the antibody. A nucleic acid herein may include one or more subsequences, each referred to as a polynucleotide. Provided herein are nucleic acids comprising SEQ ID NO:8-14 and 16. [0184] Provided herein are nucleic acids (e.g., isolated nucleic acids) comprising a nucleotide sequence that encodes an antibody, or fragment thereof. In some embodiments, a nucleic acid encodes an immunoglobulin heavy chain variable domain of an antibody provided herein. In some embodiments, a nucleic acid encodes an immunoglobulin light chain variable domain of an antibody provided herein. In some embodiments, a nucleic acid encodes an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain of an antibody provided herein. In some embodiments, a nucleic acid comprises a nucleotide sequence that encodes an amino acid sequence of any one of SEQ ID Nos: 2-7, 15 or 17. [0185] Provided herein is a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any of any of the antibodies or antigen binding fragments provided herein. PATENT BIOLEG-1007PCT [0186] For recombinant production of an antibody, a nucleic acid encoding the antibody may be isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. In certain instances, an antibody may be produced by homologous recombination. DNA encoding an antibody can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, and origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. [0187] Suitable host cells for cloning or expressing DNA in vectors herein can be prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis, Pseudomonas such as P. aeruginosa, and Streptomyces. One preferred E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) can also be suitable. These examples are illustrative rather than limiting. [0188] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors. Saccharomyces cerevisiae, or common baker’s yeast, is the most commonly used among lower eukaryotic host microorganisms. A number of other genera, species, and strains are commonly available and useful herein, such as Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070); Candida; Trichoderma reesia (EP 244,234); Neurospora crassa; Schwanniomyces such as Schwanniomyces occidentalis; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger. PATENT BIOLEG-1007PCT [0189] Suitable host cells for the expression of antibodies can also be derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori (silk moth) have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present technology, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts. [0190] Suitable host cells for the expression of antibodies also may include vertebrate cells (e.g., mammalian cells). Vertebrate cells may be propagated in culture (tissue culture). Examples of useful mammalian host cell lines include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod. 23:243- 251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2). [0191] Host cells may be transformed with the above-described expression or cloning vectors for antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Host cells used to produce antibodies provided herein may be cultured in a variety of media. Commercially available media such as Ham’s F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco’s Modified Eagle’s Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et PATENT BIOLEG-1007PCT al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem.102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Pat. Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. [0192] When using recombinant techniques, antibodies can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163- 167 (1992) describe a procedure for isolating antibodies that are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by centrifugation. Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants. [0193] The antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human heavy chains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for PATENT BIOLEG-1007PCT all mouse isotypes and for human γ3 (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be achieved with agarose. Where the antibody comprises a CH3 domain, Bakerbond ABX.TM. resin (J. T. Baker, Phillipsburg, N.J.) is useful for purification. Other techniques for protein purification, such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™, chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered. [0194] Following any preliminary purification step(s), the mixture comprising the antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between, e.g., about 2.5-4.5, and may be performed at low salt concentrations (e.g., from about 0-0.25M salt). VIII. Pharmaceutical formulations, dosing, and routes of administration [0195] The present disclosure provides antibodies and related compositions, which may be useful for elimination of -expressing pathogens from the body, for example, and for identification and quantification of the number of GPC4-expressing pathogens in biological samples, for example. [0196] In some embodiments, any of the antibodies or antigen binding fragments thereof may be formulated in a pharmaceutical composition that is useful for a variety of purposes, including the treatment of diseases or disorders. Pharmaceutical compositions comprising one or more antibodies may be administered using a pharmaceutical device to a patient in need thereof, and according to one embodiment of the technology, kits are provided that include such devices. Such devices and kits may be designed for routine administration, including self-administration, of the pharmaceutical compositions herein. [0197] Therapeutic formulations of an antibody may be prepared for storage by mixing the agent or antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington’s Pharmaceutical Sciences 16th edition, Osol, A. PATENT BIOLEG-1007PCT Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues ) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn- protein complexes); and/or non-ionic surfactants such as TWEENTM, PLURONICSTM, or polyethylene glycol (PEG). [0198] In some embodiments, the disease or disorder is associated with GPC4 expression. In some embodiments, the disease or disorder is associated with aberrant GPC4 expression. In some embodiments, the disease or disorder is associated with Natural Killer (NK), alpha beta T cells, gamma delta T cells, CD8+ T cells, monocytes, or dendritic cells. In some embodiments, the disease or disorder is associated with Natural Killer (NK) cells. In some embodiments, the disease or disorder is associated with alpha beta T cells. In some embodiments, the disease or disorder is associated with gamma delta T cells. In some embodiments, the disease or disorder is associated with CD8+ T cells. In some embodiments, the disease or disorder is associated with monocytes. In some embodiments, the disease or disorder is associated with dendritic cells. [0199] In some embodiments, the disease or disorder is a cancer, an infectious disease, or an autoimmune disorder. [0200] In some embodiments, the disease or disorder is a cancer. In some embodiments, the cancer is, e.g., metastatic melanoma, a solid tumor, bladder cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, hepatic metastasis of colonic origin, papillary thyroid carcinoma, acute myeloid leukemia, or asymptomatic myeloma. PATENT BIOLEG-1007PCT [0201] In some embodiments, the disease or disorder is an infectious disease. In some embodiments, the infectious disease is, e.g., human immunodeficiency virus (HIV), chronic hepatitis C, cytomegalovirus, or hantavirus. [0202] In some embodiments, the disease or disorder is an autoimmune disorder. In some embodiments, the autoimmune disorder is, e.g., Crohn’s disease, multiple sclerosis, systemic sclerosis, ocular myasthenia gravis, psoriasis or rheumatoid arthritis. [0203] In some embodiments, any of the antibodies or antigen binding fragments thereof described herein can be used to decrease the production of androgenic hormones in prostate cancer cells. [0204] In some embodiments, any of the antibodies or antigen binding fragments thereof described herein can be used to inhibit or reduce cleavage of coronavirus spike glycoproteins. In some embodiments, any of the antibodies or antigen binding fragments thereof described herein can be used to inhibit or reduce viral uptake into a host cell. [0205] Formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. [0206] Formulations for in vivo administration generally are sterile. This may be accomplished for instance by filtration through sterile filtration membranes, for example. [0207] Sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the agent/antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly (vinyl alcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and gamma ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron Depot® (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain PATENT BIOLEG-1007PCT hydrogels release proteins for shorter time periods. When encapsulated agents/antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37 °C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thiol-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions. [0208] For therapeutic applications, antibodies provided herein are administered to a mammal, e.g., a human, in a pharmaceutically acceptable dosage form such as those discussed above, including those that may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, or by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. For the prevention or treatment of disease, the appropriate dosage of agent or antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventative or therapeutic purposes, previous therapy, the patient’s clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. [0209] Depending on the type and severity of the disease, about 1 µg/kg to about 50 mg/kg (e.g., 0.1-20 mg/kg) of antibody may be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily or weekly dosage might range from about 1 µg/kg to about 20 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays, including, for example, radiographic imaging. Detection methods using the antibody to determine GPC4 levels in bodily fluids or tissues may be used to optimize patient exposure to the therapeutic antibody. PATENT BIOLEG-1007PCT [0210] In some embodiments, a composition comprising an antibody herein can be administered as a monotherapy, and in some embodiments, the composition comprising the antibody can be administered as part of a combination therapy. In some cases, the effectiveness of the antibody in preventing or treating diseases may be improved by administering the antibody serially or in combination with another drug that is effective for those purposes, such as a chemotherapeutic drug for treatment of cancer or a microbial infection. In other cases, the antibody may serve to enhance or sensitize cells to chemotherapeutic treatment, thus permitting efficacy at lower doses and with lower toxicity. Certain combination therapies include, in addition to administration of the composition comprising an antibody that reduces the number of -expressing cells, delivering a second therapeutic regimen selected from the group consisting of a chemotherapeutic agent, radiation therapy, surgery, and a combination of any of the foregoing. Such other agents may be present in the composition being administered or may be administered separately. Also, the antibody may be suitably administered serially or in combination with the other agent or modality, e.g., chemotherapeutic drug or radiation for treatment of cancer, infection, and the like, or an immunosuppressive drug. IX. Research and Diagnostic [0211] Also provided herein are diagnostic reagents comprising an antibody described herein. For example, antibodies provided herein may be used to detect and/or purify GPC4 from bodily fluid(s) or tissues. Also provided herein are methods for detecting GPC4. For example, a method may comprise contacting a sample (e.g., a biological sample known or suspected to contain) with an antibody provided herein, and, if the sample contains GPC4, detecting GPC4:antibody complexes. Also provided herein are reagents comprising an antibody described herein and methods for detecting for research purposes. [0212] Any of the antibodies or antigen binding fragments disclosed herein can be useful in diagnostic assays for detecting its presence in specific cells, tissues, or bodily fluids. Such diagnostic methods may be useful in diagnosis, e.g., of a hyperproliferative disease or disorder. Thus, clinical diagnostic uses as well as research uses are comprehended herein. In some embodiments, an antibody comprises a detectable marker or label. In some embodiments, an antibody is conjugated to a detectable marker or label. For example, for research and diagnostic PATENT BIOLEG-1007PCT applications, an antibody may be labeled with a detectable moiety. Numerous labels are available which are generally grouped into the following categories: (a) Radioisotopes, such as 35S, 14C, 125I, 3H, and 131I. The antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al., Ed. Wiley-Interscience, New York, N.Y., Pubs. (1991), for example, and radioactivity can be measured using scintillation counting. (b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin, Texas Red and Brilliant VioletTM are available. The fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a flow cytometer, imaging microscope or fluorimeter. [0213] Various enzyme-substrate labels are available. The enzyme generally catalyzes a chemical alteration of the chromogenic substrate that can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light that can be measured (using a chemilluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclicoxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O’Sullivan et al., Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym. (ed J. Langone & H. Van Vunakis), Academic press, New York, 73:147-166 (1981). [0214] Examples of enzyme-substrate combinations include, for example: PATENT BIOLEG-1007PCT (i) Horseradish peroxidase (HRP) with hydrogen peroxidase as a substrate, where the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3’,5,5’-tetramethyl benzidine hydrochloride (TMB)); (ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and (iii) β-D-galactosidase (β-D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl-β-D-galactosidase) or fluorogenic substrate 4-methylumbelliferyl-β-D-galactosidase. [0215] In certain instances, the label is indirectly conjugated with the agent or antibody. The skilled artisan will be aware of various techniques for achieving this. For example, an antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody). Thus, indirect conjugation of the label with the antibody can be achieved. [0216] In some embodiments, and antibody or antigen binding fragments thereof need not be labeled, and the presence thereof can be detected, e.g., using a labeled antibody which binds to an antibody. [0217] In some embodiments, an antibody herein is immobilized on a solid support or substrate. In some embodiments, an antibody herein is non-diffusively immobilized on a solid support (e.g., the antibody does not detach from the solid support). A solid support or substrate can be any physically separable solid to which an antibody can be directly or indirectly attached including, but not limited to, surfaces provided by microarrays and wells, and particles such as beads (e.g., paramagnetic beads, magnetic beads, microbeads, nanobeads), microparticles, and nanoparticles. Solid supports also can include, for example, chips, columns, optical fibers, wipes, filters (e.g., flat surface filters), one or more capillaries, glass and modified or functionalized glass (e.g., controlled-pore glass (CPG)), quartz, mica, diazotized membranes (paper or nylon), polyformaldehyde, cellulose, cellulose acetate, paper, ceramics, metals, metalloids, semiconductive materials, quantum dots, coated beads or particles, other chromatographic materials, magnetic particles; plastics (including acrylics, polystyrene, PATENT BIOLEG-1007PCT copolymers of styrene or other materials, polybutylene, polyurethanes, TEFLON™, polyethylene, polypropylene, polyamide, polyester, polyvinylidenedifluoride (PVDF), and the like), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon, silica gel, and modified silicon, Sephadex®, Sepharose®, carbon, metals (e.g., steel, gold, silver, aluminum, silicon and copper), inorganic glasses, conducting polymers (including polymers such as polypyrole and polyindole); micro or nanostructured surfaces such as nucleic acid tiling arrays, nanotube, nanowire, or nanoparticulate decorated surfaces; or porous surfaces or gels such as methacrylates, acrylamides, sugar polymers, cellulose, silicates, or other fibrous or stranded polymers. In some embodiments, the solid support or substrate may be coated using passive or chemically-derivatized coatings with any number of materials, including polymers, such as dextrans, acrylamides, gelatins or agarose. Beads and/or particles may be free or in connection with one another (e.g., sintered). In some embodiments, a solid support or substrate can be a collection of particles. In some embodiments, the particles can comprise silica, and the silica may comprise silica dioxide. In some embodiments the silica can be porous, and in certain embodiments the silica can be non-porous. In some embodiments, the particles further comprise an agent that confers a paramagnetic property to the particles. In certain embodiments, the agent comprises a metal, and in certain embodiments the agent is a metal oxide, (e.g., iron or iron oxides, where the iron oxide contains a mixture of Fe2+ and Fe3+). An antibody may be linked to a solid support by covalent bonds or by non-covalent interactions and may be linked to a solid support directly or indirectly (e.g., via an intermediary agent such as a spacer molecule or biotin). [0218] Antibodies and antigen binding fragments thereof provided herein may be employed in any known assay method, such as flow cytometry, immunohistochemistry, immunofluorescence, mass cytometry (e.g., Cytof instrument), competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc. 1987). Flow cytometry and mass cytometry assays generally involve the use of a single primary antibody to specifically identify the presence of the target molecule expressed on the surface of a dispersed suspension of individual cells. The dispersed cells are typically obtained from a biological fluid sample, e.g., blood, but may also be obtained from a dispersion of single cells prepared from a solid tissue sample such as spleen or tumor biopsy. The primary antibody may be directly conjugated with a detectable moiety, e.g., a PATENT BIOLEG-1007PCT fluorophore such as phycoerythrin for flow cytometry or a heavy metal chelate for mass cytometry. Alternatively, the primary antibody may be unlabeled or labeled with an undetectable tag such as biotin, and the primary antibody is then detected by a detectably labeled secondary antibody that specifically recognizes the primary antibody itself or the tag on the primary antibody. The labeled cells are then analyzed in an instrument capable of single cell detection, e.g., flow cytometer, mass cytometer, fluorescence microscope or brightfield light microscope, to identify those individual cells in the dispersed population or tissue sample that express the target recognized by the primary antibody. Detailed description of the technological basis and practical application of flow cytometry principles may be found in, e.g., Shapiro, Practical Flow Cytometry, 4th Edition, Wiley, 2003. [0219] Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein that is detected. In a sandwich assay, the test sample analyte is bound by a first antibody that is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., U.S. Pat. No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme. In a cell ELISA, the target cell population may be attached to the solid support using antibodies first attached to the support and that recognize different cell surface proteins. These first antibodies capture the cells to the support. GPC4 on the surface of the cells can then be detected by adding any of the anti-GPC4 antibodies or antigen-binding fragments thereof described herein to the captured cells and detecting the amount of the anti-GPC4 antibody or antigen binding fragment thereof attached to the cells. In certain instances, fixed and permeabilized cells may be used, and in such instances, both surface GPC4 and intracellular GPC4 may be detected. [0220] In some embodiments, any of the antibodies or antigen binding fragments thereof provided herein are formulated for immunohistochemical analysis. In some embodiments, immunohistochemical analysis includes the use of samples. In some embodiments, immunohistochemical analysis includes the use of blood and/or tissue samples. In some embodiments, the sample may be fresh or frozen or may be embedded in paraffin and fixed with PATENT BIOLEG-1007PCT a preservative such as formalin. In some embodiments, the sample is a formalin-fixed paraffin- embedded (FFPE) sample. In some embodiments, the FFPE sample is saturated with formalin (i.e. formaldehyde) and then embedded in a block of paraffin wax. In some embodiments, the FFPE sample is stable at room temperature. In some embodiments, all of the structures in the FFPE sample are preserved. In some embodiments, the intracellular and surface proteins in the FFPE sample are preserved. In some embodiments, the mRNA in the FFPE sample is preserved. In some embodiments, the mRNA, intracellular and surface proteins in the FFPE sample are preserved. In some embodiments, the surface proteins in the FFPE sample are denatured. [0221] In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 in a formalin-fixed paraffin-embedded sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 on the surface of a cell in a formalin-fixed paraffin-embedded sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting intracellular GPC4 in a formalin-fixed paraffin-embedded sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting intracellular GPC4, and GPC4 on the surface of a formalin-fixed paraffin-embedded sample. [0222] In some embodiments, the sample is a fresh sample that has been frozen. In some embodiments, the sample is a fresh sample that has been cryogenically frozen. In some embodiments, the sample is flash frozen. In some embodiments, the sample if flash frozen and stored at 80°C. In some embodiments, all of the structures in the flash frozen sample are preserved. In some embodiments, the intracellular and surface proteins in the flash frozen sample are preserved. In some embodiments, the mRNA in the flash frozen sample is preserved. In some embodiments, the mRNA, intracellular and surface proteins in the flash frozen sample are preserved. In some embodiments, the surface proteins in the flash frozen sample are denatured. [0223] In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 in a frozen sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting GPC4 on the surface of a frozen sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are PATENT BIOLEG-1007PCT capable of detecting intracellular GPC4 in a frozen sample. In some embodiments, any of the anti-GPC4 antibodies or antigen binding fragments thereof provided herein are capable of detecting intracellular GPC4, and GPC4 on the surface of a frozen sample. [0224] The antibodies herein also may be used for in vivo diagnostic assays. Generally, the antibody is labeled with a radionuclide (such as 111In, 99Tc, 14C, 131I, 125I, 3H, 32P, or 35S) so that the bound target molecule can be localized using immunoscintillography. Also provided herein are reagents comprising anti-GPC4 agent/antibody described herein for non-diagnostic use. Also provided herein are reagents comprising anti-GPC4 agent/antibody described herein for non-therapeutic use. Also provided herein are reagents comprising anti-GPC4 agent/antibody described herein for non-diagnostic and non-therapeutic use. For example, provided herein are reagents comprising an anti-GPC4 agent/antibody described herein for use in research applications. Research applications may include investigating GPC4 and its role in one or more of cell division, growth regulation, cell signaling (e.g., Wnt, BMP, FGF signaling), cancer (e.g., pancreatic cancer, colorectal cancer), and the like. Also provided herein are methods for detecting GPC4 and/or measuring GPC4 levels in a non-biological sample. For example, a method may comprise contacting a non-biological sample (e.g., a laboratory research sample known or suspected to contain GPC4) with an antibody provided herein, and, if the sample contains GPC4, detecting GPC4:antibody complexes. Laboratory research samples may include non-human animal models, samples from non-human animal models, cell lines, products produced by cell lines, and the like. X. Detection of GPC4 [0225] Provided herein are antibodies and methods for detecting GPC4. In some embodiments, antibodies and methods are provided for detecting GPC4 in a biological sample. In some embodiments, the biological sample is a solid tissue, fluid, or cell. In some embodiments, the GPC4 is detected on the surface of the cell. In some embodiments, the GPC4 is detected intracellularly. In some embodiments, the detection of GPC4 is in vitro. In some embodiments, the detection of GPC4 is in vivo. [0226] The solid tissue may comprise solid tissue from one or more of adipose tissue, bladder, bone, brain breast cervix, endothelium, gallbladder, kidney, liver, lung, lymph, ovary, prostate, PATENT BIOLEG-1007PCT salivary gland, stomach, testis, thyroid, urethra, uterus, vagina, and vulva. In some embodiments, the fluid comprises one or more of amniotic fluid, bile, blood, breast milk, breast fluid, cerebrospinal fluid, lavage fluid, lymphatic fluid, mucous, plasma, saliva, semen, serum, spinal fluid, sputum, tears, umbilical cord blood, urine, and vaginal fluid. [0227] In some embodiments, the sample comprises immune cells. In some embodiments, the sample comprises a heterogeneous population of immune cells. In some embodiments, the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs). [0228] In some of any embodiments, any of the antibodies or antigen binding fragments thereof provided herein can be used in the characterization of single cells by measurement of gene-expression levels and cellular proteins. Among such known single cell sequencing platforms suitable for integration with the antibodies or antigen binding fragments thereof described herein is the Drop-seq method, including, but not limited to, microfluidic, plate-based, or microwell, Seq-Well™ method and adaptations of the basic protocol, and InDrop™ method. In another embodiment, a single cell sequencing platform suitable for integration with the antibodies or antigen binding fragments thereof described herein is l0x genomics single cell 3’ solution or single cell V(D)J solution, either run on Chromium controller, or dedicated Chromium single cell controller. Other suitable sequencing methods include Wafergen iCell8™ method, Microwell-seq method, Fluidigm CI™ method and equivalent single cell products. Still other known sequencing protocols useful with the antibodies or antigen binding fragments thereof described herein include BD Resolve™ single cell analysis platform and ddSeq (from Illumina® Bio-Rad® SureCell™ WTA 3’ Library Prep Kit for the ddSEQ™ System, 2017, Pub. No. 1070-2016-014-B, Illumina Inc., Bio-Rad Laboratories, Inc.). In still other embodiments, the antibodies or antigen binding fragments thereof described herein are useful with combinatorial indexing based approaches (sci-RNA-seq™ method or SPLiT-seq™ method) and Spatial Transcriptomics, or comparable spatially resolved sequencing approaches. The methods and compositions described herein can also be used as an added layer of information on standard index sorting (FACS) and mRNA-sequencing-based approaches. PATENT BIOLEG-1007PCT [0229] In some of any embodiments, any of the antibodies or antigen binding fragments thereof described herein can be used to detect the presence, absence or amount of the various nucleic acids, proteins, targets, oligonucleotides, amplification products and barcodes described herein. [0230] In some embodiments, the biological sample is from a healthy subject. In some embodiments, the sample is from a subject with a disease or condition. In some embodiments, the detection of GPC4 indicates the presence or absence of a disease or disorder. In some embodiments, the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, a neurologic disorder, or an infection. In some embodiments, the cancer is the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma. [0231] In some embodiments, the disease or disorder is associated with GPC4 expression, In some embodiments, the disease or disorder is associated with aberrant GPC4 expression. In some embodiments, the disease or disorder is associated with Natural Killer (NK), alpha beta T cells, gamma delta T cells, CD8+ T cells, monocytes, or dendritic cells. In some embodiments, the disease or disorder is associated with Natural Killer (NK) cells. In some embodiments, the disease or disorder is associated with alpha beta T cells. In some embodiments, the disease or disorder is associated with gamma delta T cells. In some embodiments, the disease or disorder is associated with CD8+ T cells. In some embodiments, the disease or disorder is associated with monocytes. In some embodiments, the disease or disorder is associated with dendritic cells. In some of any embodiments, the disease or disorder is chosen from non-viral cancers, virus- associated cancers, cancers associated with HBV infection, cancers associated with Epstein-Barr virus (EBV) infection, cancers associated with polyomavirus infection, erythema nodosum leprosum (ENL), autoimmune diseases, autoimmune inflammation, autoimmune thyroid diseases, B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin’s Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, B-cell leukemias, myelodysplastic PATENT BIOLEG-1007PCT syndromes, solid phase cancer, herpes viral infections, and/or rejection of transplanted tissues or organs. [0232] In some embodiments, the disease or disorder is a cancer, an infectious disease, or an autoimmune disorder. [0233] In some embodiments, the disease or disorder is a cancer. In some embodiments, the cancer is metastatic melanoma, a solid tumor, bladder cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, hepatic metastasis of colonic origin, papillary thyroid carcinoma, acute myeloid leukemia, or asymptomatic myeloma. [0234] In some embodiments, the disease or disorder is an infectious disease. In some embodiments, the infectious disease is human immunodeficiency virus (HIV), chronic hepatitis C, cytomegalovirus, or hantavirus. [0235] In some embodiments, the disease or disorder is an autoimmune disorder. In some embodiments, the autoimmune disorder is Crohn’s disease, multiple sclerosis, systemic sclerosis, ocular myasthenia gravis, psoriasis or rheumatoid arthritis. In some embodiments, the autoimmune disorder is Crohn’s disease, multiple sclerosis, systemic sclerosis, ocular myasthenia gravis, psoriasis or rheumatoid arthritis. [0236] In some embodiments, any of the antibodies or antigen binding fragments thereof can be used in generating a nucleic acid molecule comprising all or a portion of the sequence of the oligonucleotide or a complement thereof. In some of any embodiments, the antibody or antigen binding fragment thereof can be used in a method of associating presence or abundance of GPC4 with a location of interest of a tissue sample. [0237] In some embodiments, any of the antibodies or antigen binding fragments thereof can be used in the construction of a protein library. In some of any embodiments, the construction of a protein library comprises sequencing. In some of any embodiments, the construction of a protein library comprises the use of flow cytometry. [0238] In some of any embodiments, provided herein is a method of detecting GPC4, comprising PATENT BIOLEG-1007PCT [0239] a) contacting a sample with the antibody or antigen binding fragment thereof of any of the antibodies or antigen binding fragments thereof under conditions to bind said antibody or antigen binding fragment thereof to a GPC4 receptor on said sample, wherein the binding generates the production of a receptor/antibody or antigen binding fragment thereof of complex; b) detecting the presence of the receptor/antibody or antigen binding fragment thereof of complexes; c) wherein the detecting comprises the presence or absence of the GPC4 receptor on said sample. [0240] In some of any embodiments, provided herein is a method of treating or preventing a disease or disorder associated with GPC4 in a subject, comprising: a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof any of the antibodies or antigen binding fragments thereof, b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the antibody or antigen binding fragment thereof of any of the antibodies or antigen binding fragments thereof. [0241] In some of any embodiments, provided herein is a method of diagnosing a disease or disorder, comprising: a) isolating a sample from a subject, b) incubating the sample with the antibody or antigen binding fragment thereof of any of any of the antibodies or antigen binding fragments thereof, for a period of time sufficient to generate GPC4:anti-GPC4 complexes; c) detecting the presence or absence of the GPC4:anti-GPC4 complexes from the isolated tissue, and d) associating presence or abundance of GPC4 with a location of interest of a tissue sample. [0242] In some of any embodiments, the increase of GPC4 over a control level in the location of interest of the tissue sample is indicative of a disease or disorder in a subject. [0243] In some of any embodiments, the detection comprises hybridization of a detectable moiety to the antibody or antigen binding fragment thereof. In some of any embodiments, the sample is contacted with a second antibody. In some of any embodiments, the second antibody is an antibody comprising a detectable moiety. In some of any embodiments, the detectable moiety comprises an oligonucleotide. In some of any embodiments, the detectable moiety comprises a fluorescent label. In some of any embodiments, the measurement comprises sequencing. In some of any embodiments, the detectable moiety comprises immunofluorescence. In some of any PATENT BIOLEG-1007PCT embodiments, the sample is a formalin-fixed paraffin-embedded sample. In some of any embodiments, the sample comprises a cell. In some of any embodiments, the sample comprises a tissue sample. XI. Kits incorporating anti- antibodies [0244] An antibody herein may be provided in a kit, for example, a packaged combination of reagents in predetermined amounts with instructions for use (e.g., instructions for performing a diagnostic assay; instructions for performing a laboratory assay). In some embodiments, the kit is a diagnostic kit configured to detect GPC4 in a sample (e.g., a biological sample). Where the antibody is labeled with a fluorophore, the kit may include an identical isotype negative control irrelevant antibody to control for non-specific binding of the antibody. Where the antibody is labeled with an enzyme, the kit may include substrates and cofactors required by the enzyme (e.g., substrate precursor which provides the detectable chromophore or fluorophore). Additional additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer), and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay. In certain instances, reagents may be provided as dry powders (e.g., lyophilized powder), including excipients that on dissolution will provide a reagent solution having the appropriate concentration. XI. Certain implementations Following are non-limiting examples of certain implementations of the technology. A1. An antibody or antigen binding fragment thereof that binds GPC4 or a portion thereof, comprising: a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementarity determining region 1 (CDRH1) comprising SEQ ID NO:2; (ii) a heavy chain complementarity determining region 2 (CDRH2) comprising SEQ ID NO:3; (iii) a heavy chain complementarity determining region 3 (CDRH3) comprising SEQ ID NO:4; and PATENT BIOLEG-1007PCT b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO:5; (ii) a light chain complementarity determining region 2 (CDRL2) comprising SEQ ID NO:6; and (iii) a light chain complementarity determining region 3 (CDRL3) comprising SEQ ID NO:7. A2. The antibody or antigen binding fragment thereof of embodiment A1, wherein the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 4. A3. The antibody or antigen binding fragment thereof of embodiment A1 or A2, wherein the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4. A4. The antibody or antigen binding fragment thereof of any one of embodiments A1-A3, wherein the immunoglobulin light chain variable domain comprises: a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 5, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5; a CDRL2 comprising PATENT BIOLEG-1007PCT the sequence of amino acids set forth in SEQ ID NO: 6, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 7, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 7. A5. The antibody or antigen binding fragment thereof of any one of embodiments A1-A4, wherein the immunoglobulin light chain variable domain comprises: a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 5; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 6; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 7. A6. The antibody or antigen binding fragment thereof of any one of embodiments A1-A5, wherein the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 2; the CDRH2 comprises the sequence of amino acids set forth in SEQ ID NO: 3; the CDRH3 comprises the sequence of amino acids set forth in SEQ ID NO: 4; the CDRL1 comprises the sequence of amino acids set forth in SEQ ID NO: 5; the CDRL2 comprises the sequence of amino acids set forth in SEQ ID NO: 6; and the CDRL3 comprises the sequence of amino acids set forth in SEQ ID NO: 7. A7. The antibody or antigen binding fragment thereof of any one of embodiments A1-A5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 2 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2, the CDRH2 comprises the sequence set forth in SEQ ID NO: 3 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3; the CDRH3 comprises the sequence set forth in SEQ ID NO: 4 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 4; the CDRL1 comprises PATENT BIOLEG-1007PCT the sequence set forth in SEQ ID NO: 5 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 5, the CDRL2 comprises the sequence set forth in SEQ ID NO: 6 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 7 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 7. A8. The antibody or antigen binding fragment thereof of any one of embodiments A1-A7, wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15. A9. The antibody or antigen binding fragment thereof of any one of embodiments A1-A8, wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in any of SEQ ID NO: 15. A10. The antibody or antigen binding fragment thereof of any one of embodiments A1-A9, wherein the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17. A11. The antibody or antigen binding fragment thereof of any one of embodiments A1-A10, wherein the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17. A12. The antibody or antigen binding fragment thereof of any one of embodiments A1-A11, PATENT BIOLEG-1007PCT wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15; and wherein the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 17. A13. The antibody or antigen binding fragment thereof of any one of embodiments A1-A12, wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15; and wherein the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17. A14. The antibody or antigen binding fragment thereof of any one of embodiments A1-A13, comprising one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain. A15. The antibody or antigen binding fragment thereof of any one of embodiments A1-A13, comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. A16. The antibody or antigen binding fragment thereof of any one of embodiments A1-A15, wherein the antibody or antigen binding fragment thereof is isolated. A17. The antibody or antigen binding fragment thereof of any one of embodiments A1-A16, wherein the antibody or antigen binding fragment thereof is humanized. A18. The antibody or antigen binding fragment thereof of any one of embodiments A1-A17, wherein the antibody or antigen binding fragment thereof is conjugated. PATENT BIOLEG-1007PCT A19. The antibody or antigen binding fragment thereof of any one of embodiments A1-A18, further comprising an oligonucleotide. A20. The antibody or antigen binding fragment thereof of embodiment A19, wherein the oligonucleotide comprises a sample barcode sequence. A21. The antibody or antigen binding fragment thereof of any one of embodiments A19 or A20, wherein the oligonucleotide comprises a binding site for a primer and an anchor. A22. The antibody or antigen binding fragment thereof of any one of embodiments A1-A21, wherein the antibody or antigen binding fragment thereof is conjugated to a detectable marker or label. A23. The antibody or antigen binding fragment thereof of embodiment A22, wherein the detectable marker or label is conjugated directly to the antigen or antigen binding fragment thereof. A24. The antibody or antigen binding fragment thereof of embodiment A22, wherein the detectable marker or label is conjugated to the oligonucleotide. A25. The antibody or antigen binding fragment thereof of embodiment A22, wherein the detectable marker or label comprises a detectable moiety. A26. The antibody or antigen binding fragment thereof of embodiment A22, wherein the detectable moiety is a radioisotope, fluorescent label or enzyme-substrate label. A27. The antibody or antigen binding fragment thereof of any one of embodiments A1-A26, wherein the antibody or antigen binding fragment thereof is non-diffusively immobilized on a solid support. PATENT BIOLEG-1007PCT A28. The antibody or antigen binding fragment thereof of any one of embodiments A1-A27, that is a single chain fragment. A29. The antibody or antigen binding fragment thereof of embodiment A28, wherein the single chain fragment is a single chain variable fragment (scFv). A30. The antibody or antigen binding fragment thereof of any one of embodiments A1-A29, for use in the detection of GPC4 in a sample. A31. The antibody or antigen binding fragment thereof of any one of embodiments A1-A29, wherein the antibody or antigen binding fragment thereof binds to a cell expressing GPC4 in a sample. A32. The antibody or antigen binding fragment of embodiment A30 or A31, wherein the sample comprises immune cells. A33. The antibody or antigen binding fragment of embodiment A30 or A31, wherein the sample comprises a heterogenous population of immune cells. A34. The antibody or antigen binding fragment of embodiment A32 or A33, wherein the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs). A35. The antibody or antigen binding fragment thereof of embodiments A30 or A31, wherein the sample comprises a cell with a disease or disorder. A36. The antibody or antigen binding fragment thereof of embodiment A35, wherein the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, a neurologic disorder, or an infection. PATENT BIOLEG-1007PCT A37. The antibody or antigen binding fragment thereof of embodiment A36, wherein the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, breast, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma. A38. The antibody or antigen binding fragment thereof of any one of embodiments A30-A37, wherein the detection comprises the use of a single antibody or antigen binding fragment thereof to bind a portion of GPC4. A39. The antibody or antigen binding fragment thereof of any one of embodiments A30-A37, wherein the detection comprises the use of two antibody or antigen binding fragments thereof, each capable of binding to a different portion of GPC4. A40. The antibody or antigen binding fragment thereof of any one of embodiments A30-A37, wherein the detection of GPC4 is on the surface of a cell. A41. The antibody or antigen binding fragment thereof of any one of embodiments A30-A37, wherein the detection of GPC4 is intracellular. A42. The antibody or antigen binding fragment thereof of any one of embodiments A30-A37, wherein the detection of GPC4 indicates the presence or absence of a disease or disorder. A43. The antibody or antigen binding fragment thereof of any one of embodiments A30-A42, wherein the detection is performed in vitro. A44. The antibody or antigen binding fragment thereof of any one of embodiments A30-A42, wherein the detection is performed in vivo. A45. The antibody or antigen binding fragment thereof of any one of embodiments A1-A44, wherein the antibody or antigen binding fragment thereof binds to a GPC4 expressing cell. PATENT BIOLEG-1007PCT A46. A diagnostic antibody or antigen binding fragment thereof comprising the antibody or antigen binding fragment thereof of any of embodiments A1-A45. A47. The isolated antibody or antigen binding fragment thereof of any one of embodiments A1- A44, for non-diagnostic use and/or non-therapeutic use. B1. A kit comprising the antibody or antigen binding fragment thereof of any one of embodiments A1-A45 or the diagnostic antibody or antigen binding fragment thereof of embodiment A46. B2. The kit of embodiment B1, comprising a diagnostics kit configured to detect GPC4 in a biological sample. C1. A composition comprising the antibody or antigen binding fragment thereof of any of embodiments A1-A45, and a pharmaceutically acceptable excipient. C2. The composition of embodiment C1, wherein the antibody or antigen binding fragment thereof of is used as an adjuvant or in conjunction with an adjuvant. D1. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the antibody or antigen binding fragment thereof of any of embodiments A1-A45. D2. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any of embodiments A1-A45. D3. A recombinant expression vector comprising the isolated nucleic acid of embodiment D1 or D2. PATENT BIOLEG-1007PCT D4. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of embodiments A1-A45, and the second expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any one of embodiments A1-A45. D5. The recombinant expression vector of embodiment D4, wherein the first and second expression cassettes comprise a promoter. D6. A host cell transfected with the recombinant expression vector of embodiments D3-D5. E1. An agent-drug conjugate comprising antibody or antigen binding fragment thereof of any of embodiments A1-A45. E2. A composition comprising the antibody-drug conjugate of embodiment E1, and a pharmaceutically acceptable carrier. F1. A method of detecting GPC4 comprising a) contacting a sample with the antibody or antigen binding fragment thereof of any of embodiments A1-A45, under conditions to bind said antibody or antigen binding fragment thereof to a GPC4 receptor on said sample, wherein the binding generates the production of a receptor/antibody or antigen binding fragment thereof complex; b) detecting the presence of the receptor/antibody or antigen binding fragment thereof complexes; c) wherein the detecting comprises the presence or absence of the GPC4 receptor on said sample. F2. A method of treating or preventing a disease or disorder associated with GPC4 in a subject, comprising: PATENT BIOLEG-1007PCT a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof of any of embodiments A1-A45, b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the antibody or antigen binding fragment thereof of any of embodiments A1-A45. F3. A method of diagnosing a disease or disorder, comprising: a) isolating a sample from a subject b) incubating the sample with the antibody or antigen binding fragment thereof of any of embodiments A1-A45, for a period of time sufficient to generate GPC4:anti-GPC4 complexes; c) detecting the presence or absence of the GPC4:anti-GPC4 complexes from the isolated tissue, and d) associating presence or abundance of GPC4 with a location of interest of a tissue sample. F4. The method of embodiment F3, wherein the increase of GPC4 over a control level in the location of interest of the tissue sample is indicative of a disease or disorder in a subject. F5. The method of embodiment F2 or F3, wherein the method is performed in vitro. F6. The method of embodiment F2 or F3, wherein the method is performed in vivo. F7. The method of any one of embodiments F1-F6, wherein the detection comprises intracellular detection. F8. The method of any one of embodiments F1-F6, wherein the detection comprises detection on the surface of a cell. PATENT BIOLEG-1007PCT F9. The method of any one of embodiments F1-F6, wherein the detection comprises hybridization of a detectable moiety to the antibody or antigen binding fragment thereof. F10. The method of any one of embodiments F1-F9, wherein the sample is contacted with a second antibody. F11. The method of embodiment F10, wherein the second antibody is an antibody comprising a detectable moiety. F12. The method of embodiment F11, wherein the detectable moiety comprises an oligonucleotide. F13. The method of embodiment F11, wherein the detectable moiety comprises a fluorescent label. F14. The method of any one of embodiments F1-F9, wherein the detecting comprises sequencing. F15. The method of embodiment F11, wherein the detectable moiety comprises immunofluorescence. F16. The method of any one of embodiments F1-F13 and F15, wherein the sample is a formalin-fixed paraffin-embedded sample. F17. The method of any one of embodiments F1-F16, wherein the sample comprises a cell. F18. The method of any one of embodiments F1-F16, wherein the sample comprises a tissue sample. F19. The method of any one of embodiments F1-F16, wherein the sample comprises immune cells. PATENT BIOLEG-1007PCT F20. The method of embodiment F19, wherein the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs). F21. The method of any one of embodiments F1-F16, wherein the sample comprises a tissue or cells associated with a disease or disorder. F22. The method of embodiment F21, wherein the disease or disorder is a cancer, an autoimmune disorder, an inflammatory disorder, or an infection. F23. The method of embodiment F21, wherein the disease or disorder is chosen from non-viral cancers, virus-associated cancers, cancers associated with HBV infection, cancers associated with Epstein-Barr virus (EBV) infection, cancers associated with polyomavirus infection, erythema nodosum leprosum (ENL), autoimmune diseases, autoimmune inflammation, autoimmune thyroid diseases, B-cell lymphoma, T-cell lymphoma, acute myeloid leukemia, Hodgkin’s Disease, acute myelogenous leukemia, acute myelomonocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, B cell large cell lymphoma, malignant lymphoma, acute leukemia, lymphosarcoma cell leukemia, B- cell leukemias, myelodysplastic syndromes, solid phase cancer, herpes viral infections, and/or rejection of transplanted tissues or organs. G1. The antibody or antigen binding fragment thereof of any of embodiments A1-A45, for use in a method of associating presence or abundance of GPC4 with a location of interest of a tissue sample. G2. The antibody or antigen binding fragment thereof of any of embodiments A1-A45, for use in a method of detecting GPC4 in a tissue sample. PATENT BIOLEG-1007PCT G3. The antibody or antigen binding fragment thereof embodiment G1 or G2, wherein the method comprises generating a nucleic acid molecule comprising all or a portion of the sequence of the oligonucleotide or a complement thereof. G4. The antibody or antigen binding fragment thereof of any of embodiments A1-A45, for use in the construction of a protein library. G5. The antibody or antigen binding fragment thereof of embodiment G4, wherein the construction of a protein library comprises sequencing. G6. The antibody or antigen binding fragment thereof of embodiment G4, wherein the construction of a protein library comprises the use of flow cytometry. EXAMPLES [0245] The examples set forth below illustrate certain embodiments and do not limit the technology. EXAMPLE 1: CREATION AND CHARACTERIZATION OF ANTI-GPC4 HYBRIDOMAS [0246] The Hybridomas that secrete monoclonal antibodies that react with GPC4 as expressed in vivo were prepared as described in this Example. [0247] A common strain of laboratory mice, e.g., BALB/c or C57/Bl6, or rats, e.g., Sprague Dawley, were immunized with a GPC4 immunogen. Following successful immunization of mice, hybridomas were formed using standard protocols to fuse myeloma cells with spleen and to drain lymph node cells harvested from the animals. Following selection of successful fusions in HAT medium and cloning to approximately one cell/well in microtiter plates, the culture supernatants were tested against GPC4-expressing cell transfectants, e.g., HEK 293 or RBL, by flow cytometry. Wells with successful staining profiles were sub-cultured into larger vessels until sufficient cells were present to allow subcloning. Further characterization of the hybridoma subclone candidates was performed by flow cytometry using GPC4-transfected cells. Clones selected as the best candidates were further screened by flow cytometry against human blood PATENT BIOLEG-1007PCT cells divided into distinct subsets (e.g., lymphocytes, monocytes, and the like) and against one or more cell lines generated from diseased and/or infected human cells. As compared to an isotype control, the percentage of positive cells in each blood cell subset was quantified. [0248] The Exemplary clones were selected based on strong reactivity against immune cells that express GPC4 (e.g., lymphocytes) but no appreciable reactivity against other blood cell populations, detection of GPC4 on the cell surface of immune cells (e.g., lymphocytes), and/or intracellular detection of GPC4. EXAMPLE 2: SEQUENCING OF THE ANTI-GPC4 ANTIBODY VARIABLE REGIONS [0249] Cells from well-performing anti-GPC4 hybridoma cell lines (described in Example 1, above) were grown in standard mammalian tissue culture media. Total RNA was isolated from hybridoma cells from various clones expressing anti-GPC4 monoclonal antibodies using a procedure based on the RNeasy Mini Kit (Qiagen). The RNA was used to generate first strand cDNA. Both light chain and heavy chain variable domain cDNAs were amplified by a 5’-RACE technique. Positive clones were prepared by PCR and then subjected to DNA sequencing of multiple clones. [0250] Amino acid sequences of the individual variable domains (CDRs and Framework regions), including the CDR1, CDR2, and CDR3 regions, for both the heavy and light chains for AB2 are shown in Table 1 below. The full sequence of AB2 is shown below Table 1. Table 1. Amino Acid and Nucleic Acid Sequences of the CDRs. Name SEQ ID NO Amino Acid SEQ ID Nucleic Acid A
Figure imgf000079_0001
PATENT BIOLEG-1007PCT CDRH3 4 GGHYGLFDY 10 GGGGGGCACTACGGCC TCTTTGACTAC A
Figure imgf000080_0001
eavy c a n: sequence ( bp) (S Q O: ) Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 ATGGATTGGCTGTGGAACTTGCTATTCCTGATGGCAGCTGCCCAAAGTGCCCAAGCA CAGATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAA GATCTCCTGCAAGGCTTCTGGGTATACCTTCACAAACTATGCAATGAACTGGGTGAAG CAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAACACCTACACTGGAGAGC CAACATATGCTGATGACTTCAAGGGACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGC ACTGCCTATTTGCAGATCAACAACCTCAAAAATGAGGACATGGCTACATATTTCTGT GCAAGAGGGGGGCACTACGGCCTCTTTGACTACTGGGGCCAAGGCACCACTCTCACA GTCTCCTCA Heavy chain: Amino acid sequence (137 aa) (SEQ ID NO:15) MDWLWNLLFLMAAAQSAQAQIQLVQSGPELKKPGETVKISCKASGYTFTNYAMNWVK QAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDMATYFC ARGGHYGLFDYWGQGTTLTVSS Light chain: DNA sequence (384 bp) (SEQ ID NO:16) Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 PATENT BIOLEG-1007PCT ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATAT CCAGAGGACAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGG AGAAGGTCACCATGACCTGCAGTGCCAGGTCAAGTGTAAGTTACATGCACTGGTACCA GCAGAAGTCAGGCTCCTCCCCCAAAAGATGGATTTATGACACATCCAAACTGGCTTCT GGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATC AGCAACATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTGGAGAAGTAAC CCACTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA Light chain: Amino acid sequence (128 aa) (SEQ ID NO:17) MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSARSSVSYMHWYQQKS GSSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAEDAATYYCQQWRSNPLTFG AGTKLELK EXAMPLE 3: DETECTION OF CELLS EXPRESSING GPC4 [0251] This Example describes the ability of exemplary generated anti-GPC4 antibody AB2 to detect cells expressing GPC4 by flow cytometry. [0252] In a first experiment, exemplary anti-GPC4 antibod AB2 was assessed on cells from a human cell line exhibiting a phenotype resembling committed CNS neuronal precursor cells (NTERA-2; ATCC® CRL-1973TM). [0253] ANTERA-2 cells were grown in DMEM media supplemented with 10% FBS in T75 culture flask, to about 80% confluency. Exemplary generated PE-conjugated anti-GPC4 antibody was added at a concentration of 1µg/1 million cells, and allowed to incubate for 15 minutes. A commercially available antibody (CAb) was used as control. Cells where washed with FACS buffer and analyzed on a BD LSRII flow cytometer. As shown in FIG. 1, AB2 positively stained NTERA-2 cells. [0254] In a similar experiment, AB2 was further assessed on a cell line that does not express GPC4 (U-937; ATCC® CRL-1539.2TM). As shown in FIG. 2, AB2 demonstrated negative staining on U-937 cells. PATENT BIOLEG-1007PCT [0255] In another experiment, anti-GPC4 antibody AB2 or a commercially available antibody were tested for cross-reactivity with GPC homologues GPC1 (45% homology), GPC2 (42% homology) and GPC6 (65% homology), using cell lines known to express each respective GPC, including A431 cells (GPC1), Molt4 cells (GPC2) and HepG2 cells (GPC6). As shown in FIGs. 3A-3C, anti-GPC4 antibody AB2 did not show cross reactivity with GPC1 (FIG. 3A), GPC2 (FIG. 3B) or GPC6 (FIG. 3C). These results demonstrate the ability of exemplary anti-GPC4 antibody to specifically recognize cells expressing the cognate receptor GPC4, with minimal to no non-specific binding. EXAMPLE 4: ASSESSMENT OF GPC4 MEDIATED WNT3A SIGNALING [0256] This example describes a functional assay based on the ability of exemplary generated anti-GPC4 antibody AB2 to block GPC4-mediated enhancement of Wnt3a signaling. In another experiment, AB2 was assessed for its ability to block Wnt3a signaling in NTERA-2 cells. Briefly, NTERA-2 cells were cultured in black 96 well plates with glass bottom to about 80% confluency after which 5 µg/mL of exemplary antibody AB2, a commercially available antibody (CAb) or isotype control were added in culture media for 15 minutes. After antibody incubation, cells were stimulated with 200ng/ml recombinant human Wnt3a (R&D Systems) for 3h or left unstimulated. Cells were fixed using True Nuclear Transcription Factor Fix (BioLegend True Nuclear Buffer Set, cat# 424401) 1x working solution for 30 minutes and washed twice with True Nuclear Perm Buffer (BioLegend True Nuclear Buffer Set, cat# 424401). Cells were then stained with anti-human beta catenin antibody (BioLegend clone 12F7, cat# 844601) followed by Alexa Fluor® 594 anti-mouse IgG. Cells were imaged using an inverted epifluorescence microscope (Olympus IX83). Fluorescence intensity in the cytoplasm and the nucleus was quantified using ImageJ, and the nuclear/cytoplasmic fluorescence ratio calculated. Untreated cells and Wnt3a only stimulated cells were used as controls. As shown in FIG. 4, AB2 is capable of reducing Wnt3a-induced translocation of beta-catenin to the nucleus. As shown in FIG.5, exemplary antibody AB2 was capable of reducing Wnt3a induced beta- catenin translocation to the nucleus, whereas the commercially available antibody did not demonstrate this effect. As shown in FIG. 6, exemplary antibody AB2 was capable of reducing Wnt3a induced beta-catenin translocation to the nucleus at all concentrations tested, whereas the commercially available antibody did not demonstrate this effect.

Claims

PATENT BIOLEG-1007PCT WHAT IS CLAIMED IS: 1. An antibody or antigen binding fragment thereof that binds GPC4 or a portion thereof, comprising: a) an immunoglobulin heavy chain variable domain comprising: i) a heavy chain complementarity determining region 1 (CDRH1) comprising a sequence of amino acids that exhibits at least 80% sequence identity to SEQ ID NO:2; ii) a heavy chain complementarity determining region 2 (CDRH2) comprising a sequence of amino acids that exhibits at least 80% sequence identity to SEQ ID NO:3; iii) a heavy chain complementarity determining region 3 (CDRH3) comprising a sequence of amino acids that exhibits at least 80% sequence identity to SEQ ID NO:4; and/or b) an immunoglobulin light chain variable domain comprising: i) a light chain complementarity determining region 1 (CDRL1) comprising a sequence of amino acids that exhibits at least 80% sequence identity to SEQ ID NO:5; ii) a light chain complementarity determining region 2 (CDRL2) comprising a sequence of amino acids that exhibits at least 80% sequence identity to SEQ ID NO:6; and iii) a light chain complementarity determining region 3 (CDRL3) comprising a sequence of amino acids that exhibits at least 80% sequence identity to SEQ ID NO:7. 2. The antibody or antigen binding fragment thereof of claim 1, wherein the immunoglobulin heavy chain variable domain comprises: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 2; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 3; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 4. PATENT BIOLEG-1007PCT 3. The antibody or antigen binding fragment thereof of any one of claims 1-2, wherein the immunoglobulin light chain variable domain comprises: a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 5; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 6; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 7. 4. The antibody or antigen binding fragment thereof of any one of claims 1-3, wherein the immunoglobulin heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80% amino acid sequence identity to SEQ ID NO: 15. 5. The antibody or antigen binding fragment thereof of any one of claims 1-4, wherein the immunoglobulin light chain comprises the amino acid sequence set forth in SEQ ID NO: 17, or a sequence having at least 80% amino acid sequence identity to SEQ ID NO: 17. 6. The antibody or antigen binding fragment thereof of any one of claims 1-5, for use in the detection of GPC4 in a sample. 7. A diagnostic antibody or antigen binding fragment thereof comprising the antibody or antigen binding fragment thereof of any of claims 1-6. 8. A kit comprising the antibody or antigen binding fragment thereof of any one of claims 1-6. 9. A composition comprising the antibody or antigen binding fragment thereof of any of claims 1-6, and a pharmaceutically acceptable excipient. 10. The composition of claim 9, wherein the antibody or antigen binding fragment thereof is used as an adjuvant or in conjunction with an adjuvant. 11. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the antibody or antigen binding fragment thereof of any of claims 1-6. PATENT BIOLEG-1007PCT 12. A recombinant expression vector comprising the isolated nucleic acid of claim 11. 13. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of claims 1-6, and the second expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the antibody or antigen binding fragment thereof of any one of claims 1- 6. 14. A host cell comprising the recombinant expression vector of claim 12 or claim 13. 15. A method of detecting the presence or absence of GPC4 in an in vitro sample, the method comprising: a) contacting the in vitro sample with the antibody or antigen binding fragment thereof of any one of claims 1-6, under conditions to bind said antibody or antigen binding fragment thereof to GPC4 in said sample, wherein the binding generates the production of at least one complex comprising GPC4 and the antibody or an antigen binding fragment thereof; and, b) detecting the presence or absence of the produced at least one complex comprising GPC4 and the antibody or an antigen binding fragment thereof to detect the presence or absence of GPC4 in the in vitro sample. 16. A method of treating or preventing a disease or disorder associated with GPC4 in a subject, the method comprising: a) contacting a sample known or suspected to contain GPC4 with the antibody or antigen binding fragment thereof of any of claims 1-6, b) detecting the presence of complexes comprising GPC4 and the antibody or antigen binding fragment thereof; wherein the presence of the complexes indicates the presence of a disease or disorder; and PATENT BIOLEG-1007PCT c) administering to the subject the antibody or antigen binding fragment thereof of any of claims 1-6.
PCT/US2024/048385 2023-09-27 2024-09-25 Anti-gpc4 antibodies Pending WO2025072313A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363540896P 2023-09-27 2023-09-27
US63/540,896 2023-09-27

Publications (1)

Publication Number Publication Date
WO2025072313A1 true WO2025072313A1 (en) 2025-04-03

Family

ID=93061468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/048385 Pending WO2025072313A1 (en) 2023-09-27 2024-09-25 Anti-gpc4 antibodies

Country Status (1)

Country Link
WO (1) WO2025072313A1 (en)

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
EP0173494A2 (en) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by DNA splicing and expression
EP0183070A2 (en) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0244234A2 (en) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation of trichoderma
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
WO1996032478A1 (en) 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5861155A (en) 1993-12-08 1999-01-19 Astra Ab Humanized antibodies and uses thereof
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6329511B1 (en) 1998-12-01 2001-12-11 Protein Design Labs, Inc. Humanized antibodies to γ-interferon
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US6479284B1 (en) 1998-03-13 2002-11-12 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US6500931B1 (en) 1992-11-04 2002-12-31 Medarex, Inc. Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO2014182528A2 (en) 2013-04-30 2014-11-13 California Institute Of Technology Multiplex labeling of molecules by sequential hybridization barcoding
WO2016018960A1 (en) 2014-07-30 2016-02-04 President And Fellows Of Harvard College Systems and methods for determining nucleic acids
WO2018026873A1 (en) 2016-08-01 2018-02-08 California Institute Of Technology Sequential probing of molecular targets based on pseudo-color barcodes with embedded error correction mechanism
WO2018089438A1 (en) 2016-11-08 2018-05-17 President And Fellows Of Harvard College Multiplexed imaging using merfish, expansion microscopy, and related technologies
WO2018144813A1 (en) 2017-02-02 2018-08-09 New York Genome Center Methods and compositions for identifying or quantifying targets in a biological sample
WO2021188838A1 (en) 2020-03-18 2021-09-23 Chan Zuckerberg Biohub, Inc. Single-cell combinatorial indexed cytometry sequencing

Patent Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A2 (en) 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by DNA splicing and expression
EP0183070A2 (en) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987000195A1 (en) 1985-06-28 1987-01-15 Celltech Limited Animal cell culture
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0244234A2 (en) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US6639055B1 (en) 1991-06-14 2003-10-28 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6350861B1 (en) 1992-03-09 2002-02-26 Protein Design Labs, Inc. Antibodies with increased binding affinity
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US6500931B1 (en) 1992-11-04 2002-12-31 Medarex, Inc. Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5861155A (en) 1993-12-08 1999-01-19 Astra Ab Humanized antibodies and uses thereof
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
WO1996032478A1 (en) 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6479284B1 (en) 1998-03-13 2002-11-12 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
US6329511B1 (en) 1998-12-01 2001-12-11 Protein Design Labs, Inc. Humanized antibodies to γ-interferon
WO2014182528A2 (en) 2013-04-30 2014-11-13 California Institute Of Technology Multiplex labeling of molecules by sequential hybridization barcoding
WO2016018960A1 (en) 2014-07-30 2016-02-04 President And Fellows Of Harvard College Systems and methods for determining nucleic acids
WO2018026873A1 (en) 2016-08-01 2018-02-08 California Institute Of Technology Sequential probing of molecular targets based on pseudo-color barcodes with embedded error correction mechanism
WO2018089438A1 (en) 2016-11-08 2018-05-17 President And Fellows Of Harvard College Multiplexed imaging using merfish, expansion microscopy, and related technologies
WO2018144813A1 (en) 2017-02-02 2018-08-09 New York Genome Center Methods and compositions for identifying or quantifying targets in a biological sample
WO2021188838A1 (en) 2020-03-18 2021-09-23 Chan Zuckerberg Biohub, Inc. Single-cell combinatorial indexed cytometry sequencing

Non-Patent Citations (69)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Immunology", vol. 1, 2, 1991, WILEY-INTERSCIENCE
"Fundamental Immunology", 1993, RAVEN PRESS
"Remington's Pharmaceutical Sciences", 1980
AL-LAZIKANI ET AL., J.MOL.BIOL, vol. 273, no. 4, 1997
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUC. ACIDS RES., vol. 25, 1977, pages 3389 - 3402
ARNON ET AL.: "Monoclonal Antibodies And Cancer Therapy", 1985, ALAN R. LISS, INC., article "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", pages: 243 - 56
AUSUBEL ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1995
BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 147 - 158
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546 - 552
CHO, URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
CHOTHIA C. ET AL.: "Conformations of immunoglobulin hypervariable regions", NATURE, vol. 342, 1989, pages 877 - 883, XP002030586, DOI: 10.1038/342877a0
CHOTHIA C. ET AL.: "structural repertoire of the human VH segments", J. MOL. BIOL., vol. 227, 1992, pages 799 - 817, XP024020608, DOI: 10.1016/0022-2836(92)90224-8
CHOTHIALESK: "Canonical structures for the hypervariable regions of immunoglobulins", J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59
GREENWALD, R. B. ET AL., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 217 - 50
GUSS ET AL., EMBO J., vol. 5, 1986, pages 15671575 - 103
HAGIHARA KAZUKI ET AL: "Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells - Hagihara - 2000 - Developmental Dynamics - Wiley Online Library", 21 September 2000 (2000-09-21), XP093229835, Retrieved from the Internet <URL:https://anatomypubs.onlinelibrary.wiley.com/doi/full/10.1002/1097-0177(2000)9999:9999<::AID-DVDY1059>3.0.CO;2-#> DOI: 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1059>3.0.CO;2-%23 *
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44
HELLSTROM ET AL.: "Controlled Drug Delivery", 1987, MARCEL DEKKER, INC., article "Antibodies For Drug Delivery", pages: 623 - 53
HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1989, pages 10915
HERMANSON: "Bioconjugate Techniques", 1996, ACADEMIC PRESS, INC.
HUSTON ET AL., PROC. NAT. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614 - 3619
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
LEFRANC,M.-P.: "IMGT, the international ImMunoGeneTics database", NUCLEIC ACIDS RES., vol. 29, no. 1, 1 January 2001 (2001-01-01), pages 207 - 9, XP002281078, DOI: 10.1093/nar/29.1.207
LI NAN ET AL: "The Role of Glypicans in Cancer Progression and Therapy", JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 6 July 2020 (2020-07-06), Los Angeles, CA, pages 841 - 862, XP055817927, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/10.1369/0022155420933709> [retrieved on 20210624], DOI: 10.1369/0022155420933709 *
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13
MACCALLUM ET AL.: "Antibody-antigen interactions: Contact analysis and binding site topography", J. MOL. BIOL., vol. 262, no. 5, 1996, pages 732 - 745, XP002242391, DOI: 10.1006/jmbi.1996.0548
MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288
MARTIN ET AL., METHODS ENZYMOL., vol. 203, 1991, pages 121 - 153
MARTIN ET AL., PROC. NATL ACAD. SCI. USA, vol. 86, 1989, pages 9268 - 9272
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77 - 82
MOREL ET AL., MOLEC. IMMUNOL., vol. 25, no. 1, 1988, pages 7 - 15
MORRISON ET AL., PNAS USA, vol. 81, 1984, pages 6851 - 6855
MORRISONOI, ADV. IMMUNOL., vol. 44, 1988, pages 65 - 92
MUNSON ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255
NEUBERGER ET AL., NATURE, vol. 312, 1984, pages 604 - 608
NORTH ET AL., J MOL BIOL., vol. 406, no. 2, 2011, pages 228 - 256
OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608
O'SULLIVAN ET AL.: "Methods in Enzym.", vol. 73, 1981, ACADEMIC PRESS, article "Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay", pages: 147 - 166
PADLAN, MOLEC. IMMUN., vol. 28, 1991, pages 489 - 498
PADLAN, MOLEC. IMMUN., vol. 31, no. 3, 1994, pages 169 - 217
PEDERSEN ET AL., IMMUNOMETHODS, vol. 1, 1992, pages 126
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
REES ET AL.: "Methods in Molecular Biology", vol. 66, 1996, OXFORD UNIVERSITY PRESS, article "Epitope Mapping Protocols", pages: 141 - 172
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
ROBERTS, M. J. ET AL., ADV. DRUG DELIV. REV., vol. 54, 2002, pages 459 - 76
ROGUSKA ET AL., PROC. NATL. ACAD. SCI USA, vol. 91, 1994, pages 969
ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98
RUIZ ET AL.: "IMGT, the international ImMunoGeneTics database", NUCLEIC ACIDS RES., vol. 28, 2000, pages 219 - 221
SHAPIRO: "Practical Flow Cytometry", 2003, WILEY
STACLENS ET AL., MOL. IMMUNOL., vol. 43, 2006, pages 1243
STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242 - 253
TAN ET AL., J. IMMUNOL., vol. 169, 2002, pages 1119
THORPE ET AL.: "Monoclonal Antibodies '84: Biological And Clinical Applications", 1985, article "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", pages: 475 - 506
THORPE ET AL.: "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., vol. 62, 1982, pages 119 - 58, XP001179872, DOI: 10.1111/j.1600-065X.1982.tb00392.x
TM4, MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
VERONESE, F. M. ET AL., DRUG DISC. TODAY, vol. 10, 2005, pages 1451 - 8
WINTERMILSTEIN, NATURE, vol. 349, 1991, pages 293
ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062

Similar Documents

Publication Publication Date Title
JP6719490B2 (en) Anti-IL-36R antibody
TWI655209B (en) Antibody against human plan death (PROGRAMMED DEATH) ligand 1 (PD-L1)
US20240360228A1 (en) Anti-ccr8 antibodies, antigen-binding fragments thereof, and agents and compositions and methods for making and using the same
JP2020512344A (en) Anti-IL-36R antibody combination treatment
JP2016179979A (en) PCSK9 antagonist
WO2022187050A1 (en) Anti-cd117 agents and compositions and methods for making and using the same
US20250052767A1 (en) Cd28 binding antibodies and antigen binding fragments thereof
US12441806B2 (en) Anti-TLR9 agents and compositions and methods for making and using the same
WO2023133470A2 (en) Tmprss2 binding antibodies and antigen binding fragments thereof
WO2022093641A1 (en) Anti-nkg2a agents and compositions and methods for making and using the same
WO2025072313A1 (en) Anti-gpc4 antibodies
US12006363B2 (en) Anti-tetraspanin 33 agents and compositions and methods for making and using the same
WO2024243217A1 (en) Ceacam6 binding antibodies and antigen-binding fragments thereof
WO2022221314A1 (en) Compositions and methods involving severe acute respiratory syndrome coronavirus 2 receptor binding domain
US20250313650A1 (en) Chi3l1 binding antibodies and antigen binding fragments thereof
CN118613505A (en) CD28 binding antibodies and antigen-binding fragments thereof
EP4558523A1 (en) Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
EP4572854A2 (en) Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2022182562A1 (en) ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
CN115427447B (en) Anti-TLR 7 agents and compositions and methods of making and using the same
WO2025230843A2 (en) Kir binding antibodies and antigen binding fragments thereof
AU2023373741A1 (en) Compositions and methods involving integrin alpha3beta1
JP2025518726A (en) Anti-BMP9 antibodies and methods of use thereof
HK1210785B (en) Antibodies that bind to human programmed death ligand 1 (pd-l1)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24787636

Country of ref document: EP

Kind code of ref document: A1